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ABSTRACT 
 Scaffold-mediated nonviral gene delivery avoids several drawbacks of systemic 
injection such as clearance by the reticulo-endothelial system and serum aggregation. 
Existing synthetic and natural polymers used in gene delivery scaffolds are primarily 
derived from other tissue engineering applications with design parameters focused on 
the physicochemical properties of the scaffold and its biocompatibility. Common 
synthetic materials used in polymeric scaffolds such as PEG are practically bio-inert with 
minimal cell and protein interaction. Therefore, an opportunity exists for the rational 
design novel gene delivery scaffolds with components capable of increasing the 
expression of incorporated transgene by including scaffold components that interact with 
cellular processes and pathways. Amphiphilic block copolymers including triblock 
poloxamers and 4-arm poloxamines have recently emerged as potent biological 
response modifiers capable of interacting with cellular pathways in order to address 
several intracellular barriers to nonviral gene delivery. In particular, poloxamines are 
attractive candidates for scaffold incorporation due to the tetrafunctional structure of the 
copolymer. While the activity and mechanism of poloxamers in nonviral gene delivery 
with polymer gene carriers is relatively well understood, the use of poloxamines in 
polymer- or lipid-mediated gene delivery has not been studied.  
In this dissertation, the activity and mechanism of one poloxamine formulation, 
Tetronic T904, in polyplex transfection was thoroughly investigated. We found that like 
poloxamers, T904 had the ability to significantly enhance the expression of transgene. 
However, T904 was not limited by the promoter design of the vector and its application 
extended to lipid-based transfection as well. It also differed mechanistically from 
poloxamers, having no effect on vector internalization in the cell or nuclear import. 
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Instead, T904 enhanced transgene expression by significantly increasing the production 
of transgene mRNA transcripts. Having validated the efficacy of Tetronics in nonviral 
gene delivery, a hybrid hydrogel was developed incorporating the cell adhesive 
properties of fibrin with T904 to provide scaffold-mediated nonviral gene delivery. The 
resulting hybrid hydrogel maintained the enzymatic degradability of fibrin and allowed 
the controlled release of incorporated DNA and polymer/DNA complexes. T904/fibrin 
hydrogels containing polymer/DNA complexes were able to transfect clusters of cells 
seeded in 3D with transgene expression detected for up to one month. Hybrid hydrogels 
implanted in a cutaneous wound model maintained the bioactivity of incorporated 
polymer/DNA complexes and facilitated the migration of cells and expression of 
transgene in vivo. 
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CHAPTER 1 
INTRODUCTION 
1.1 Regenerative Medicine and Tissue Engineering 
Regenerative medicine can be defined as a set of therapeutic technologies and 
strategies aimed toward achieving the complete restoration of lost functionality and/or 
structural integrity of diseased or injured tissues and organs. In instances where organ 
transplantation or tissue replacement may be difficult to achieve due to issues with 
availability or compatibility, regenerative medicine represents an alternative approach to 
realize therapeutic recovery. Tissue engineering represents one of the key strategies 
involved in regenerative medicine and can be divided into three primary areas of 
interest: the bolus delivery of soluble signaling molecules or cells, the transplantation of 
cells in scaffolds, and the scaffold-based delivery of small molecule drugs, proteins, and 
genes. The ultimate goal of tissue engineering is the functional recovery of damaged 
tissue through the stimulation of endogenous regenerative pathway controlled by a 
group of regulatory proteins and cell signaling molecules [1]. Cell transplantation 
addresses the lack of endogenous regenerative signaling molecules by introducing 
healthy or modified cell colonies capable of secreting biomolecules critical to tissue 
regeneration. Like cell-based therapy, the direct delivery of small biomolecules seeks to 
increase the availability of molecular cues for regeneration. Cells or proteins may be 
incorporated into biomaterial scaffolds that provide a foundation in which new tissue 
formation or ECM deposition may occur to replace damaged or missing native tissue. 
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The present work focuses on inductive tissue engineering, defined as the presentation of 
exogenous molecular cues to induce activity in local, endogenous cells 
The molecular cues involved in signaling the regeneration of tissue consist of a 
diverse group of biomacromolecules including but not limited to: growth factors, 
morphogens, mitogens, ECM proteins, proteoglycans, and cell surface receptors [2]. The 
availability of these signaling molecules during critical therapeutic time points represents 
a significant challenge in the rational design of tissue engineering scaffolds capable of 
stimulating regeneration. Among the myriad of biomolecules involved in tissue 
regeneration, growth factors have been identified as the most critical family of proteins 
involved in signal transduction pathways, transcription factor instructions, and protein 
regulation [1]. In general, the primary challenge in the delivery of protein and other small 
molecule drugs is in the transport of the molecule to the target tissue and/or organ. 
Unlike hormones that act on the endocrine system and may experience some degree of 
success when delivered systemically, growth factors act locally and necessitate short 
range diffusion toward target cells in order to achieve a therapeutic response.  
While the benefits of protein-based therapeutics such as growth factor delivery 
are numerous, care must be taken to regulate dosage and identify non-specific 
interactions that may lead to deleterious side-effects. For example, vascular endothelial 
growth factor (VEGF) is considered a powerful tool for angiogenesis and 
lymphangiogenesis in many wound healing applications [3]. The availability of VEGF is 
critical to the restoration of blood supply in ischemic tissue and for accelerating re-
endothelialization in vascular grafts or injured arteries [4]. However, dosage must be 
carefully regulated as an excess amount of VEGF can cause severe complications such 
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as vascular tumor formation [5] and hypertension [6]. Enhanced lymphangiogenesis as a 
result of VEGF activity can lead directly to tumor growth and lymphatic metastasis [7,8]. 
Aberrant expression of specific angiogenic growth factors like FGF with mitogenic 
activity can enhance the malignant progression of tumors [9,10]. Furthermore, the 
activity of the FGF signaling pathway and FGF receptor are present in a vast majority of 
human tumor cell lines. The above evidence suggests that the concentration and 
delivery of angiogenic growth factors for wound healing must be regulated carefully in 
order to avoid the devastating potential for malignant tumorigenesis. Tissue engineering 
and more specifically, scaffold-based delivery of small biomolecules offers a convenient 
mechanism for controlling the delivery of growth factors by acting as a reservoir that can 
be implanted or injected to provide localized, controlled release of growth factors. 
The general goal of an inductive biomaterial scaffold is to provide an implantable 
three-dimensional environment in which cell-based [11] or acellular [12] therapies can be 
used for regenerative medicine. Toward this end, significant efforts have been made to 
create scaffolds composed of a wide variety of natural and synthetic polymers that mimic 
the native extracellular environment [13–16]. Growth factors can be incorporated into 
biomaterials scaffolds in two ways: surface immobilization through crosslink mechanisms 
or bulk encapsulation. Surface immobilization allows careful control of the availability 
and presentation of molecular cues facilitated by cell invasion and migration into the 
scaffold. It avoids problems with loading efficiency and the initial loss of loosely 
incorporated therapeutic molecules due to uncontrolled burst release. Zisch et al. 
created polyethylene glycol (PEG) scaffolds with VEGF121-Cys grafted via Michael-type 
addition [17]. VEGF-conjugated scaffolds supported three-dimensional endothelial cell 
migration in vitro and formed vascularized tissue within the scaffold matrix in vivo. On 
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the other hand, bulk encapsulation allows diffusible growth factors to mediate cell activity 
outside the bounds of the scaffold itself as cell invasion is not required. Kanczler et al. 
explored the bulk encapsulation of VEGF165 into porous biodegradable poly(DL-lactic) 
acid (PLA) scaffolds generated by supercritical carbon dioxide for angiogenesis [18]. The 
resulting VEGF-incorporated matrix stimulated the formation of new blood vessel 
networks in an ex vivo chick chorioallantoic membrane (CAM) model. The PLA scaffold 
was able to sequester and maintain high amounts of bioactive VEGF over the course of 
21 days during which the rate of VEGF release was roughly linear. De la Riva and 
coworkers were able to control the burst release of scaffold-encapsulated VEGF by first 
encapsulating VEGF inside alginate microspheres and subsequently incorporating the 
microspheres into chitosan-alginate composite matrices [19]. The burst release of 
encapsulated VEGF was limited to only 13% of total scaffold-incorporated growth factor 
in the first 24 h and steady, linearized release was observed over the course of 5 weeks. 
VEGF released from composite matrices implanted in rat femurs remained localized 
adjacent to the implantation site with negligible systemic exposure. 
While the delivery of growth factors and recombinant proteins in general has 
gained traction as viable methods for tissue engineering and regenerative medicine, 
several key challenges still exist. The resistance of proteins against serum proteases 
and clearance mechanisms in the body can hinder their distribution and availability due 
to significant reductions in plasma half-life [20]. Post-translational modifications such as 
glycosylation are often necessary to ensure the activity of the protein in target cell types 
[21]. In addition, the stability, conformation, and purity of the protein following synthesis 
and large-scale manufacturing in host cells represent significant barriers to the 
successful production of protein therapeutics [22]. Finally, the substantial cost of 
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recombinant proteins inhibits their widespread use due to the inefficient allocation of 
financial resources in health-care. 
1.2 Gene Delivery 
Gene delivery has emerged as an attractive alternative to the delivery of growth 
factors for tissue engineering. Instead of relying on the growth factor to remain stable 
after injection or implantation in a scaffold, gene delivery harnesses the ability for 
endogenous cells to produce the necessary growth factors themselves by introducing a 
transgene capable of inducing protein production. The delivery of exogenous genes was 
initially conceived as a treatment for hereditary diseases and genetic disorders [23,24], 
but has since expanded toward the treatment of a broad range of acquired diseases 
such as cancer [25], cardiovascular disease [26], neurological disease [27], and immune 
disorders [28]; as well as repair of traumatic injury through tissue regeneration [29] and 
augmented wound healing [30]. In tissue engineering, gene delivery can potentially 
overcome the challenges associated with the exogenous delivery of therapeutic growth 
factors by sidestepping concerns associated with protein stability, in vivo half-life, and 
the incompatibility of some recombinant proteins [31]. Instead, transgene packaged into 
nano-scale vectors will provide the necessary genetic material required for native cells 
located at the target therapeutic site to produce proteins critical to tissue regeneration. 
Gene therapy models employ either recombinant viruses or synthetic non-viral 
polymers and lipids to deliver genetic material. Viral vectors represent the dominant 
vector type in clinical trials due to their innate ability to survive the extracellular 
environment and hijack intracellular transport mechanisms to efficiently deliver their 
genomic payloads to the nucleus or cytosol. Various types and designs of viral vectors 
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including retrovirus, adenovirus, the herpes simplex virus, lentivirus, and the vaccinia 
virus have been the subject of extensive review [32–34]. They are capable of highly 
efficient permanent expression of transgene, but drawbacks including oncogenic 
potential, insertional mutagenesis, packaging capacity, helper-virus contamination, and 
neurotoxicity hinder their application in many diseases. Despite the significant safety 
related drawbacks of viral vectors, a vast majority of existing clinical trials in gene 
therapy involve the delivery of viral vectors [35]. Even with the high efficiency of viral 
vectors displayed in both cell culture and animal models, as of 2013 the FDA Center for 
Biologics Evaluation and Research (CBER) has yet to approve a single human gene 
therapy product 
(http://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/default.htm). 
On the other hand, the current generation of non-viral vectors is characterized by their 
ease of production and preparation, but in general lack efficient gene transfer [36]. 
Therefore, the impetus lies with the development of safe non-viral vectors that are not 
only non-immunogenic and relatively inexpensive to produce, but also replicate the high 
efficiency of their viral counterparts. 
The most basic form of nonviral delivery is the local or systemic injection of 
naked plasmid DNA derived from bacterial culture containing transgene. When delivered 
systemically, nucleic acids are highly vulnerable to a variety of physical and chemical 
factors that may affect their bioavailability. Endogenous nucleases may readily degrade 
naked DNA, drastically reducing the half-life of transgenes in circulation. In 
circumstances where chemical modification or physical approaches may be insufficient 
for the successful protection of polynucleotides, packaging with nonviral vectors provides 
an additional means to stabilize vulnerable nucleic acids during circulation. Nonviral 
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vectors are primarily derived from natural or synthetic materials designed to package 
nucleic acids into nano- and micro-scale size particles for the evasion of clearance 
mechanisms during circulation and efficient endocytosis into target cells [37]. These 
vectors are primarily composed of a group of cationic lipids and polymers capable of 
non-specific electrostatic interactions with negatively charged nucleic acids. The vector 
condenses DNA into sizes amenable to cell entry, enabling the transfer of exogenous 
genetic material to the inside of the cell. Due to the transient nature of gene expression 
following nonviral transfection and the poor efficiency of most nonviral vectors, 
significant efforts have been made toward the development of novel vectors capable of 
addressing a series of extracellular and intracellular barriers associated with nonviral 
gene delivery. 
Like other fields with substantial variability in in vitro experimental design, the 
translation of nonviral gene delivery from the bench to the clinical setting represents a 
significant challenge for a large number of nonviral transfection systems. Over the last 
three decades, an extensive number of nonviral transfection reagents, vectors, and 
methodologies have been developed [38]. While our understanding and breadth of 
knowledge in nonviral vector design has expanded greatly, the comparative value 
between individual reagents has been difficult to quantify and at times outright 
contradictory [39]. As a result, the variation in conditions used for the primary starting 
point in nonviral vector design, in vitro transfection, represents one of the most difficult to 
control aspects in the development of consistent transfection reagents. This has led to 
the inability for nonviral vectors to be compared directly with each other and hinders the 
translation of nonviral vectors due to the presence of singular experiments or studies 
that may discredit certain types or lines of vector design. Furthermore, in vitro 
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transfection screenings correlate poorly with in vivo results [39]. Therefore, significant 
attention has focused on addressing a myriad of mechanisms related to the efficiency of 
nonviral vectors. Ideally, addressing these extracellular and intracellular barriers to 
nonviral transfection may help identify key factors in rational vector design.  
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1.3 Types of Nonviral Vectors 
1.3.1 Cationic Lipids 
 
Figure 1.1. Structures of some cationic lipids commonly used in gene therapy. [40] 
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Cationic lipid-DNA complexes (lipoplexes) represent the most popular vector for 
nonviral vector delivery due to their high transfection efficiency in vitro. While there exists 
significant variability in lipoplex design, most cationic lipids contain three main structural 
groups: the cationic head group, the hydrophobic tail domain, and the linker structure 
that connects the head and the tail [41]. Figure 1.1 shows the structures of some cationic 
lipids commonly used in gene therapy. The primary function of the cationic head group is 
condensation of nucleic acids through electrostatic interactions leading to the creation of 
positively charged nanoparticles capable of cellular uptake and endosomal escape. The 
head group usually consists of monoamines, although some groups have investigated 
replacing the ammonium group with different monovalent cationic moieties to varying 
degrees of success [42]. Modifying the existing amine moiety can also improve 
transfection efficiency. Bennett et al. observed that the in vivo transfection activity of 
cationic lipids may be directly related to the hydration potential of the cationic head 
group [43]. Decreasing the hydration potential of the head group decreases the stability 
of the lipoplex and enhances its fusogenic properties.  
The hydrophobic tail of the lipid consists of aliphatic hydrocarbon chains or 
steroids such as cholesterol. Its primary functions are in the formation of the lipoplex and 
cell membrane fusion/exchange for uptake [44]. The transfection efficiency of the 
lipoplex can be increased by modifying the length and type of aliphatic chain used in the 
tail [45]. Transgene expression generally increases with decreasing chain length with 
some exceptions and cationic lipids with more than one or two hydrophobic chains can 
cause unwanted cytotoxicity or reduced transfection efficiency [46]. All cationic lipids 
used in nonviral transfection require a linker group between the cationic head group and 
the hydrophobic tail. The identity of the linker group has a significant impact on the 
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stability, biodegradability, and transfection efficiency of the lipoplex [47]. Common 
biodegradable linkers include ethers, esters, amides, and carbamates. Ethers exhibit 
superior stability while esters are readily cleaved inside cells to promote DNA release 
[38]. Carbamates retain qualities of both ethers and esters, providing relative 
extracellular stability while remaining capable of intracellular cleavage. 
1.3.2 Cationic Polymers 
 
Figure 1.2. The structures of some cationic polymers commonly used in gene therapy 
[48]. 
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Similar to cationic lipids, cationic polymers form stable complexes with nucleic 
acids (polyplexes) through electrostatic interactions with negatively charged phosphate 
groups on DNA/RNA. The positively charged polyplex facilitates cell uptake and 
endosomal escape via the proton sponge effect where the protonation of polymer 
amines results in an influx of counter-ions from the cytoplasm, leading to the endosome 
bursting as a result of swelling caused by lower internal osmotic pressure [49]. Typical 
polymers used for gene transfer include branched and linear polyethylenimine, chitosan, 
cyclodextrin, poly(amino acid), poly-L-lysine, and dendrimers. Figure 1.2 shows the 
structures of some cationic polymers commonly used in gene therapy. The ability to 
substitute various functional groups to polymeric gene carriers for cell-targeting and 
other utilities has become a major area of focus for the development of novel nonviral 
vectors with a host of specialized functions. 
Polyethylenimine (PEI) represents the most widely used synthetic vector for 
nonviral gene delivery. First used nearly two decades ago for in vivo transgene 
expression in the adult mammalian brain [50], PEI has since been established as one of 
the most capable cationic polymers for both in vitro and in vivo transfection. Despite an 
abundance of evidence showing high in vitro efficacy of PEI and its derivatives in vitro, 
the efficiency of PEI-based vectors in a wide variety of in vivo applications remain their 
most glaring weakness [51]. PEI can be found in both branched and linear confirmations 
and is available in a variety of commercial products such as ExGen 500® and jetPEI® of 
varying molecular weights (5-25 kDa). Its popularity is primarily a result of the proton 
sponge effect, allowing PEI-based polyplexes to easily escape endosomes following cell 
uptake [52]. In general, high MW PEI has shown better transfection efficiency in cell 
culture, but suffers from cytotoxicity due to necrosis induced by the aggregation of 
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polyplex on the cell surface [53]. The toxicity of PEI can be addressed through 
hydrophilic substitution to mitigate polyplex aggregation in serum. Complexes are 
formed between PEI and DNA as a result of electrostatic interaction between the 
primary, secondary, and tertiary amines of PEI with negatively charged phosphates of 
nucleic acids. More than 90% of the charge groups of DNA must be neutralized for 
successful condensation and complex formation [51]. Polymer nitrogen to DNA 
phosphate ratio (N/P ratio) of approximately 2-3 depending on the specific PEI 
formulation may be required for complete DNA condensation [54]. The condensation of 
DNA by cationic polymers leads to the creation of nanoscale polyplexes amenable to 
both cell uptake and evasion of the reticuloendothelial system. In general, increasing 
N/P ratio improves the transfection efficiency of the vector, although additional PEI 
beyond the N/P ratios required to completely condense DNA remains uncomplexed. 
Some studies suggest that excess free PEI may enhance cell uptake due to known 
interactions with anionic cell-surface glycosaminoglycans [55]. However, high levels of 
uncomplexed PEI can cause unwanted cytotoxicity despite reductions in polyplex 
aggregation as a result of electrostatic repulsion. 
1.4 Extracellular Barriers to Nonviral Vector Delivery 
 The rational design of nonviral vectors to improve transfection efficiency 
necessitates the identification of the key bottlenecks in the biological pathways involved 
in nonviral transfection. These pathways involve several extracellular and intracellular 
barriers to nonviral vector delivery that must be addressed in order to improve the 
transfection efficiency of nonviral vectors. Prior to trafficking to their intended therapeutic 
sites, systemically injected nonviral vectors must overcome a series of extracellular 
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barriers including serum aggregation, degradation by circulatory nucleases, and 
clearance by the reticluoendothelial system. In the event that vectors do reach their 
target cell populations, a further series of intracellular barriers and events shown in 
Figure 1.3 must be navigated in order to realize the production of therapeutic proteins.  
 
Figure 1.3. Intracellular barriers to nonviral vector delivery. After navigating to target cell 
populations, vectors must enter the cell through endocytosis or membrane disruption, 
escape from endosomes, traffic to the nucleus, and cross the nuclear membrane to 
undergo transcription [56]. 
 
 
 15 
 
1.4.1 Serum Aggregation 
One formidable barrier to the delivery of nonviral vectors is aggregation of 
nanoparticulate vector/plasmid complexes during circulation as a result of nonspecific 
interactions between vectors and negatively charged plasma proteins. Lipoplexes and 
polyplexes are susceptible to aggregation in the presence of salt or serum proteins [44]. 
Increasing the ionic strength or positive zeta potential of cationic vectors induces further 
aggregation, especially in the presence of phosphate or succinate salts. Aggregation 
may lead to precipitation of the vector and ultimately lead to inhibition of endocytosis.  
Careful balance must be maintained between the charge density of the vector 
and unwanted serum aggregation resulting from increasing positive charge. For both in 
vitro and in vivo transfection, an excess of vector relative to plasmid is generally 
associated with increasing transfection efficiency, likely due to enhanced association 
between cationic lipids and target cell membranes [44] and enhanced proton sponge 
effect with cationic polymers [53]. However, aggressive increases in vector concentration 
resulting in high positive surface charge can cause significant toxicity and accumulation 
in off-target sites following systemic administration [57].  
One key strategy to combating serum aggregation is the coupling of cationic 
vectors with hydrophilic molecules like poly(ethylene glycol) (PEG). In the case of 
lipoplexes, PEGylation provides several key benefits versus the lipoplex alone. The 
conjugation of PEG moieties or simply the addition of PEG in lipoplex transfection 
solution may provide significant benefit toward avoidance of clearance mechanisms in 
vivo and provide enhanced transfection efficiency in vitro. Ambegia et al. found that 
association of lipid/plasmid nanoparticulate vectors with diffusible PEG coatings 
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attached to a lipid anchor significantly enhanced the pharmacokinetics of the resulting 
stabilized lipoplex [58]. PEG-containing lipoplexes were accumulated in target tumor 
tissues 100- to 1000-fold greater than in other tissues. Similarly, Yu et al. found that the 
addition of PEG to sterically stabilized immunoplex significantly enhanced the delivery of 
lipoplexes to target tumor cells [59]. The incorporation of PEG into the targeted lipoplex 
system inhibited clearance observed with non-PEG containing liposomes, significantly 
improving the outcome of systemically delivered liposomal gene vectors. One of the key 
limiting steps to lipoplex-mediated transfection is the association between lipoplexes and 
cell membranes, leading to the internalization of the lipoplex and eventual delivery of 
transgene. The simple addition of PEG to transfection medium can substantially 
enhance transgene in vitro by increasing lipid-membrane interactions and increasing 
lipoplex-cell association [60]. The presence of PEG resulted in both increased cell 
association as well as uptake of lipoplex and the expression of transgene. In addition to 
addressing limiting steps in the delivery of lipoplexes and improving transfection 
efficiency, PEG conjugation allows the coupling of novel environmentally responsive 
elements to the lipoplex. For example, Masson et al. demonstrated that pH-sensitive 
PEG moieties can be coupled to lipids to create pH-sensitive PEG stabilized lipoplexes 
capable of dissociation and delivery of their genetic payload in the mild acidic 
environment common to solid tumors, inflammatory tissue, and intracellular endosomal 
compartments while providing colloidal stability at neutral pH [61]. 
The PEGylation of polyplexes addresses some of the same issues associated 
with lipoplex delivery by providing additional stability during circulation and added 
functionality to improve targeting or transfection efficiency [48]. The presence of the PEG 
moiety is capable of steric stabilization, reducing serum aggregation, and improving 
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polyplex solubility. Conjugation of PEG to poly-L-Lysine (PLL)/pDNA complexes has 
been shown to improve steric stability, resulting in neutral charge ratio polyplexes with 
surfaces shielded from serum aggregation [31]. Minimal amounts of PEG were required 
to neutralize surface charge, prevent polyplex aggregation, and improve polyplex 
stability in physiological saline compared to PLL alone although in vivo circulation half-
life was not significantly altered. However, increasing PEG concentration resulted in 
tangible benefits in circulation times and even in vivo gene expression. Similar 
observations were made by Verbaan et al. using sterically stabilized PEG grafted poly(2-
(dimethylamino)ethyl methacrylate)-based polyplexes [62]. PEGylation of preformed 
complexes resulted in graft polyplexes that showed minimal interaction with blood 
components such as albumin and erythrocytes with prolonged circulation time in mice 
following intravenous injection with improved tumor accumulation. While both 
PEGylation prior to polyplex formation as well as PEGylation of preformed polyplexes 
were examined, the latter displayed superior properties for systemic delivery.  
In general, high molecular weight PEI/pDNA polyplexes exhibit superior 
transfection efficiency in vitro due to higher charge ratios, but suffer from high 
cytotoxicity both in vitro and in vivo [63]. While PEI has demonstrated high efficiency 
relative to other polycations for nonviral transfection, it also presents with high 
cytotoxicity when used in concentrations necessary for therapeutic delivery [64]. PEG-g-
PEI copolymers provide a potential method to reduce the in vivo cytotoxicity of PEI-
based vectors. Neu and coworkers were able to substantially reduce the cytotoxicity of 
branched 25 kDa PEI by creating conjugating one or two 20 kDa or 30 kDa PEG chains 
to PEI [65]. The resulting graft copolymer maintained the ability to efficiently condense 
pDNA while significantly increasing intravenous circulation time following injection into 
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mice and improving transfection efficiency 10-fold. Blood levels of plasmid using 
PEGylated PEI/pDNA were also improved 125% compared to PEI/pDNA alone. 
While evidence suggests a low degree of PEGylation may resolve stability issues 
associated with a number of polyplexes, a high degree of PEG substitution may also 
inhibit association between polyplexes and cell membrane, reducing transfection 
efficiency [66]. In the case of PEI molecules with high degrees of PEG substitution, steric 
hindrance as a result of the presence of PEG provides superior protection against serum 
aggregation, but impedes internalization of polyplexes into cells. As a result, increased 
N/P ratios may be required to improve the delivery of plasmids from highly modified 
PEG-PEI polyplexes, resulting in increased cytotoxicity. Increasing degree of PEG 
substitution also inhibits polycation condensation of pDNA, resulting in substantially 
reduced transgene expression [67]. In the same study, it was found that copolymers with 
a low degree of substitution by high molecular weight PEG (20 kDa) resulted in low 
transfection efficiency and low cytotoxicity while substitution with low molecular weight 
PEG (550 Da) resulted in high transfection efficiency in vitro, high surface charge, and 
decreased protection against polyplex aggregation. Therefore, care must be taken to 
ensure retention of vector activity following hydrophilic modification to prolong circulatory 
half-life. 
1.4.2 Circulatory Nucleases 
Beyond serum aggregation, several other factors contribute to the necessity of 
deliberate vector design to maximize the effectiveness of systemically delivered nonviral 
vectors. Condensation of plasmid by nonviral vectors significantly reduces the negative 
impact of serum nucleases on plasmid stability by sterically hindering nuclease cleavage 
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of vulnerable nucleic acids. In the absence of vector, systemically delivered naked 
plasmid are rapidly degraded and subject to urinary secretion [68]. Cui et al. 
demonstrated that entrapment of pDNA in nanoparticles provided protection against 
serum nucleases whereas absence of the vector lead to in complete digestion of the 
plasmid [69]. As a result, the bioavailability and circulation half-life of the complex were 
significantly improved over naked plasmid. Itaka et al. showed that entrapment of DNA 
within polyion complexes composed of PEG-PLL block copolymers significantly reduced 
the susceptibility of the nucleic acid to dissociation following exposure to serum-
containing medium [70]. High ratios of PLL to PEG resulted in increased bioavailability 
and stability of pDNA in blood. Lipid-plasmid systems are also capable of negating the 
effects of enzymatic digestion on nucleic acids. PEG coated 
dioleoylphosphatidylethanolamine mediated lipoplexes were capable of both particle 
stabilization as well as protection of DNA from DNase I and serum nucleases [71]. 
1.4.3 First-pass Organ Accumulation 
The liver presents a significant physical barrier to the systemic delivery of 
nonviral vectors [72]. The two primary modes of hepatic clearance are nonspecific 
uptake and Kupffer cell mediated phagocytosis, both of which contribute to the rapid 
elimination of systemically administered pDNA. When injected alone, plasmids and even 
some polyplexes and lipoplexes are taken up by the liver nonparenchymal cells [73]. 
Liver endothelial cells were thought to be a major contributor to vector clearance as 
gadolinium chloride induced Kupffer cell blockage had no effect on hepatic uptake. 
Kircheis et al. found that even with transferrin-mediated polyplex targeting, a substantial 
fraction of systemically administered PEI-based polyplexes accumulated in the liver and 
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were removed from circulation by Kupffer cells [74]. Labeled DNA molecules were 
largely identified in single cells scattered throughout the liver with no apparent 
association between endothelial cells and polyplexes. Despite significant DNA uptake by 
Kupffer cells, transgene expression in the liver was minimal. Like Kupffer cells in the 
liver, mononuclear phagocytic cells that reside in the spleen are members of the reticulo 
endothelial stem (RES) and are capable of eliminating circulatory nonviral vectors [75]. 
The spleen is heavily involved in the immune response against intravenously injected 
nonviral vectors. In particular, the systemic delivery of lipoplexes has been shown to 
induce significant proinflammatory cytokine production in blood that inhibits transgene 
expression [76]. Treatment of mice with gadolinium chloride was shown to substantially 
reduce the production of proinflammatory cytokines such as TNA-α, IFN-γ, and IL-12. 
The reduction in the serum concentration of these cytokines resulted in reduced liver 
accumulation of lipoplexes and increased bioavailability of the transgene. 
The accumulation of polyplexes and lipoplexes in the lung also presents a 
significant barrier to systemic delivery [77]. The lung sequesters the vector due to the 
sieve effect of pulmonary capillaries [57]. The initial biodistribution of systemically 
administered vector within the lungs may be as high as 80-90% of the dose and likely 
caused by polyplex aggregation due to interaction with plasma proteins. However, 
subsequent filtration reduces the concentration of vector within the lungs and secondary 
redistribution directs remaining vectors toward the liver [78], but not before the high level 
of polycations within the lung significantly reduces the viability of endogenous cells and 
threatens the survival of the animal subject. 
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1.5 Intracellular Barriers to Nonviral Gene Delivery 
1.5.1 Intracellular Transport and Endocytosis 
After navigating the formidable extracellular barriers to nonviral vector delivery, 
complexed nucleic acids must then offload their genetic payload into the cytoplasm and 
ultimately the cell nucleus in order to induce transgene expression. In the absence of 
cationic vectors or nanoparticles designed to infiltrate the cell membrane, physical 
perturbation of the plasma membrane by electroporation, sonoporation, gene gun, or 
microinjection have been used to deliver plasmids directly to the cytoplasm [79]. 
However, physical disruption of the plasma membrane to facilitate plasmid entry is 
limited in clinical use due to its invasive nature, potential to damage target cells, and 
relative difficulty in accessing deeper tissues. Nonviral vectors overcome these 
challenges by interfacing with the plasma membrane and initiating endocytosis. It is 
generally accepted that the interaction of cationic vectors with cell membrane during in 
vitro transfection relies on nonspecific electrostatic interactions between the vector and 
the cell membrane [80]. In addition, evidence suggests that heparin sulfate 
proteoglycans may also play a critical role in the binding of cationic liposomes and 
polymers to the cell membrane [81]. Removal or inhibition of cell surface 
glycosaminoglycans resulted in substantial decreases in transgene expression by both 
lipoplexes and polyplexes.  
The two primary pathways involved in the uptake of nonviral vector are clathrin- 
and caveolae-mediated endocytosis [82]. Rejman et al. found that lipoplexes and 
polyplexes behaved differently and likely follow separates routes for cell internalization 
[83]. Lipoplex internalization was completely blocked following administration of 
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chlorpromazine and potassium ions, inhibitors of clathrin-mediated endocytosis. In 
contrast, polyplex internalization was prevented by both the inhibitors of clathrin-
mediated uptake as well as inhibitors of caveolae-mediated uptake, filipin and genistein. 
While both caveolae- and clathrin-mediated endocytosis were involved in the 
internalization of polyplex, only internalization by caveolae led to transfection. Polyplex 
internalized by clathrin-mediated endocytosis targeted to the lysosomal compartment 
where vector and transgene were eventually degraded. 
Several cell penetrating peptides (CPPs) capable of mediating protein 
transduction across the cell membrane have been identified for improving vector 
internalization. CPPs designed to form stable complexes with drug and gene carriers are 
capable of efficiently delivering their cargo in a large variety of applications [84]. Their 
activity is independent of normal endocytotic mechanisms, making CPPs an attractive 
solution for situations where reliance on endocytosis may be insufficient for the 
successful delivery of transgene. They consist of short peptide sequences capable of 
energy-independent transport across the plasma membrane [85]. Both the direct 
application of positively charged CPPs as nucleic acid carriers as well as conjugation to 
existing cationic vectors have been explored for the delivery of oligonucleotides and 
plasmids. Among the various CPP considered for gene deliver, perhaps the most well 
understood is the Tat peptide, derived from the transactivator of transcription of the 
human immunodeficiency virus [86]. The Tat peptide is capable of both direct 
association with plasmids [87] for transfection and as a targeting moiety when 
conjugated to existing polyplex vectors [88]. In general, Tat-conjugated polyplexes 
display high transfection efficiency in vitro relative to their unmodified polyplex 
counterparts. However, while cationic Tat/pDNA with no additional polyplex mitigates 
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some cytotoxicity concerns of polyplex vectors, their overall transfection efficiency is still 
quite low.  
1.5.2 Endosomal Escape 
The next step in transfection following internalization for a vast majority of 
lipoplex and polyplex vectors is endosomal escape. For cationic liposomes, this involves 
fusogenic activity between the lipoplex and the endosomal membrane, leading to the 
transfer of the vector from the inside of the lumen side of the endosome to the cytosolic 
side. The act of membrane exchange destabilizes the lipid, leading to the release of 
nucleic acid cargo from the liposome [89]. The flip-flop mechanism of endosomal 
membrane mediation by the lipoplex dictates that successful lipid-based vectors must 
maintain favorable fusogenic properties to establish high transfection efficiency as 
endosomal escape presents one of the most challenging barriers to effective transgene 
delivery. Helper lipids such as dioleoylphosphatidylethanolamine (DOPE) or cholesterol 
have been shown to significantly enhance the transfection efficiency of lipoplexes by 
disrupting the endosomal membrane and increasing the cytoplasmic bioavailability of 
nucleic acid cargo [90]. In conjunction with the cationic lipid, DOPE promotes the 
formation of non-bilayer lipid structures to promote HII phase organization. Partial or 
large-scale induction of the non-bilayer as a result of phase organization promotes DNA 
release into the cytoplasm. 
While polyplex vectors also require endosomal escape capabilities, the method 
by which they achieve endosomal membrane disruption is quite different from lipoplexes. 
PEI-based vectors and starburst polyamidoamine dendrimers are intrinsically capable of 
endosomalysis by taking advantage of the proton sponge effect [91]. As the polyplex 
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enters the endosome, protonation of primary, secondary, and tertiary amine groups on 
the polymer allows the vector to absorb protons [52]. The accumulation of protons leads 
to an influx of chloride counter-ions into the endosomal lumen, increasing osmotic 
pressure. As a result, water flows into the endosomal lumen and the endosomal 
membrane weakens from swelling, eventually rupturing and releasing the polyplexes 
inside. However, the proton sponge effect is only applicable to polymers with pKa around 
or slightly below physiological pH. In the case of polymers with buffering capacity at low 
pH, the disruptive effect of the proton sponge effect is minimal [92]. In circumstances 
where polyplexes are unable to take advantage of the proton sponge effect, membrane 
disruptive peptides can be used to break down the endosomal membrane. Some 
synthetic disruptive peptides mimic the fusogenic properties of viral peptide residues to 
destabilize the endosome [91]. For example, the hemagglutinin (HA2) short chain of N-
terminal amphiphilic anionic peptide residues can undergo conformational change with 
pH. At acidic pH within the endosomal compartment, the HA2 subunit transitions into a 
stable helical secondary structure due to protonation of glutamic and aspartic acids. This 
helical structure contains hydrophobic and hydrophilic faces that favor endosomal 
disruption. Many CPPs derived from viral transduction domains also have the ability to 
adopt α-helical structures similar to HA2 and provide endosomal escape functionality to 
naked peptide or polyplexes [93]. Melittin, a cationic endosomalytic peptide derived from 
bee sting venom demonstrated the capacity to substantially increase the transfection 
efficiency of PEI-based polyplexes without significantly affecting the viability of target 
cells [94]. Unconstrained polyplexes with melittin substitution were found in significantly 
higher quantities within the cytoplasm compared to unmodified polyplexes that were 
largely contained inside cytoplasmic vesicles. 
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1.5.3 Cytosolic Transport 
The movement of free nucleic acids or polyplexes after endosomal escape 
toward the nucleus presents yet another rate limiting step in nonviral transfection. 
Molecular crowding and nonspecific binding to cytoplasmic and nucleoplasmic proteins 
severely restricts the diffusion of DNA [95]. Dextran fragments were found to traffic much 
more readily toward the nucleus following microinjection into the cytoplasm of HeLa cells 
than DNA fragments of similar size. Therefore, consideration must be made to enhance 
the diffusive properties of DNA after endosomal escape in order to ensure the delivery of 
transgene to the appropriate intracellular locations. Furthermore, the highly cross-linked 
actin cytoskeleton restricts movement of DNA larger than 250 base pairs [96]. Since the 
average spacing of actin cytoskeletal filaments is estimated to be 100 nm, it would be 
expected that DNA fragments with 250 base pairs and linear lengths of approximately 85 
nm would be unable to navigate the cytoplasm due to steric hindrance. Therefore, the 
primary mechanism for DNA or polyplex trafficking likely involves active transport via the 
cytoskeleton. However, unlike viral vectors that take advantage of nuclear-directed 
dynein motors on microtubules, nonviral vectors are often trafficking away from the 
nucleus toward lysosomes [97].  
The intracellular transport of nonviral vectors can be enhanced in several 
different ways. Oba et al. demonstrated that substitution of polymeric micelles with RGD-
peptide directed localization of the vector toward lipid rafts and caveosomes instead of 
endosomes as a result of preferential internalization via caveolae-mediated endocytosis 
instead of clathrin-mediated uptake [98].  As a result, polymeric micelles with RGD 
trafficked much more readily toward the nucleus than polymeric micelles alone, 
 26 
 
culminating in significantly enhanced transfection efficiency. Barua and Rege treated 
cells with the histone deactylase 6 (HDA6) inhibitor tubacin, which acetylates the tubulin 
of microtubules in the cytoplasm and mitigates some of the restrictive properties of the 
cytoskeleton [99]. They were able to reduce sequestration of the polyplex at the 
perinuclear recycling compartment/microtubule organizing center and increase trafficking 
toward the nucleus, resulting in forty-fold increase in transgene expression compared to 
polyplex alone. In a separate study, nuclear and perinuclear accumulation of lipid-DNA 
complexes leading to enhanced transgene expression was achieved through 
microtubule disassembly induced by nocodazole [100]. Treatment with nocodazole lead 
to changes in microtubule-dependent vesicle formation by directing traffic away from 
lysosomes where lipid-DNA complexes would normally be degraded. 
1.5.4 Nuclear Import 
The most formidable barrier to DNA-mediated nonviral gene therapy is nuclear 
import. Several lines of evidence in the literature suggest nuclear translocation may be 
the rate-limiting step in plasmid delivery. Microinjection of pDNA into the nucleus results 
in significantly higher gene expression compared to cytoplasmic delivery [101]. 
Inefficient nuclear localization of plasmid results in high dosage requirements for nonviral 
vectors and unwanted cytotoxicity [102]. Perhaps the most significant line of evidence 
detailing the restrictive properties of the nuclear membrane is the difference in transgene 
expression between cells with high and low rates of proliferation. Fasbender et al. 
observed that cells in mitosis were much more likely to express transgene due to 
disruption of the nuclear membrane allowing diffusive access to the nucleus and cellular 
machinery for transcription [103]. A low rate of cell division caused 90% reduction in the 
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transfection efficiency of lipoplex mediated gene transfer to airway epithelium. Grosse et 
al. found that nuclear localization of PEI/pDNA complexes was largely dependent on 
passive import as a result of nuclear membrane permeability during mitosis [104]. The 
inability for nonviral vectors to efficiently traffic into the nucleus in non-mitotic cells must 
be addressed as a large number of in vivo therapeutic targets for gene therapy contain 
non-dividing cells. Therefore, addressing the biophysical barrier to nuclear transport 
caused by the nuclear membrane represents one of the most important strategies 
toward increasing the transfection efficiency of nonviral vectors. 
The nuclear envelope represents a physical barrier against macromolecules with 
molecular size greater than 40 kDa [105]. Transport is closely regulated by a series of 
specific proteins called nucleoporins that interact with the nuclear pore complex (NPC). 
Nucleoporins contain multiple discrete phenylalanine-glycine domains and repeat motifs 
that play an intimate role in nuclear translocation [105]. The exact mechanism of NPC-
assisted transport remains controversial with evidence suggesting both physical and 
chemical restrictions may a play role. The NPC physically impedes the diffusion of all but 
the smallest molecules while active transport requires receptor binding to nucleoporins. 
Transport receptors capable of recognition with nucleoporins and the NPC are critical to 
the identification and nuclear translocation of cargo. Among them, the family of 
importins/exportins/transportins and more specifically importin-β are involved in 
trafficking large molecule proteins across the nuclear membrane [106]. It is clear that the 
successful nuclear translocation of nonviral vectors may require binding to one or more 
molecules capable of interacting with the NPC and accessing active transport 
mechanisms. 
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Initiating interaction between the NPC and nonviral vectors necessitates careful 
consideration of the receptors involved in active nuclear translocation. This has led to 
the development of vectors incorporating nuclear localization sequences (NLSs) that are 
capable of binding importins and initiating transport across the nuclear membrane [107]. 
DNA-NLS conjugates have demonstrated efficacy in the delivery of transgene through 
binding with importin-α and importin-β [108]. Several different synthetic NLS peptides 
have demonstrated efficacy in vitro [109] and a majority of efforts in NLS conjugation 
involve the SV40 T Large antigen NLS-sequence, 
 126PKKKRKV132, derived from the 
Simian virus 40 (SV40). Conjugation of SV40 NLS peptides to both GFP and LacZ 
plasmids resulted in at least 5-fold increase in transfection efficiency [110]. The 
application of NLS toward polyplex or lipoplex delivery is somewhat more controversial. 
In at least one study, delivery of DNA-NLS with linear PEI had no effect on transfection 
efficiency [37]. In addition, cationic polymers such as PEI and PLL may mimic some 
functionality of NLS signaling peptides, eliminating the need for nuclear targeting. 
Furthermore, NLS sequences derived from viral coatings may also elicit unwanted 
immune response.  
Alternatively, plasmid DNA can initiate transport across the nuclear membrane 
via DNA targeting sequences (DTSs) specific capable of binding with transcription 
factors for NPC-mediated nuclear membrane translocation. Dean and coworkers 
observed that cytoplasmic injection of plasmids incorporating the SV40 early promoter 
resulted in nuclear localization of plasmid with colocalization with the SC-35 splicing 
complex antigen and intranuclear localization of DNA to areas of high transcriptional 
activity [111]. Inhibition of transcription blocked DNA import but not protein import, 
indicating a critical role of transcription factors in the sequence-specific nuclear 
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translocation of DNA. In a separate study, it was shown that 72-bp repeats of the SV40 
enhancer played a critical role in nuclear targeting of pDNA [112]. Plasmids with human 
cytomegalovirus (CMV) immediate-early promoter and Rous sarcoma virus LTR were 
unable to efficiently traffic to the nucleus of African green monkey kidney cells (TC7). 
However, modification of the CMV-promoter GFP plasmid with the SV40 enhancer and 
microinjection with as few as 3 to 10 copies of plasmid per cell led to transgene 
expression whereas no transfection was detected following microinjection with more 
than 1000 copies per cell of GFP plasmid containing no SV40 enhancer sequences. 
Nuclear import was also inhibited by the addition of antibodies against nucleoporins, 
suggesting that the SV40 DNA-targeting abilities were at least partially reliant on the 
activity of nucleoporins and the NPC. DTS like the SV40 enhancer rely on the activity of 
general transcription factors present in the cytoplasm [56]. These transcription factors 
(AP1, NF-κB, EF1, etc.) contain NLS and are capable of binding to DTSs and assisting 
nuclear import through importin associated NPC translocation. While some viral 
promoters such as CMV contain multiple transcription factor binding sites, the absence 
of DTS abilities is likely due to the unfavorable conformation of transcription factors 
bound to certain potential DTS sequences. For example, while the GAL4 transcription 
factor is capable of binding to both plasmid DNA and importin-α separately, its physical 
structure does not allow binding to both at the same time [113]. Relying on DTS over 
synthetic NLS peptides appears to add unnecessary steps to the nuclear import 
pathway, but using DTS avoids concerns with immune and inflammatory responses 
caused by virally derived NLS peptides.  
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1.5.5 Intranuclear Events 
Recently, efforts have been made to identify key events after nuclear import that 
may contribute to the efficacy of nonviral vectors. Unlike readily identifiable intracellular 
pathways outside the nucleus, the fate of pDNA in the intranuclear environment and the 
impact of intranuclear localization on transfection efficiency remain difficult to discern. As 
previously mentioned, certain plasmids may require as little as 3 copies within the 
nucleus to initiate transgene expression [112]. However, in some cases the amount of 
plasmid copies per nucleus necessary for detectable levels of expression may number in 
the thousands [114]. The disparity in plasmid copy threshold may be due to a number of 
factors that occur after nuclear import including intranuclear localization to areas of high 
transcription, activation of transcription factors, and translational efficiency. Certain cell 
types may also be more amenable to the expression of transgene. 
Hama et al. illustrated the importance of intranuclear transcription by comparing 
the events leading to transgene expression using adenovirus and Lipofectamine Plus 
[115]. The lipoplex displayed significantly higher cell uptake than adenovirus, 
comparable endosomal escape, and slightly reduced nuclear import. However, the 
lipoplex required 3 orders of magnitude more intranuclear gene copies compared to the 
adenovirus in order to achieve similar levels of transgene expression. Unlike lipoplex 
vectors that release their genetic cargo after endosomal escape, polyplex vectors often 
traffic into the nucleus still complexed [116]. In polyplex transfection, the decondensation 
of DNA following nuclear entry presents a further rate-limiting step in transgene 
expression. Akita et al. observed that intranuclear transcription was inhibited by using an 
SV40 NLS sequence modified on the μ-peptide for strong condensation of pDNA [117]. 
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While the μ-peptide conjugated pDNA displayed significantly stronger nuclear import 
mechanism than PLL, transgene expression measured following nuclear microinjection 
was poor using the modified vector compared to PLL. Hsu et al. observed following 
polyplex transfection that cells displaying high pDNA nuclear localization did not always 
express GFP [118]. Decondensation of polyplex following nuclear entry played a vital 
role in transgene expression as competitive interaction between dissociated polyplex 
and endogenous genetic material such as newly transcribed mRNA likely inhibited 
translation. Therefore, efficient decondensation mechanisms may lead to high gene 
expression. Yamada and coworkers were able to achieve high transfection efficiency by 
integrating a multifunctional envelope-type nano device with a biocleavable polyrotaxane 
to condense plasmid [119]. The combination synthetic vector was able to readily 
dissociate upon nuclear import following disulfide cleavage, initiating high levels of 
transgene expression. Altogether, these studies demonstrate that as the design of 
nonviral vectors matures, efforts in bridging the gap between nonviral and viral 
transfection must include consideration for the discrepancy in intranuclear transcriptional 
efficiency between the two vector types. 
1.6 Amphiphilic Block Copolymers 
 
Figure 1.4. General structure of poloxamers [120]. 
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Figure 1.5. General structure of poloxamines [121]. 
Triblock poloxamers (Pluronics®/Lutrol®) and 4-arm poloxamines (Tetronics®) 
belong to a family of amphiphilic block copolymers that contain hydrophilic polyethylene 
oxide (PEO) and hydrophobic polypropylene oxide (PPO) groups (Figures 1.4 and 1.5). 
They are primarily used as industrial surfactants in a host of different applications such 
as coatings, cosmetics, pharmaceuticals, petrochemical processing, and even mouth 
wash [122]. Water soluble, non-ionic surfactants such as Pluronics are useful in large 
scale manufacturing applications. In the medical field, amphiphilic block copolymers 
have received increased attention in drug delivery due to both their activity as unimers 
and their ability to form polymeric micelles and internalize drugs inside their hydrophobic 
core [123]. The function and effectiveness of Pluronic micelles and other self-assembling 
polymeric micelles in drug delivery has been the subject of extensive review [124,125]. 
Briefly, the triblock structure of Pluronics allows the formation of a core-shell structure 
with a hydrophobic core containing PPO groups capable of internalizing hydrophobic 
drugs such as the potent anti-cancer agent Doxorubicin. The hydrophilic outer shell 
composed of PEO groups enhances the solubility of the micelle and increases the 
circulation time of the drug. 
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While the use of Pluronic micelles is the subject of significant efforts in drug 
delivery research, the long standing paradigm of amphiphilic block copolymers as inert 
drug carriers has since been challenged by an increasing literature suggesting that both 
micelles and unimers of Pluronics/Tetronics are capable of eliciting biological responses 
from cells [126]. One area of study in the effects of Pluronics on cell processes that has 
garnered significant attention is in the treatment of multi-drug resistance (MDR) cancers 
[127]. The addition of both Pluronic P85 and L61 reduces resistance to doxorubicin in 
sensitive cell lines such as human ovarian carcinoma SKVLB and SKOV3. They have 
also shown efficacy in vivo for treatment of induced cancers in mice using doxorubicin in 
tumor types including intraperitoneal murine leukemia, subcutaneous murine myelomas, 
intravenous and subcutaneous Lewis lung carcinoma, subcutaneous human breast 
carcinomas, and human head/neck carcinoma [128]. The activity of Pluronics in MDR 
cells may be due to several cell processes interrupted or promoted by the block 
copolymer. Batrakova et al. showed that Pluronic P85 enhances the delivery of 
anticancer drug digoxin the brain both in vitro and in vivo by inhibiting the effect of P-
glycoprotein (Pgp) on drug efflux [129]. Co-administration of 1% P85 with digoxin 
increased the penetration of the drug in wild type mice to levels detected in P-
glycoprotein deficient mice. A secondary consequence of Pluronics in MDR cell lines is 
increased energy depletion detected by ATP activity. Slepnev et al. first observed that 
exposure of Jurkat T-cell lymphoma to P85 depleted intracellular levels of ATP [130]. 
Subsequent studies by Batrakova et al. demonstrated that the energy depletion of 
Pluronics was selective, exhibiting enhanced effectiveness in MDR resistant cell lines 
[131]. They found that the apparent sensitivity of MDR cell lines to P85 was a result of 
Pgp efflux inhibition caused by both membrane fluidization as well as ATP depletion. An 
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alternative route of energy depletion by Pluronics may be related to respiratory activity 
within mitochondria. Pluronics have been shown to traffic readily to mitochondria 
following caveolae-mediated endocytosis [132] and were able to inhibit respiratory chain 
complexes I and IV [126]. As a result, ATP activity levels in cells treated with Pluronics 
were selectively reduced in MDR cells. 
Like Pluronics, Tetronics have demonstrated efficacy in drug delivery 
applications in micellar systems, but its uses are more limited due to the presence of 
ionic central amine moieties [123]. As a result, Tetronics are significantly more sensitive 
than Pluronics to changes in pH due to protonation of the central diamine group causing 
the unimers to repel each other [133]. This limits the range of physical and chemical 
conditions under which Tetronics may be useful for drug delivery. However, the 
environmentally responsive behavior of poloxamines may be advantageous for 
applications in which stimuli-responsive materials may be required. Riberio et al. 
observed that Tetronic T1107 was able to improve the solubility of α-tocopherol for 
topical ocular treatment [134]. The apparent concentration-dependent viscoelastic 
behavior of T1107 would allow delivery of the drug in the form of an in situ gelation 
system. Combination therapeutics using co-micelles containing both Tetronics and 
Pluronics can help improve the stability of Tetronic micelles. Chiappetta et al. created 
binary systems of Pluronic F127 and Tetronic T304 or T904 using co-micellization, 
resulting in 8340-fold increase in solubility and significantly enhanced physical stability 
compared to pure poloxamine micelles [135]. Outside drug delivery, the effect of 
Tetronic unimers or micelles on cell processes remains largely unknown except for one 
particular application, the intramuscular delivery of plasmid DNA. 
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1.7 Pluronics and Tetronics in Gene Delivery 
1.7.1 In Vivo Naked Plasmid Transfection with Pluronics and Tetronics 
Initial efforts to use amphiphilic block copolymers in gene delivery revolved 
around their potential to assist naked plasmid transfection. Unlike cationic polymers, 
Pluronics and Tetronics are unable to efficiently condense pDNA to form polyplexes. 
Instead, the applications of block copolymers in gene delivery are more akin to a 
pharmaceutical adjuvant [136]. Lemieux et al. first demonstrated that a combination of 
two Pluronics L61 and F127 into the formulation SP1017 was capable of 10-fold 
enhanced gene expression of reporter gene β-galactosidase following intramuscular 
administration with naked pDNA [137]. Importantly, the optimal dose of plasmid when 
using SP1017 was 500-fold less than pDNA alone. The effectiveness of SP1017 varied 
substantially with plasmid design. Transgene expression following the delivery of pDNA 
containing CMV promoter or NF-κB responsive elements was markedly higher than 
plasmids containing SV-40 or AP-1 response elements [138]. The promoter-selective 
nature of SP1017 suggests that the combination Pluronic acted not as a carrier for the 
plasmid, but rather as a pharmaceutical adjuvant capable of modifying the response of 
muscle cells to the transgene. In contrast to the success of naked plasmid delivery in 
vivo, SP1017 had negligible effects on pDNA delivery in vitro. Similar outcomes were 
observed by Pitard et al. in skeletal and cardiac muscle injections using Pluronic PE6400 
and a plasmid expressing the β-galactosidase gene [139]. PE6400 was able to eliminate 
the ceiling on plasmid-mediated gene expression where increasing amounts of pDNA 
would normally not enhance transfection efficiency. Up to 35% of muscle fibers from 
mouse tibia cranial muscle were transfected following simultaneous delivery of PE6400 
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and pDNA. In contrast, the Pluronic had no effect on simple gene delivery into isolated 
cardiomyocytes in vitro. In addition to the aforementioned PEO-PPO-PEO blocked 
Pluronics, reverse Pluronics (PPO-PEO-PPO) such as Pluronic 25R2 have been used to 
enhance the transfection efficiency of naked plasmid in skeletal muscles [140]. Levels of 
transgene expression following the addition of 25R2 were significantly higher than 
plasmid alone and comparable to equal concentrations of Pluronic P105.  
Like Pluronics, Tetronics have experienced moderate success in the delivery of 
pDNA in vivo. Prokop et al. observed that simultaneous delivery of Tetronic T908 with a 
luciferase reporter plasmid via intradermal injection resulted in significant increase in 
gene expression compared to pDNA alone [141]. In addition, Tetronic T704 and 90R4 
were used in combination with a gene gun to enhance transgene delivery compared with 
spermidine. Roques et al. compared the efficiency of Tetronic T304 with Pluronic L64 
and PEI-based polyplexes for both skeletal and cardiac muscle gene delivery [142]. The 
objective of the study was to compare strongly cationic (PEI), weakly cationic (Tetronic) 
and nonionic (Pluronic) polymer/DNA formulations for effective in vivo transgene 
delivery. Despite exhibiting positive charge in solution, T304 had only partially 
condensed pDNA and were readily destabilized at physiological pH. Mixtures of pDNA 
with T304 had similar mobility in an electric field compared to plasmid alone. Both T304 
and L61 significantly enhanced transgene delivery following intramuscular administration 
to skeletal muscle resulting in up to 90% decrease in DNA load for similar transfection 
efficiency. However, intrapericardial administration was completely ineffective with no 
observation of any transgene expression. In contrast, a separate study by Pitard and 
coworkers observed that T304 was capable of eliciting transient gene expression in both 
skeletal and heart muscles, increasing luciferase expression by a factor of 17 and 30 
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using 5 and 10% T304 respectively compared to naked pDNA [121]. They observed that 
the efficient expression of transgene was directly related to the higher bioavailability and 
diffusion with muscle fibers of pDNA when weakly complexed to T304 compared to 
naked plasmid alone. 
1.7.2 In Vitro Polyplex and Lipoplex Transfection with Pluronics  
The success of poloxamers and poloxamines for in vivo plasmid delivery and the 
corresponding failure of in vitro delivery using naked pDNA led to investigations 
combining amphiphilic block copolymers with polyplexes instead. Unlike naked pDNA, 
polyplexes display generally detectable levels of transgene expression in vitro under the 
right conditions specified for each type of vector. The initial investigations in combination 
gene delivery using polycations and Pluronics were made using copolymer conjugates of 
PEI and Pluronics [143]. Graft copolymers containing 2 kDa or 25 kDa PEI and either 
P123 or PEO were made. P123-g-PEI (2 kDa) displayed significantly reduced 
transfection efficiency compared to both 25 kDa PEI and the dendrimer  Superfect in 
vitro. However, the low transfection efficiency of P123-g-PEI (2 kDa) was significantly 
improved following the addition of free P123 (9:1 w/w) to the PEI-g-P123 formula, 
resulting in high transfection efficiency in vitro higher than 25 kDa PEI controls. 
Furthermore, transgene expression using graft copolymer with free P123 was confirmed 
in the spleen, heart, lungs, and liver 24 hours after intravenous injection into mice. 
Gebhart et al. observed similar results using P123-g-PEI (2K) for in vitro transfection 
[144]. The addition of either free P123 or F127 resulted in significantly enhanced 
transgene expression in PC-3 cells compared to polyplex alone. 
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Efforts to elucidate the mechanisms behind Pluronics in gene delivery led to 
subsequent in vitro transfection studies by Kabanov’s group using transient and stable 
transfection [145]. Transfection in NIH-3T3 and C2C12 cells was performed using 
luciferase and GFP reporter genes containing CMV, NF-κB, or AP-1 response elements. 
Survey of various Pluronics identified a group of formulations (L61, L64, P85, P103, 
P123) capable of enhancing PEI (25 kDa) and dendrimeric Superfect transfection using 
CMV promoter plasmids. While observed increases in transfection efficiency using the 
CMV promoter or NF-κB response elements were consistent across all cell lines, 
plasmids containing the AP-1 response element were ineffective in C2C12 myoblasts. 
However, this may likely have been a result of low baseline transfection. Less than 2% 
of cells were transfected with the GFP plasmid driven by AP-1 in C2C12 cells. These 
results were corroborated by other observations from both Kabanov’s group and others 
indicating that some Pluronics may have promoter-selective activity [140,146]. Increase 
in transfection efficiency was detected in simultaneous delivery of vector and Pluronics 
as well as transiently transfected/stably transfected cells, indicating that the Pluronics 
were involved biological pathways inside the cells unrelated to uptake mechanisms 
[145]. It was observed that both the levels of transgene mRNA as well as mRNA levels 
of an endogenous gene for a stress inducible heat shock protein (hsp68) were 
significantly increased with the addition of Pluronics. The evidence of transcriptional 
activation on hsp68 as well as CMV-promoter dependent increase in transfection 
efficiency, suggests that the mechanism of Pluronics were closely related to the NF-κB 
and stress-related pathways. Yang et al. confirmed these observations in a separate 
study by demonstrating that P85 and P123 were capable of significantly enhancing the 
transfection efficiency of 22 kDa linear PEI (ExGen 500) in NIH-3T3 and PC-3 cells 
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[147]. The mechanism of Pluronics in polyplex transfection was assessed by flow 
cytometry whereby both the cell uptake and nuclear localization of YOYO-1 labeled 
plasmids were found to be significantly increased by P85 and P123. In addition, gene 
array analysis showed that several targets in the NF-κB pathway were upregulated 
following the exposure of cells to 1% P85 for only 5 minutes. Taken altogether, the work 
of Kabanov’s group strongly suggests that the activity of Pluronics may be closely 
related to the activation of the NF-κB pathway leading to enhanced nuclear localization 
of pDNA and transcriptional activation. Unlike Pluronics, no studies on mechanisms of 
Tetronics in polyplex transfection or in vitro nonviral transfection in general have been 
performed. 
1.8 Localized Gene Delivery 
1.8.1 Design Aspects of Scaffold-Mediated Gene Delivery 
Of the barriers to gene delivery previously mentioned, one of the most critical in 
the clinical setting is bioavailability of the transgene. Like other nanoparticulate drugs, 
nonviral vectors are susceptible to clearance and traffic poorly to target areas, even in 
the case of tumors. Therefore, the design of implantable or injectable reservoirs for 
nonviral vectors capable of both extending therapeutic duration and providing localized 
delivery presents an attractive alternative to systemic delivery [148]. The optimal design 
for a nonviral vector reservoir in tissue engineering would be a biomaterial scaffold 
composed of cytocompatible elements that mimic the native ECM capable of supporting 
cell adhesion and can be remodeled to induce new tissue formation . The scaffold would 
be capable of initially sequestering the nonviral vector and protecting it from degradation. 
Over time, the scaffold would either release the vector through controlled degradation or 
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facilitate reverse transfection as cells remodel the scaffold. The scaffold is ultimately 
resorbed and replaced with ECM deposited by endogenous cells following the release of 
transgene cargo. 
The temporal delivery of transgene using scaffold-mediated gene delivery 
represents a significant advantage over bolus injection where the initially high 
concentration of vector rapidly decreases over time. Scaffold-mediated gene delivery 
addresses nearly all of the extracellular barriers to gene delivery by reducing significant 
concerns with serum aggregation, first-pass organ accumulation, and serum nucleases 
by virtue of proximity to the target site and eliminating the need to inject vector into the 
blood stream. Several cell processes that are the target of potential gene therapy 
applications may benefit from the extended availability of therapeutic nonviral vectors 
[149,150]. Nonviral vectors delivered from scaffolds provide significantly increased 
duration of localized transgene expression compared to vector alone [151]. Although 
scaffold-mediated delivery can increase the duration of transfection, the level of 
transgene expression at each time point may be relatively low compared to bolus 
delivery. The first primary design criteria to consider when designing a scaffold for the 
delivery of biomacromolecules is the rate of scaffold degradation. In a significant portion 
of gene delivery scaffolds, the rate of scaffold degradation mediated by enzymes or 
hydrolysis is a major factor in how quickly the release of incorporated vector occurs. Fast 
degrading naturally derived materials may incorporate chemical crosslinking to facilitate 
controlled degradation of encapsulated therapeutic molecules [152]. The degradation of 
these naturally derived materials is usually mediated by enzymatic activity, taking 
advantage of cell-secreted enzymes to access incorporated vectors. Different degrees of 
crosslinking may impede the activity of proteases that break down the scaffold, allowing 
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gels to be tailor made for specific applications where various time-scales of therapeutic 
delivery may be required [153]. Cytocompatible, non–immunogenic crosslinkers such as 
PEG enhance the stability of the hydrogel. As the concentration of the synthetic 
crosslinker increases, the degradation rate of the hydrogel decreases and the release of 
incorporated transgene can be slowed. 
Another important consideration for scaffold mediated nonviral delivery is the 
cytocompatibility of the materials used. The implantation or injection of biomaterials can 
induce unwanted inflammatory responses from the host that may influence the 
degradation rate of the biomaterial, infiltration of cells into the scaffold, and expression 
profile of incorporated transgene [148]. Even highly cytocompatible materials such as 
chitosan may elicit a chemotaxic response from macrophages and neutrophils [15]. 
While the initial inflammatory response of biocompatible materials may have minimal 
impact on the stability and release of incorporated nonviral vectors, subsequent 
angiogenic activity as a result of macrophage and fibroblast recruitment may be 
determining factors in the delivery of transgene. Recent advances in biomaterials design 
have resulted in the creation of scaffold components tailor-made for tissue engineering 
applications where the release of therapeutic molecules may be desired. Hydrogels are 
a specific class of biomaterials uniquely equipped to handle the challenges of 
biocompatibility while maintaining desirable material properties. They can be readily 
formed under mild conditions amenable to the incorporation of nonviral vectors, and 
many types of hydrogels can be crosslinked in situ to allow minimally invasive injection 
[154]. In addition, hydrogels can be formulated to have transport capabilities that allow 
deep nutrient and oxygen penetration even when utilizing scaffold dimensions where 
cells would normally not survive due to the hypoxic environment created by thick 
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scaffolds [155]. The advantages of hydrogels as materials for tissue engineering and cell 
encapsulation makes them exceptionally well equipped for use in nonviral gene delivery. 
1.8.2 Methods for Incorporating Vectors into Scaffolds 
The two primary modes for the incorporation of nonviral into scaffold are 
substrate-mediated delivery and scaffold encapsulation [156]. In substrate-mediated 
delivery, nonviral vectors are immobilized on the surface of the scaffold and cells 
internalize transgene through reverse transfection as cells come into contact with the 
scaffold. Reverse transfection technology can be employed for high throughput 
screenings of vector libraries and long-term storage of lyophilized vector due to 
enhanced stability and vector availability compared to conventional liquid phase in vitro 
transfection using gravity sedimentation or cell suspensions [157,158]. Bengali et al. 
observed that surface immobilized vector on polystyrene facilitated significantly 
enhanced transgene expression compared to bolus delivery in cell culture [159]. The 
effect of surface immobilization was particularly apparent at small DNA dosages and 
DNA:lipid ratios where vectors were normally most inefficient in conventional 
transfection. At low dosages, the surface immobilization of polyplex or lipoplex 
maintained high levels of transgene expression whereas bolus delivery experienced 
large drops in transfection efficiency. In scaffold-mediated gene delivery, surface 
immobilization provides enhanced vector stability and prevents the excessive diffusion of 
vector.  Villa-Diaz et al. observed that modification of standard reverse-transfection 
procedures using Matrigel as a substrate instead of tissue culture polystyrene further 
enhanced the transfection efficiency of immobilized lipoplex [160]. They were able to 
promote the expression of transgene in human embryonic stem cells due to the higher 
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degree of affinity between stem cells and Matrigel compared to a normal well plate. 
Porous scaffolds are particularly effective for the immobilization of polyplex or naked 
plasmid due enhanced cell invasive properties [161]. Biodegradable scaffolds composed 
of polyester elastomers with surface-adsorbed polyplex were capable of sustaining the 
viability of seeded cells and induced high levels of transgene expression in vitro. Due to 
the porous nature of the polyester scaffold, encapsulated cells readily spread and 
invaded throughout the scaffold, easily gaining access to immobilized vector. In addition, 
plasmid immobilized scaffolds resulted in observable transgene expression in vivo in an 
intraperitoneal fat model. Jang et al. observed that polyplex immobilized on the surface 
of a poly(lactide-co-glycolide) (PLG) scaffold via adsorption resulted in higher 
transfection efficiency compared to bolus delivery with equal or more amounts of DNA 
[162]. Interestingly, expression levels in substrate-mediated delivery were higher initially 
(<24h) than in bolus delivery. 
Unlike reverse transfection where it may be necessary for cells to adhere to the 
scaffold in order to access immobilized transgene, nonviral vectors incorporated via 
scaffold encapsulation may be released through proteolytic degradation of the scaffold 
and can be deposited into the surrounding tissue. In general, the quantity of vector 
available from scaffold encapsulation is significantly higher than surface immobilization 
due to more reliable sustained release and elimination of cell-invasive requirements 
[163]. Jang et al. were able to achieve extended expression of transgene following 
plasmid-mediated transfection in vivo using a porous PLG sponge formed by gas 
foaming [164]. Expression persisted for more than 100 days with high dosage of pDNA, 
likely due to increased loading efficiency and homogenous vector distribution allowed by 
a wet granulation procedure for scaffold formation. Transfection was initially observed in 
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the periphery of scaffold at day 3, adjacent to the polymer at day 17, and deep within the 
scaffold interior at day 126. Dadsetan et al. observed similar albeit not as impressive 
results in the co-encapsulation of bone tumor cells with plasmid DNA in 
oligo(polyethylene glycol) fumerate [165]. Continuous expression of transgene was 
observed over the course of 21 days. Many fibrin scaffolds for gene delivery employ the 
vector encapsulation approach. The vector is usually mixed with fibrinogen precursor 
prior to thrombin mediated polymerization [166]. Fibrin is natively cell adhesive and 
readily degrades in contact with plasmin and other endogenous proteases, allowing for 
fast and reliable release of encapsulated vector. 
1.9 Types of Scaffolds for Gene Delivery 
Polymeric biomaterials dominate ongoing research into novel gene delivery 
scaffold technologies. The various scaffold components can be categorized into two 
major types of biomaterials: natural and synthetic polymers [167]. A host of different 
polymeric gene delivery scaffolds can be seen in Table 1.1 with varying degrees of 
consideration made for the aforementioned scaffold requirements in the previous 
section. The distinctions between scaffolds made from natural and synthetic polymers 
will be briefly discussed with special consideration for biosynthetic hybrid hydrogels 
containing aspects of both. 
1.9.1 Natural Scaffolds 
Polymeric scaffolds composed of natural materials take advantage of the innate 
cell adhesive and biocompatible properties of various proteins and other ECM/plasma 
components. The primary benefit of using most natural polymers are their innate ability 
to support cell adhesion and generally lower toxicity in vivo [168]. Lei et al. encapsulated 
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large quantities of caged polyplexes into HA-acrylate hydrogels covalently crosslinked by 
dithiothreitol (Michael addition) and enzymatically crosslinked fibrin hydrogels [169]. Both 
types of hydrogels were able to achieve efficient transgene expression in vivo. 
Importantly, polyplexes were able to remain homogenous inside each hydrogel with less 
than 1% of DNA lost to burst release from diffusion in PBS, indicating high levels of 
loading efficiency. Des Rieux et al. were able to achieve 19 days of sustained plasmid or 
lipoplex release from pure fibrin hydrogels with over 70% loading efficiency [170]. The 
critical determinant for transfection in vitro was the rate of cell infiltration and availability 
of vector. Cells co-encapsulated with vector within hydrogel precursor were transfected 
at a much higher rate than cells seeded alongside hydrogels that depended on cell 
invasion to access encapsulated lipoplexes. 
While the innate cytocompatibility of natural polymers makes them attractive 
materials for many tissue engineering applications, their high susceptibility to rapid 
enzymatic degradation and poor mechanical properties must be addressed in order to 
use pure natural hydrogels for nonviral vector delivery [171,172]. One method for 
deterring fast proteolytic degradation is through the incorporation of inhibitory molecules 
such as aprotinin into hydrogel precursors. Kulkarni et al. were able to improve the in 
vivo transgene expression of a luciferase reporter by including 3000 KIU of aprotinin in 
lipoplex incorporated fibrin hydrogel [173]. A second more popular strategy for improving 
the mechanical properties and slowing the degradation rate of a number of naturally 
derived biomaterials is through the addition of crosslinks. Segura et al. used a 
poly(ethylene glycol) diglycidyl ether (PEGDG) crosslinker to improve the mechanical 
properties of hyaluronic acid (HA) and HA/Collagen hydrogels [174]. The inclusion of the 
crosslinker significantly reduced the rate of HA degradation while maintaining the ability 
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for cells to remodel the gel. Krebs et al. used photocrosslinking to reduce the rate of 
alginate degradation and extend the bioavailability of incorporated siRNA [175]. Scaffold 
incorporated siRNA remained bioactive for up to 2 weeks, nearly completely inhibiting 
the expression of GFP by GFP positive cells in vitro at day 3 following co-encapsulation 
of cells in 3D. 
1.9.2 Synthetic Scaffolds 
The vast range of physicochemical properties available in synthetic polymeric 
biomaterials represents their most significant advantage over natural polymers. They are 
relatively easy to manufacture and reproduce in large quantities and can be surface or 
bulk modified to contain properties useful in a wide range of tissue engineering 
applications. However, many modern synthetic biomaterials oversimplify the natural 
ECM and attempt to mimic the functions of native tissue while lacking its complexity 
[176]. Some of the most popular polymers used in tissue engineering such as PEG lack 
cell adhesive properties and degrade relatively slowly via hydrolysis [177]. In addition, 
safety related drawbacks including the long-term fate of degradation products and 
complexities associated with purification of scaffold materials must be addressed in 
order to improve their effectiveness in tissue engineering applications. 
Porous scaffold such as poly(lactic-co-glycolic acid) (PLGA) represents a 
physical approach to allowing cell invasion without the addition of biochemical cues. 
Most PLGA scaffolds for gene delivery are formed via a supercritical or high pressure 
carbon dioxide foaming process which forms pockets and bubbles within the PLGA 
matrix through which cells may migrate and nutrients may diffuse. Huang et al. used 
polyplex-incorporated PLGA scaffolds for subcutaneous transgene delivery in mice 
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[178]. The porous nature of the polymeric sponge allowed significant cell invasion, 
leading to positive transfection identification in 55-60% of cells found inside the PLG 
scaffold. Levels of gene expression as a result of scaffold-mediated polyplex delivery 
were one order of magnitude higher than bolus injection at the two week time point, and 
nearly two orders of magnitude after eight weeks. Other groups have focused on micro-
scale techniques to fabricate PLGA microspheres encapsulating free plasmid and 
polyplexes capable of facilitating the controlled release of vector [179]. Like other 
synthetic biomaterials, PLGA supports additional functionalization to improve 
transfection outcomes in specific applications. Nie and Wang created composite 
scaffolds of PLGA/Hydroxyapatite (Hap) for the delivery of plasmid DNA and 
DNA/chitosan complexes in bone morphogenesis [180]. The resulting scaffold presented 
with microfibrous structure predominantly formed from PLGA with dispersed Hap 
nanoparticles inside the polymeric matrix. Release tests in vitro confirmed that HAp 
accelerated the release of encapsulated DNA cargo and that released vectors remained 
bioactive.  
While the need for cell invasion can be addressed by manipulating the physical 
structure of the hydrogel, chemical modification may be required in order to provide 
controlled release of incorporated nonviral vectors. Quick et al. addressed the relatively 
slow hydrolysis of PEG through substitution with PLA to create PEG-PLA copolymers 
[181]. However, while the addition of various weight percentages of PLA did have an 
effect on the release rate of incorporated pDNA, release profiles were mostly still heavily 
reminiscent of hydrolytic degradation where only a low amount of DNA (<25%) was 
detected in solution for 5-15 days depending on gel formulation after which rapid (24 h) 
hydrolytic collapse of the hydrogel was observed and the entirety of the rest of the DNA 
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load was released in less than a day. However, some formulations containing a blend of 
lactic acid blocks of varying lengths were able to overcome the limitations of bulk 
hydrolytic degradation of a homogeneous network, producing a relatively linear release 
profile over the course of 10 days [182]. DNA released from PEG-PLA hydrogels 
remained bioactive, successfully transfecting NIH-3T3 cells in well plates when 
complexed with cationic lipid or polymer. PEG hydrogels can be further modified to 
provide additional functionality and responsiveness to environmental cues. Li et al. 
created thermosensitive biodegradable hydrogels for gene delivery used PEG-PLGA-
PEG block copolymers [183]. Plasmid released from the thermosensitive gel 
successfully transfected mice skin wounds at as little as 24h with transient transfection 
persisting for 72h. The triblock polymer was able to overcome slow release via 
hydrolysis of typical PEG gels with release profiles following zero-order kinetics for up to 
12 days in vitro. 
1.9.3 Hybrid Biosynthetic Hydrogels 
As a specific application of inductive tissue engineering, nonviral gene delivery 
necessitates some characteristics native to both natural and synthetic biopolymers to 
fully realize cell-responsive scaffolds capable of localized, controlled release of 
therapeutic transgene vectors. Neither purely natural nor synthetic hydrogels contain the 
entire spectrum of properties necessary to create the ideal gene delivery system. 
Therefore, recent efforts have been made to combine natural ECM and plasma 
biomolecules with synthetic polymers to synthesize hybrid multicomponent hydrogel 
systems that combine the advantages of both natural and synthetic hydrogels into 
biosynthetic scaffolds [184]. The two main types of biomolecules used in hybrid 
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hydrogels are macromolecules (proteins, polysaccharides, proteoglycans) and peptides 
[185]. The myriad of components are combined via covalent conjugation, enzymatic 
crosslinking, or physical association. Some hydrogels use more than one method for 
multicomponent construction resulting in semi- or fully-interpenetrating networks where 3 
or more components are either covalently crosslinked or physically associated. In 
nonviral gene delivery, the primary motivation for creating complex hydrogel systems is 
the ability to control the release and/or availability of the vector while maintaining 
cytocompatibility and cell adhesion. 
The precise control over both physicochemical and biological properties imparted 
by peptides makes them attractive for hydrogel modification and crosslinking. When 
structural modifications to improve cell invasion fail to provide sufficient biochemical 
cues for cell growth due to the lack of cell adhesion, peptide motifs such as the oft-used 
RGD sequence can be surface immobilized on synthetic hydrogels to provide the 
requisite molecular cues for cell attachment. Shepard et al. patterned the growth of 
DRG’s in vitro using the delivery of plasmid nerve growth factor on RGD-peptide 
conjugated PEG/PDMS [186]. Increasing the concentration of surface immobilized RGD 
led a significant increase in neurite extension. Synthetic hydrogels can be made 
enzymatically degradable by introducing matrix metalloproteinase (MMP) degradable 
linkages to crosslink hydrogel precursors. Lutolf et al. were able to create cell-adhesive 
and enzymatically degradable hydrogels by combining both adhesion ligands and MMP-
sensitive linkages to PEG hydrogels [187]. The resulting hydrogel was highly susceptible 
to cell invasion and remodeling, allowing cell-based remodeling to create complex 
network morphologies that mimic the native extracellular environment. Lei et al. created 
biodegradable PEG hydrogels with cell adhesive properties by incorporating MMP-
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degradable peptides via Michael-type covalent conjugation to RGD-modified PEG 
[188,189]. Over 65% of encapsulated PEI-based polyplexes remained bioactive and the 
inclusion of vector had no effect on the mechanical properties of the hydrogel. In 
addition, they were able to achieve extended transgene expression by mesenchymal 
stem cells in vitro over the course of 21 days incubation. The ability for cells to access 
homogenously distributed polyplexes was attributed primarily to cell invasion elicited by 
the MMP-degradable motifs. The ability for cells to invade at the right time-scales may 
be the critical factor in determining the success of peptide-mediated hydrogel 
degradation for gene delivery. The in vivo efficacy of the MMP-degradable hydrogel was 
demonstrated through plasmid vascular endothelial growth factor (VEGF) delivery to 
chick chorioallantoic membrane of E8 chicks [190]. Large quantities of polyplex were 
efficiently incorporated into the scaffold by increasing the viscosity of the gelation 
precursor using agarose. As a result they were able to incorporate polyplexes into MMP-
degradable PEG gels at concentrations where cationic polymers would normally 
aggregate into macroparticles and fail to delivery transgene. Shepard et al. made a 
similar PEG-peptide hydrogel system using photocrosslinked four-arm PEG-acrylates 
with cell-adhesive and MMP-degradable peptide motifs [191]. Lipoplexes incorporated 
into the body of the hydrogel though simple encapsulation remained bioactive, promoting 
transgene expression up to 7 days in both two- and three-dimensional cell cultures. Both 
HT-1080 and NIH-3T3 cells readily invaded into PEG-peptide hydrogels. Increasing the 
distance and time over which cells were able to migrate within the hydrogel produced 
significantly higher amounts of transgene expression, indicating that the critical 
determining factor in transfection was the ability for cells to invade with the hydrogel. 
Therefore, retention of the vector within the hydrogel and not overall release of vector 
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from the hydrogel into the solution was most important for improving the delivery of DNA 
copies to migrating cells. 
While the precision afforded by peptide-mediated hydrogels represents an ideal 
building block for cell adhesive hydrogels with controlled release capabilities, custom 
peptides are still relatively expensive to produce [192], although recent advances in the 
manufacture of common peptides such as RGD have brought down costs for small-
peptides considerably [193]. In contrast to custom peptides, biomacromolecules such as 
hyaluronic acid, fibrinogen, and collagen/gelatin are available in great abundance and 
can be readily purified for use in biomaterial scaffolds. Despite the loss of precise control 
in biochemical properties of the hydrogel, proteins and proteoglycans provide additional 
complexity and enhanced bioactivity that more closely mimics the native ECM. For 
example, Chung et al. developed a small linear peptide sequence (QPQGLAK) with 
MMP-13 sensitivity as a crosslinker for bone repair using artificial ECM [194]. However, 
the peptide degradation kinetics were much slower than the MMP degradable 
macromolecule, collagen type II, due to the increased MMP-13 reactivity of collagen 
versus the linear peptide. Hyaluronic acid is one of the most popular ECM components 
for incorporation into the structure of synthetic hydrogels in order to provide enzymatic 
degradability due to its large molecular weight and inherent cytocompatibility. Wieland et 
al. created PEG-HA hydrogels for the delivery of naked plasmid and polyplexes through 
photocrosslinking acrylated HA and PEG [153]. The resulting hydrogel displayed release 
profiles heavily dependent on the ratio of natural to synthetic content of its precursors. 
Hydrogels with more HA released vectors earlier and at a much higher rate and pDNA 
released quicker than polyplex. Hosseinkhani et al. reinforced a commonly used 
collagen sponge scaffold with poly(glycolic acid) (PGA) fibers to improve the strength of 
 52 
 
the scaffold [195]. Acetylated PEI-based polyplexes incorporated into the scaffold 
retained bioactivity and successfully delivered transgene in vitro and in vivo. 
Osteoinductive activity was observed following the in vitro delivery of plasmid bone 
morphogenic protein (BMP-2) to MSC and osteogenic activity was observed in vivo 
following implantation in the back of mice. Nie et al. combined the ability for chitosan to 
be both a polycationic DNA carrier and a scaffold material with a PLGA backbone to 
create composite foam scaffolds capable of sustained DNA release for up to nine weeks 
[196]. The incorporation of chitosan significantly improved cell adhesion and viability. 
1.10 Conclusion 
Compared to recombinant protein therapeutics, scaffold-mediated localized gene 
delivery offers a promising alternative toward the treatment of disease and injury by 
taking advantage of endogenous cells to produce growth factors and enzymes 
necessary for tissue regeneration and functional recovery. However, limitations in the 
efficacy of nonviral vectors must be addressed before nonviral gene delivery can 
successfully transition from the laboratory to the clinic. One approach to increasing the 
efficiency of nonviral gene delivery using a novel hybrid hydrogel scaffold will be 
discussed in the following sections. 
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Table 1.1. Nonviral vector incorporated hydrogels for localized gene deliver 
Scaffold Carrier Plasmid Loading Model Ref. 
Equine 
Collagen 
b-PEI (25k), 
5% sucrose 
P55pCMV-
IVS-luc+ 
500 
ug/sponge 
Subcutaneous implant 
in rat (vivo) 
 
NIH-3T3 (vitro) 
[197] 
Type 1 
bovine 
dermal 
collagen 
PEI (25k, 
BASF), 150 
mM NaCl 
pGL3-CMV-
luc+ 
0.3 ug/well 
(96 well 
plates) 
L-929 (vitro) [198] 
Type 1 
bovine 
collagen 
Superfect 
(dPAMAM) 
Plasmid 
gLUC 
1 ug/sponge 
(10,000 
cells with 
50% 
adherence) 
rSMC (vitro), various 
(vitro) 
[151] 
Type 1 
bovine  
collagen 
Poly-D-
lysine 
pEGFP-N1 
(SV40), 
pcDNA3-
FGF2 (SV40), 
pNGVL-3-
CMV-(GFP, 
FGF2, BDNF, 
NT3) 
2.5-7.5 
ug/1-2mg 
collagen 
paste 
BHK (vitro) 
 
severed optic nerve 
axons adult Wister 
rats (vivo) 
[199] 
Type 1 
bovine 
collagen 
Poly-D-
lysine 
pNGVL-3-
CMV-TK 
30 ug/GAM Dorsal-T8 in Wistar 
rats in transection 
below meninges (vivo) 
[200] 
Type 1 
bovine 
dermal 
collagen 
PEI (800k, 
Sigma) 
pcDNA3-
Alkaline 
phosphatase 
(AP) 
10 ug 3T3, 293, rSMC, 
MDA-BM-231 (vitro) 
 
Subdermal/perivascul
ar in Sprague-Dawley 
(vivo) 
[201] 
Type 1 
bovine 
collagen/PL
GA 
Polyamidoa
mine 
(PAMAM) 
dendrimer 
starburst 
generation 
5, 6, 9 EDA 
core MW 
28, 826, 
116, 493, 
467, 162 Da 
pCF1CAT, 
pCF1-Luc, 
pEGF1 
10-100 ug 
per 
membrane 
COS-1, 3T3, Rat2 
(vitro) 
 
Hairless Skh-hr-1 
mice. Film covered 
flanks of mice stripped 
by cellophane tape 15 
times (vivo) 
[202] 
Hyaluronic 
acid/collage
n 
Linear PEI 
(water or 
150 mM 
NaCl) 
pGFP, pLUC 2 ug per gel 3T3 (vitro) [174] 
Chitosan/Alg
inate 
b-PEI (25k), 
5% glucose 
pEGFP-C1-
CMV, 
pVR1055-
20 ug/mL 
WSC 
precursor 
HEK293, HDF (vitro) [203] 
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bFGF-CMV 
Agarose Polylysine 
(CK30PEG1
0k 
countered 
by acetate) 
pKCERlucSV
5.9 (ELF1α) 
25 ug/gel Adult Harlan Sprague 
dawley rats 
intradermal injection 
(vivo) 
[204] 
Fibrin Peptide, 
Poly-L-
lysine (PLL) 
in NaCl (0-
2.5 M) 
pEGFPN1 2 mg 
DNA/mL 2% 
FgN 
COS-7, HFF, 293T3 
(vitro) 
[205] 
Fibrin/PMMA 
templated 
L-PEI (25k) gWiz-Luc, 
pBLAST49-
hVEGF 
0.6 mg 
DNA/mL 
scaffold 
3T3 (vitro) [206] 
Fibrin Transfect® 
Lipoplex 
pEGFP-Luc-
CMV 
1 ug 
DNA/gel 
3T3 (vitro) [170] 
Porcine 
small 
intestinal 
submucosa 
b-PEI (25k) pCMV-luc-
EGFP, 
pCMV-EGFP, 
pCMV-β-
galactosidase 
Approx. 0.5 
ug DNA/cm
2
 
ECM 
HT-1080 (vitro) [207] 
PLG b-PEI (25k) pCMV-
luc/GFP 
1.3 ug/disk 3T3, HDF (vitro) [159] 
PEG/HA b-PEI (25k) pCMV-Luc-
EGFP 
33.3 ug/mL 
gel 
MCF-7, WS8 (vitro) [153] 
PEG-peptide L-PEI (25k) pSEAP, 
pEGFP-Luc 
15-50 ug 
DNA/100 uL 
gel 
Bone marrow MSC 
(D1, CRL12424) 
(vitro) 
[188] 
HA/Fibrin L-PEI (25k), 
agarose to 
counteract 
polyplex 
aggregation 
w/ HA and 
fibrin 
pCMV-VEGF, 
pCMV-
NGVL1-β-
galactosidase 
300 ug 
DNA/100 uL 
gel 
Chick chorioallantoic 
membrane (CAM) 
(vivo~?) 
[169] 
Fibrin Lipofectami
ne 
pCSCZ 2 ug/gel 293T/17, 3T3 (vitro) [208] 
PLGA b-PEI (25k) Oligodeoxyth
ymidilate 
pdT17 
4-4.5 ug 
pdT16/mg 
microsphere
s 
HeLa (vitro) [179] 
PLGA b-PEI (25k), 
1% sucrose 
pNGVL-β-
galactosidase 
(CMV) 
200 
ug/sponge 
Subcutaneous Lewis 
rats (vivo) 
[178] 
PLGA b-PEI (25k), 
150 mM 
NaCl 
pLuc, p-β-
galactosidase 
50 
ug/scaffold 
HEK293T, 3T3 (vitro) [162] 
PLGA PLL (25k) Supercoiled 
pDNA 
0.6% drug 
loading 
N/A [209] 
PEG-PLG-
DM 
PEI (25k) pSEAP, 
pGFP 
2-6 ug 
DNA/mg 
Primary chondrocytes 
(vitro) 
[181] 
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monomer 
PEG-peptide Transfect 
lipoplex 
pCMV-EGFP-
Luc 
 
3.0 ug/15 uL 
gel 
HT-1080 in 25 mg/mL 
fibrin clots (vitro), cells 
pre-transfected in 
precursor 
[191] 
PEG-PLGA-
PEG 
pDNA pNGVL3-Luc 200 ug/50 
uL gel 
7x7 mm full thickness 
skin biopsy dorsum of 
CD-1 mice (vivo) 
[183] 
Poly (D,L-
lactide)/colla
gen 
L-PEI (25k) pCEF1α-
DNT-IgSP-
eGFP 
2.5 ug 
DNA/disk 
BHK (vivo) [210] 
Poly(D,L-
lactide) 
Polyamidoa
mine 
(PAMAM) 
gWiz-Luc 140 ug 
DNA/140 
mg PDDLA 
powder in a 
Teflon mold 
A549 (vitro) [211] 
Star 
oligo/Poly(D,
L-lactide) 
PAMAM 
(G5) 
pEGFP-C1, 
pGL3-Luc 
1 ug 
DNA/film 
3T3 (vitro) [212] 
PLGA/Hap Chitosan PT7T3D-
PacI-BMP-2 
(N/A, 
unclear) 
hMSC (vitro) [180] 
Type 1 
Collagen/PG
A 
Acetylated 
b-PEI (25k), 
150 mM 
NaCl 
pBacBH2-
BMP-2 
40 
ug/sponge 
Primary MSC (vitro) 
 
Subcutaneous Wister 
rats (vivo) 
[195] 
HA-peptide L-PEI (25k) pGluc 5 ug/gel mMSC (vitro), 500 
000 cells/gel 
[213] 
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CHAPTER 2 
RESEARCH OBJECTIVES 
 The overall goal of this dissertation is to demonstrate the advantages of choosing 
scaffold components for gene deliver with properties capable of enhancing the 
delivery/efficiency of incorporated nonviral vectors. The key benefit of choosing an 
amphiphilic block copolymer such as Tetronic T904 over current popular hydrogel 
components like PEG or HA lies in the unique bioactive property of amphiphilic block 
copolymers in nonviral transfection. Unlike largely bio-inert synthetic scaffold polymers 
chosen specifically for their cytocompatibility and physicochemical properties, Tetronics 
have the potential to introduce additional functionality to the gene delivery scaffold by 
addressing key intracellular barriers to nonviral vector delivery. 
In the following chapters, scaffold-mediated polyplex delivery from a novel hybrid 
hydrogel system composed of a natural soluble protein, fibrinogen, and an amphiphilic 
block copolymer, T904 will be explored in detail. Figure 1.6 shows a basic outline for the 
logical progression of research objectives needed to demonstrate how T904 can be 
used as a bioactive hydrogel component to enhance the delivery of nonviral vectors. 
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Figure 2.1. Outline of research objectives. 
Chapter 2 addresses a key gap in the knowledge of poloxamines in gene delivery 
by characterizing the efficacy of T904 in polyplex transfection. The magnitude of T904’s 
ability to enhance the transfection efficiency of PEI/pDNA complexes in routine in vitro 
transfection is investigated. In addition, the mechanism behind T904 activity is studied 
using flow cytometry to assess cell uptake and nuclear import as well as RT-PCR to 
quantify mRNA transcript production. 
Chapter 3 extends the application of T904 to a biosynthetic hybrid hydrogel 
system for scaffold-mediated gene delivery in vitro. Hybrid hydrogels composed of 
fibrinogen and varying concentrations T904 are developed and the controlled release of 
both naked DNA and polyplex is characterized. Furthermore, the ability for hybrid 
hydrogels to support 2D and 3D gel transfection in vitro is visualized and quantified. 
Chapter 4 evaluates the in vivo nonviral gene delivery capabilities of the hybrid 
hydrogel. The ability for T904/fibrin hybrid hydrogels to support cell invasion and 
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maintain bioactivity of incorporated polyplex in vivo is demonstrated using a cutaneous 
excisional wound model.  
The major conclusions of the work will be drawn in chapter 5 along with 
recommendations for future studies. Ultimately, the dissertation will provide motivation 
for T904 as a superior gene delivery scaffold material. 
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CHAPTER 3 
EFFICACY AND MECHANISM OF POLOXAMINE-ASSISTED 
POLYPLEX TRANSFECTION 
Abstract 
Amphiphilic block copolymers acting as biological response modifiers provide an 
attractive approach to improving the transfection efficiency of polycationic polymer/DNA 
complexes (polyplexes) by altering cellular processes crucial to efficient transgene 
expression. The objective of this study was to investigate the effect of the poloxamine 
Tetronic T904, a 4-arm polyethylene oxide / polypropylene oxide block copolymer, on 
polyplex transfection and determine its mechanism of action by analyzing cellular uptake 
of polyplex, nuclear localization of plasmid, and RNA transcript production. T904 
significantly increased the transfection efficiency of polyplexes based on 25 kDa 
branched polyethylenimine in a dose-dependent manner in the presence of serum in C6 
glioma cells, as well as human fibroblasts and mesenchymal stem cells. The activity of 
T904 was not promoter-dependent, increasing expression of reporter genes under both 
CMV and SV40 promoters. While T904 did not affect internalization or nuclear uptake of 
plasmid, mRNA expression levels from both promoters showed dose-dependent 
increases that closely paralleled increases in gene expression. This study demonstrates 
that T904 significantly increases polyplex transfection efficiency and suggests a 
mechanism of increased transcriptional activity. As a 4-arm, hydroxyl-terminated 
polymer, T904 is amenable to a variety of end group functionalization and covalent 
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crosslinking strategies that have been developed for preparing hydrogels from multi-arm 
polyethylene glycol, making it particularly attractive for scaffold-mediated gene delivery.  
Keywords: gene delivery, poloxamine, polyplex, gene expression, promoter, amphiphilic 
block copolymer 
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3.1 Introduction 
Recent efforts to improve the transfection efficiency of nonviral vectors have 
resulted in a myriad of polymer- and lipid-based gene carriers using a variety of 
modifications to address the intracellular barriers, extracellular barriers, and rate-limiting 
steps to successful gene delivery [38]. Several key vectors that display high in vitro 
transfection efficiency have been the target of commercialization as reference vectors 
and tools for research. Despite the high levels of transgene efficiency achieved by these 
vectors in vitro, the barriers toward clinical translation remain high. The reason for 
disconnect between in vivo and in vitro nonviral gene delivery lies in the dissimilar 
requirements for successful gene delivery between the two environments. For example, 
particles with large hydrodynamic diameter greater than 200 nm transfect well in vitro 
using gravity-induced sedimentation to increase transfection efficiency, but are less 
relevant for in vivo applications due to issues with toxicity and clearance [214]. 
Modifications such as the conjugation of targeting moieties that result in higher levels of 
in vitro transgene expression may be irrelevant for in vivo gene delivery due to the 
higher priority of systemic bioavailability compared to cell-specific vector targeting. 
Nonviral gene carriers and vectors may be designed with in vitro transfection parameters 
in mind, ignoring common problems associated with in vivo delivery such as serum 
aggregation, dose-dependent toxicity, and plasmid promoter/enhancer specificity in 
certain tissue types [112]. In addition, certain vector/carrier combinations may display 
high transgene expression in specific cell lines that cannot be replicated across multiple 
transfection conditions [215]. Differences in transfection efficiency as a result of plasmid 
promoter type [216], particle size [214], reagent to DNA mixing order [54], complexation 
medium [52], and cell culture conditions [217] have confounded efforts to identify a 
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unified approach to vector design due to large variations in efficiency and cytotoxicity 
experienced by major or minor modifications to the carrier. Despite the aforementioned 
limitations, in vitro transfection screenings remain the most powerful tool for initial 
investigations into the efficacy of novel vectors due to the ability to quickly screen high 
volumes of potential vector and carrier combinations 
The ultimate goal in the rational design of a novel nonviral vector is to address 
the established extracellular and intracellular barriers to delivery. Due to the disparate 
design requirements associated with each barrier, modifying the gene carrier itself 
through chemical substitution or physical association to address multiple rate-limiting 
barriers may be costly and difficult. In order to reduce the dependency of nonviral 
transfection on the design of the vector and in vitro transfection conditions, the current 
study will use amphiphilic block copolymers as biological response modifiers as they do 
not require integration with the vector to increase transfection efficiency. Instead, they 
will induce cellular behaviors in target cell lines or tissues that reduce intracellular 
barriers to non-viral transfection. Soluble and micellar Pluronics were originally 
considered inert molecules mainly used for stabilization and protection of drugs from 
degradation. However, recent work from Kabanov’s group has demonstrated that 
Pluronics are capable biological response modifiers in drug delivery that can affect cell 
membrane microviscosity and multidrug resistance through inhibition of drug efflux 
transporters [126,218]. Pluronic unimers can enter difficult to penetrate cells such as 
neurons with pathogen-like intracellular trafficking to mitochondria and neuronal 
dendrites [132]. Due to their vector independent nature, Pluronics and Tetronics have 
been implicated as potent biological response modifiers for enhancing plasmid delivery. 
For example, both Pluronics as well as Tetronics have been used to enhance 
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intramuscular delivery of naked plasmid delivery in vivo [219–221]. Roques et al. found 
that although weak association between amphiphilic block copolymers and DNA makes 
them relatively unfavorable for transfection compared to polyplexes, solutions containing 
Tetronic and pDNA were nonetheless able to achieve efficient gene expression in 
skeletal muscles [142]. While no studies have been done on the effects of Tetronics in 
polyplex transfection, several studies have demonstrated improved transfection 
efficiency using polyplex systems with Pluronics [147,222]. The activity of some 
Pluronics (P85, P123) is thought to be promoter dependent, acting primarily through 
activation of the NF-κB transcription factor to facilitate nuclear translocation and 
transcriptional activation [145,147]. Pluronics with high PEO content may increase 
transfection efficiency through facilitated plasma membrane transport, elevating uptake 
of polymers and even cationic lipids in a promoter independent manner [223]. In 
addition, Pluronics help stabilize polyplexes and provide additional protection from 
serum aggregation [224]. 
The objective of this study was to investigate the efficacy of Tetronic T904 as a 
biological response modifier for improving transfection efficiency of polyplex vectors 
using 25 kDa branched-PEI as a reference carrier. We investigated the transfection 
efficiency and promoter dependence of T904 using plasmids containing both 
cytomegalovirus (CMV) and Simian virus 40 (SV40) promoters that have shown different 
efficacy in previous studies with Pluronics [138,146]. We show that T904 significantly 
increases transfection efficiency and gene expression in a dose-dependent manner that 
is not promoter-dependent. In addition, we observe that T904 has little effect on polyplex 
internalization or nuclear uptake, while mRNA transcript levels closely parallel increases 
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in gene expression, suggesting that T904 acts through a mechanism of increasing 
transcriptional activity. 
3.2 Methods 
3.2.1 Cell culture 
Rat C6 glioma (C6, ATCC, Manassas, VA) were cultured in Dulbecco’s 
Modification of Eagle’s Medium/Ham’s F-12 50/50 mix with L-glutamine (DMEM/F12, 
Mediatech, Manassas, VA) with 5% bovine growth serum (BGS) (Hyclone, Logan, UT) 
and 1% penicillin and streptomycin (Mediatech). Normal human dermal fibroblasts 
(NHDF, Lonza, Walkersville, MD) were cultured in DMEM/F12 with 10% BGS and 1% 
penicillin and streptomycin. Human mesenchymal stem cells (hMSC, Lonza) were 
cultured in low glucose DMEM (Life Technologies, Carlsbad, CA) with 10% MSC-
qualified fetal bovine serum (FBS, Life Technologies), 10 ng/mL fibroblast growth factor-
2 (Peprotech, Rocky Hill, NJ), 1% GlutaMax (Life Technologies), and 1% penicillin and 
streptomycin. All cells were grown in a humidified incubator at 37°C in 5% CO2 
atmosphere. 
3.2.2 Polyplex formation and characterization 
Plasmids encoding Monster Green Fluorescent Protein phMGFP Vector under a 
CMV promoter (pCMV-GFP, Promega, Madison, WI) and beta-galactosidase under SV-
40 promoter (pSV40-β-gal, Promega) were transformed into Escherichia coli DH5α (Life 
Technologies), amplified in the presence of ampicillin, and purified using the Qiagen 
Mega Plus Prep kit (Qiagen, Valencia, CA). Plasmid concentrations were determined by 
UV spectrophotometry with Take 3 (Biotek, Winooski, VT). Polyplexes for transfection 
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were prepared by mixing pCMV-GFP or pSV40-β-gal and 25 kDa branched 
polyethylenimine (PEI, Sigma-Aldrich, St. Louis, MO) in water at PEI nitrogen to pDNA 
phosphate ratios (N/P) of 7.5/1 and incubated for 30 minutes at 37°C. T904 (generously 
donated by BASF, Florham Park, NJ) was dissolved in water (1 mM) and added to 
polyplex solutions to yield final concentrations specified in each experiment and 
thoroughly mixed prior to characterization or transfection. Particle size and zeta potential 
of polyplexes mixed with 5 μM Pluronics (F127, F68, P123, P85) or Tetronics (T1107, 
T304, T90R4) and varying amounts of T904 (0.1-10 μM) were measured by dynamic 
light scattering and electrophoresis using a ZetaPlus analyzer (Brookhaven, 
Worcestershire, UK) with sample size n=6.  
3.2.3 Initial investigation of the transfection efficiency and cytotoxicity of P85, P123, and 
T904 
 C6 cells were seeded in 12 well plates at densities yielding approximately 70% 
confluence after 24 hours incubation. Prior to transfection, growth medium was 
exchanged with fresh medium containing 5% serum. 100 µL polyplex solution 
(PEI/pCMV-GFP at N/P ratio 7.5/1, 2 µg pDNA) with P85, P123, or T904 at 10 μM final 
concentration per well was added drop wise into each well. Medium was exchanged with 
fresh medium containing 5% serum at 24 h post-transfection and incubated an additional 
24 hrs. Transfection efficiency or cytotoxicity was assessed 48 h post-transfection. Flow 
cytometry was used to determine transfection efficiency for cells transfected with pCMV-
GFP. Cells were washed with PBS, trypsinized, centrifuged at 1500 rpm for 3 minutes, 
fixed with 1% formaldehyde, and assayed using 5000 counts per sample in a Guava 
easyCyte flow cytometer (Millipore, Billerica, MA). Transfection efficiency for PEI/pCMV-
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GFP at each T904 concentration was expressed as % total cells transfected as well as 
transfection efficiency relative to PEI/pCMV-GFP with 0 µM T904 using mean 
fluorescence per cell (n=6). Relative transfection was calculated as the ratio of mean 
fluorescence per cell for each individual T904 concentration to the mean fluorescence 
per cell at 0 μM additives. Cytotoxicity was evaluated by MTT assay (n=6). 
3.2.4 Dose-dependent transfection efficiency and cytotoxicity using T904 
C6, NHDF, and hMSC cells were seeded in 12 well plates at densities yielding 
approximately 70% confluence after 24 hours incubation. Prior to transfection, growth 
medium was exchanged with fresh medium containing 5% serum. 100 µL polyplex 
solution (PEI/pDNA at N/P ratio 7.5/1, 2 µg pDNA) with T904 (0–10 µM final 
concentration in wells) was added drop wise into each well. Medium was exchanged 
with fresh medium containing 5% serum at 24 h post-transfection and incubated an 
additional 24 hrs. Transfection efficiency or cytotoxicity was assessed 48 h post-
transfection. Flow cytometry was used to determine transfection efficiency for cells 
transfected with pCMV-GFP as previously described. Gene expression in cells 
transfected with pSV40-β-gal was measured using the Pierce β-Galactosidase Assay Kit 
(Thermo Scientific). β-gal expression was normalized to total protein content determined 
by Pierce BCA Protein Assay Kit (Thermo Scientific). Transfection efficiency for PEI/ 
pSV40-β-gal at each T904 concentration was expressed as transfection efficiency 
relative to PEI/ pSV40-β-gal with 0 µM T904 using absorbance per mg protein with 
sample size n=6. Relative transfection was calculated as the ratio of absorbance per mg 
protein for each individual T904 concentration to the absorbance per mg protein at 0 μM 
T904. Cytotoxicity was evaluated by MTT assay (each experiment (n=3) independently 
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replicated 3 times). For visualization of transfection efficiency, cells were fixed using 4% 
paraformaldehyde 48 h after transfection and imaged using an epifluorescent 
microscopy (Zeiss Axiovert 200). 
3.2.5 Effect of delayed addition of T904 on transfection efficiency 
These studies evaluated the effect of T904 when added separately at various 
time points post-transfection. C6 cells were seeded, transfected with polyplexes (7.5/1 
N/P ratio, 2 µg DNA / well) in the presence of 5% serum for 4 h, and then changed to 
fresh medium with 5% serum. After an additional 0, 4, 8, or 24 h incubation, soluble 
T904 was added drop-wise into each well to a final concentration of 5 or 10 µM with 
medium exchange 24 h following the addition of T904. Transfection efficiency was 
assessed by flow cytometry 48 h after the initial 4 h transfection period regardless of the 
time point of T904 addition with sample size n=3. 
3.2.6 Plasmid and T904 labeling 
All reagents for labeling were purchased from Sigma-Aldrich unless otherwise 
stated. For transfection using labeled plasmids, pDNA was incubated with the nucleic 
acid stain YOYO-1 iodide (YOYO-1, Life Technologies) at a ratio of 0.02 µL YOYO-1 per 
microgram pDNA for 10 minutes at room temperature prior to complexation with PEI. 
T904 was labeled with rhodamine B isothiocyanate (RITC) using an adapted protocol 
[147]. The hydroxyl groups of T904 (200 mg) were activated using 213 mg 1,1’-
carbonyldiimidazole in 10 mL of acetonitrile for 2 h at 37°C and then reacted with 313 
mg ethylenediamine in 20 mL ethanol for 12 h at room temperature. The reaction 
mixture was first dialyzed in a 2 kDa MWCO membrane (Spectrum Laboratories, 
Rancho Dominguez, CA) against 15% ethanol for 24 h and then dialyzed against 
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deionized water for 48 h and finally lyophilized to obtain amino-T904. Amino-T904 (5 
mg) was dissolved in 2 mL acetonitrile, mixed with 2 mL 0.1 M sodium carbonate buffer, 
and reacted with 10 mg RITC in 1 mL dimethylformamide. After 2 h reaction at room 
temperature T904-RITC was dialyzed against 20% ethanol for 24 h and then deionized 
water for 48 h at 4 °C in the dark and lyophilized. 
3.2.7 Polyplex and T904 localization using confocal microscopy 
Localization of polyplex and T904 was examined using a Nikon Ti laser-scanning 
confocal microscope (Melville, NY). C6 cells were seeded (150,000 cells/mL) in 
chambered cell culture slides (Thermo Scientific, Rochester, NY) with 1 mL working 
volume and surface area similar to 12 well plate wells. After 24 h, media was exchanged 
with DMEM/F12 without phenol-red (Mediatech) containing 5% serum and polyplex 
solution (2 μg YOYO-1 labeled pCMV-GFP) with or without a 5 µM T904-RITC mixture 
(T904-RITC:T904 = 1:10) was added drop-wise to each well. In addition, 5 µL Hoechst 
33342 trihydrochloride (2 mg/mL in water) was added to each chamber 10 minutes prior 
to imaging to visualize nuclei. Fluorescent images were obtained in a z-stack with 1 
horizontal image at the approximate center of each stack used to visualize the 
distribution of internalized T904-RITC and YOYO-1-labeled pDNA and the nucleus. 
3.2.8 Polyplex uptake 
Cells were transfected as described above using polyplexes containing YOYO-1 
labeled pCMV-GFP or pSV40-β-gal with 0-5 µM T904 or P123. At 0.5, 2, and 4 h post-
transfection, cells were washed with cold PBS, fixed, and cellular uptake of polyplexes 
measured using flow cytometry and expressed as mean fluorescence per cell relative to 
PEI/pCMV-GFP at 30 minutes with sample size n=3 replicated 3 times. Cell uptake of 
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YOYO-1 labeled pCMV-GFP was assessed at 4 °C where endocytosis is inhibited and 
compared to internalization at 37 °C for the possibility that non-internalized vector 
associated with the exterior of the plasma membrane may skew cell uptake results. 
Mean fluorescence per cell was assessed at 2 and 4 h post-transfection and expressed 
as mean fluorescence per cell relative to the non-transfected control with sample size 
n=3. 
3.2.9 Nuclear localization 
C6 cells were transfected as previously described with YOYO-1 labeled pCMV-
GFP or pSV40-β-gal and 0-10 µM T904 or P123. After 2, 4, or 8 h; cells were 
trypsinized, washed with cold PBS, and centrifuged at 1500 RPM for 3 minutes. To 
isolate nuclei, cell pellets with approximately 5 x 106 cells were gently resuspended in 
500 µL hypotonic buffer containing 20 mM Tris-HCl (pH 7.4), 10 mM NaCl, and 3 mM 
MgCl2 and incubated on ice for 15 minutes. Nuclei were isolated with the addition of 25 
µL 10% NP-40 (Life Technologies) and vortexing on highest setting for 8 seconds. The 
homogenate was then centrifuged for 10 minutes at 3,000 RPM and 4°C and washed 
twice with cold PBS. Recovered nuclei pellets were resuspended in PBS and assayed 
by flow cytometry. Nuclear localization for each group was expressed as mean 
fluorescence per nucleus relative to YOYO-1 labeled pCMV-GFP at 2 h (each 
experiment (n=3) independently replicated 3 times). 
3.2.10 Quantitative RT-PCR 
Total RNA was isolated from C6 cells transfected with PEI/pCMV-GFP or 
PEI/pSV40-β-gal and 0-10 µM T904 at 24 h post-transfection using the Qiagen RNeasy 
mini kit (Qiagen). Isolated RNA was treated with Turbo DNA-free DNase I Kit (Life 
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Technologies) to remove trace amounts of genomic or plasmid DNA. cDNA was 
synthesized using 1 µg of total RNA from each sample as template using Retroscript Kit 
(Life Technologies). Real-time RT-PCR was performed with Quantitect SYBR green 
PCR Kit (Qiagen) using  primers designed for the GFP (5’-
ATCATGGCCGACAAGCAGAAGAAC-3’ and 5’-TCTTGAAGTCGCAGCGGTAG-3’) and 
β-galactosidase reporter genes ( 5’CGGACACGGACAGGATTGACAGAT-3’ and 5’-
TCAATCTCGGGTGGCTGAACGC-3’) as well as endogenous genes Interleukin-6 (IL-6, 
5’-GTATGAACAGCGATGATGCAC-3’ and 5’-GACCAGAAGACCTCAAGGCA-3’), IκB-α 
(5’-TGGAGCACTTGGTGACTTTG-3’ and 5’-CAGAGCGAGGACAACTTCAC-3’), and 
heat shock protein (hsp70, 5’-GCGAGGCTGACAAGAAGAAG-3’ and 5’-
CACGTTGGGCTAGTAGTCG-3’) with glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) internal standard in a Rotor-Gene 3000 Real-Time Thermal Cycler (Qiagen). 
Relative gene expression levels were calculated using 2-ΔΔCt method with GAPDH as an 
internal standard [225] (each experiment (n=3) independently replicated 3 times). 
3.2.11 Lipoplex transfection efficiency 
Lipoplexes for transfection were prepared by mixing equal volume solutions of 
Opti-MEM (Life Technologies) containing either 0.1 μg pCMV-GFP or 0.1 μL 
Lipofectamine® 2000 (Life Technologies) and incubating for 5 minutes at room 
temperature. C6 cells were seeded in 24 well plates at densities yielding approximately 
70% confluence after 24 hours incubation. Prior to transfection, growth medium was 
exchanged with fresh medium containing 5% serum. 50 µL lipoplex solutions were 
added drop wise into each well. Medium was exchanged with fresh medium containing 
5% serum at 4 h post-transfection and incubated an additional 24 h with T904 at 0-10 
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μM final concentration per well. Transfection efficiency or cytotoxicity was assessed 48 h 
post-transfection. Gene expression in cells was measured using flow cytometry and 
expressed as both percent cells transfected and relative transfection efficiency as 
previously described. 
3.2.12 Statistical analysis 
Results were analyzed using one-way ANOVA with Tukey’s test for mean 
differences (significance p<0.05). 
3.3 Results 
3.3.1 Particle size and zeta potential 
We first examined the potential effect of T904 on the physical/chemical 
properties of 25 kDa branched PEI-based polyplexes (Table 3.1). Particle size of 
PEI/pDNA complexes was about 137 nm and increased slightly in the presence of T904. 
Zeta potential of PEI/pDNA was about 41.16 mV and modestly decreased at higher 
T904 concentrations. Overall, all complexes retained particle size less than 200 nm and 
positive charge suitable for efficient cellular uptake. 
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Table 3.1 
  Particle size and zeta potential of PEI/pDNA (N/P = 7.5/1) with various additives 
Additive Particle size (nm) Zeta potential (mV) 
 
137 ±0.6 41.16 ±0.5 
5 μM F68 151.8 ±1.7 37.19 ±0.4 
5 μM F127 150.7 ±0.8 34.17 ±0.1 
5 μM P85 144.7 ±2 37.23 ±1.2 
5 μM P123 153.1 ±2.7 36.83 ±1.1 
5 μM T90R4 158.5 ±2 38.53 ±3.6 
5 μM T304 155.9 ±1.2 35.19 ±1 
5 μM T1107 147.6 ±2 30.01 ±.3 
1 μM T904 146.4 ±1.1 41.7 ±0.1 
2.5 μM T904 142.4 ±1.2 40.26 ±1.6 
5 μM T904 152.2 ±1.6 43.18 ±2.6 
7.5 μM T904 136.7 ±2 37.22 ± 1.4 
10 μM T904 156.1 ±0.2 34.78 ±0.8 
 
3.3.2 Transfection efficiency and cytotoxicity of P85, P123, and T904 
 Prior to investigating the specific effects of T904 on polyplex transfection, we 
examined the effect of several Pluronic and Tetronic formulations previously shown to 
have positive effects on either plasmid or polyplex transfection. Figures 3.1A and 3.1B 
show that the addition of 10 μM T904, P85, and P123 significantly increased the 
transfection efficiency of PEI/pCMV-GFP (N/P = 7.5/1) relative to PEI 7.5/1 alone 
(#P<0.05). In addition, transfection efficiency with T904 was significantly higher than with 
either Pluronic (*P<0.05). Figure 3.1C shows that the viability of cells were significantly 
reduced with the addition of 10 μM T904, P85, and P123 compared to PEI 7.5/1 alone 
(P<0.05). 
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Figure 3.1. Transfection efficiency of PEI/pCMV-GFP (N/P=7.5/1) with 10 μM T904, 
P85, and P123 in the presence of 5% serum measured by flow cytometry expressed as 
% cells transfected (A) and relative expression calculated by mean fluorescence relative 
to PEI/pCMV-GFP alone (B). (*P<0.05, #P<0.05 compared to PEI/pCMV-GFP alone) 
Corresponding cell viability based on MTT assay (C). (*P<0.05 compared to PEI/pCMV-
GFP alone) 
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3.3.3 Dose-dependent transfection efficiency and cytotoxicity using T904 
We next investigated the effect of T904 at varying concentrations on polyplex-
mediated transfection and cell viability. Addition of T904 caused significant dose-
dependent increases in transfection in C6 cells (Figure 3.2A). Transfection efficiency 
increased from 12.3% without T904 to 79.5% with 10 µM T904. Relative transfection 
measured by mean fluorescence increased approximately 2-, 8-, and 18-fold at 5, 7.5 
and 10 µM T904, respectively (Figure 3.2B). Cell viability measured by MTT assay 
significantly decreased only at 10 µM relative to cells transfected with PEI/pCMV-GFP 
alone (Figure 3.2C). Cell viability in cultures transfected with PEI/pCMV-GFP alone was 
approximately 90% and greater than 75% for all groups transfected in the presence of 
T904. In a separate experiment, we also tested the cytotoxicity of T904 in non-
transfected cells and found that T904 had no significant effect on viability up to 20 μM, 
the maximum concentration tested (data not shown). Figure 3.2D shows representative 
images of cells transfected with varying concentrations of T904.  
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Figure 3.2. Transfection efficiency of PEI/pCMV-GFP (N/P=7.5/1) with T904 (0-10 μM) 
in C6 cells in the presence of serum expressed as % cells transfected measured by flow 
cytometry (A) and relative gene expression with respect to 0 μM T904 based on mean 
fluorescence measured by flow cytometry (B). Corresponding cell viability based on MTT 
assay (C). Representative fluorescent images of C6 cells transfected with PEI/pCMV-
GFP and 0-10 μM T904 (D). Original magnification, 100X. Scale bar represents 100 μm. 
(*P<0.05 compared to 0 μM T904). 
We also evaluated the effect of T904 on transfection and cell viability in primary 
human cell cultures. Transfection efficiency in NHDF increased with increasing T904 
concentration and all groups transfected in the presence of T904 exhibited significantly 
higher transfection than the group transfected with PEI/pCMV-GFP alone (Figure 3.3A). 
Cell viability significantly decreased at 10 µM T904 relative to cells transfected with 
PEI/pCMV-GFP alone (Figure 3.3B). T904 also significantly increased transfection 
efficiency in hMSC at all concentrations, although the highest level was achieved at 5 
µM T904 with 10.2% cells transfected compared to 1.6% cells transfected in the 
absence of T904 (Figure 3.3C). However, transfection efficiency subsequently 
decreased at 7.5 µM and 10 µM T904, likely caused by moderate cytotoxicity at higher 
T904 concentrations (Figure 3.3D). 
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Figure 3.3. Transfection efficiency of PEI/pCMV-GFP (N/P=7.5/1) with T904 (0-10 μM) 
in NHDF (A) and hMSC (C) in the presence of serum expressed as % cells transfected 
based on flow cytometry and corresponding cell viability of NHDF (B) and hMSC (D) 
based on MTT assay. (*P<0.05 compared to 0 μM T904) 
 In order to investigate whether the ability of T904 to increase transfection was 
promoter-dependent, transfection studies were also performed using a plasmid encoding 
beta-galactosidase under the SV-40 promoter. Transfection increased in a dose-
dependent manner with increasing T904 concentration, achieving an approximately 23-
fold increase in the presence of 10 µM T904 relative to transfection with PEI/pSV40-β-
gal alone (Figure 3.4). 
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Figure 3.4. Transfection efficiency of PEI/pSV40-β-gal (N/P=7.5/1) with T904 (0-10 μM) 
in C6 cells in the presence of serum expressed as relative transfection with respect to 0 
μM T904 based on β-gal activity normalized to total protein. (*P<0.05 relative to 0 μM 
T904) 
3.3.4 Effect of delayed T904 addition 
As a first step towards differentiating between possible effects of T904 on cellular 
internalization of polyplex versus later intracellular events, we performed a 4 hour 
transfection using PEI/pCMV-GFP polyplex alone followed by medium exchange and 
addition of soluble T904 either immediately (time 0) or at 4, 8, and 24 hours later during 
culture (Figure 3.5). Our expectation was that if cellular uptake of polyplex or to a lesser 
extent nuclear import of plasmid were the primary mechanisms by which T904 acted to 
increase transfection efficiency, delaying the delivery of T904 to cells after transfection 
would render T904 ineffective. While transfection efficiency decreased with increasing 
delay of T904 addition, all transfection conditions including a delay of 24 h between 
polyplex incubation and T904 addition resulted in significant increases in transfection 
efficiency compared to PEI/pCMV-GFP without T904. Overall transfection levels both 
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with and without T904 were slightly lower than observed in the initial dose-response 
studies, likely due to the 4 h exposure to polyplex in these studies as opposed to the 24 
h exposure time used earlier.   
 
Figure 3.5. Transfection efficiency of PEI/pCMV-GFP (N/P=7.5/1) in C6 cells in the 
presence of serum expressed as % cells transfected measured by flow cytometry. Cells 
were transfected for 4 hours, medium exchanged, and T904 added immediately (0 h) or 
4, 8, or 24 h after transfection at final concentrations of 5 and 10 μM. Analysis of all 
samples was performed 48 hours after the initial 4 hour transfection period (*P<0.05 
relative to 0 μM T904) 
3.3.5 Polyplex and T904 localization confocal microscopy 
Figure 3.6 shows representative single horizontal slices from confocal 
microscopy demonstrating high cell uptake of polyplex with and without fluorescently 
labeled 5 µM T904 after transfection with YOYO-1 labeled pCMV-GFP. At every time 
point T904-RITC was detected in both the cytoplasm and nuclei with elevated 
perinuclear localization, leading to the formation of a distinct border around the nuclei. 
No qualitative difference in cell internalization or nuclear localization of YOYO-1 labeled 
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plasmid between transfection with and without 5 µM T904 was conclusively evident by 
confocal microscopy. 
 
Figure 3.6. Representative confocal images of C6 cells transfected for 0.5, 2, and 4 
hours with YOYO-1 labeled pCMV-GFP, 5 μM RITC-labeled T904, and nuclei stained by 
Hoechst 33342 (C). Scale bar represents 25 μm. 
3.3.6 Polyplex uptake and nuclear localization 
 Fluorescently labeled pDNA was used to investigate the effects of T904 and 
P123 on polyplex internalization and nuclear uptake using pCMV-GFP and pSV40-β-gal 
plasmids. While the cell uptake of polyplex measured by mean fluorescence increased 
with increasing time of transfection, neither T904 nor P123 had any significant impact on 
cell uptake measured by mean fluorescence at 0.5, 2, or 4 h (Figure 3.7A and B) 
(P<0.05).  
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Figure 3.7. Cell internalization of YOYO-1 labeled pCMV-GFP or pSV40-β-gal following 
transfection with 0 or 5 μM T904 (A) or P123 (B) in C6 cells in the presence of serum 
expressed as mean fluorescence measured by flow cytometry relative to PEI/pCMV-
GFP at the earliest time point. 
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The impact of cell membrane bound polyplex on the mean fluorescence was 
minimal as transfection at 4 °C yielded <5% mean fluorescence relative to 
corresponding transfection conditions at 37 °C (Figure 3.8).  
 
 
 
Figure 3.8. Cell internalization of YOYO-1 labeled pCMV-GFP following transfection with 
PEI/pCMV-GFP (N/P = 7.5/1) at 4 °C and 37 °C in C6 cells in the presence of serum 
expressed as mean fluorescence measured by flow cytometry relative to the non-
transfected control. 
T904 did not significantly increase the amount of plasmid in the nucleus at 2, 4, 
or 8 h (Figure 3.9A). Although increased nuclear localization of pCMV-GFP was 
detected following the addition of P123 to PEI transfection, the results were not 
statistically significant (P<0.05) (Figure 3.9B). 
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Figure 3.9. Nuclear localization of YOYO-1 labeled pCMV-GFP or pSV40-β-gal following 
transfection with 0, 5, or 10 μM T904 (A) or P123 (B) in C6 cells in the presence of 
serum expressed as mean fluorescence measured by flow cytometry relative to 
PEI/pCMV-GFP at the earliest time point. 
3.3.7 Transcriptional activity 
The effect of T904 on GFP and β-galactosidase mRNA expression levels was 
examined by qRT-PCR after transfection of both pCMV-GFP and pSV40-β-gal. 
Regardless of plasmid promoter type, the addition of T904 to PEI/pDNA polyplexes 
increased mRNA levels in a dose-dependent manner (Figure 3.10). Following 24 h 
incubation with polyplex and 10 µM T904, relative mRNA expression levels were 
significantly higher at 7.5 and 10 µM T904 relative to polyplex alone. Expression levels 
of β-gal were significantly higher than GFP at 7.5 µM T904, but not at 10 µM.  
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Figure 3.10. mRNA expression levels of reporter genes after transfection with 
PEI/pCMV-GFP and PEI/pSV40-β-gal with T904 (0-10 μM) in C6 cells in the presence of 
serum, presented as relative changes with respect to transfection with each plasmid 
without T904 (0 μM). (*P<0.05 relative to 0 μM T904; #P<0.05 relative to other plasmid 
at same T904 concentration). 
 
The effect of T904 on mRNA expression levels of several endogenous genes 
associated with the NF-
significantly increased IL-6 expression in a dose dependent manner with both plasmid 
types at 7.5 and 10 μM T904 relative to polyplex alone (Figure 3.11). However, the 
expression levels of IκB-α and hsp70 remained relatively unchanged except for 
transfection with pSV40-β-gal and 10 μM T904 where a significant increase in IκB-α 
mRNA expression was detected. 
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Figure 3.11. mRNA expression levels of endogenous genes after transfection with 
PEI/pCMV-GFP and PEI/pSV40-β-gal with T904 (0-10 μM) in C6 cells in the presence of 
serum. The expression level of each individual gene is presented with respect to the 
non-transfected control (*P<0.05 relative to 0 μM T904). 
 
3.3.8 Lipoplex transfection 
 The ability for T904 to enhance the transfection efficiency of Lipofectamine 2000 
was examined using C6 cells. Our expectation was that if the activity of T904 could be 
attributed primarily to transcriptional activation, it would enhance the transfection 
efficiency of not only polyplexes, but also lipoplexes. T904 (5-10 μM) significantly 
enhanced the transfection efficiency of Lipofectamine 2000 measure by both percent of 
cells transfected (Figure 3.12A) as well as overall protein expression levels measured by 
mean fluorescence expressed as relative transfection efficiency (Figure 3.12B) (P<0.05). 
No significant cytotoxicity was detected due to the usage of very low reference 
concentration of Lipofectamine 2000 reagent (data not shown). 
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Figure 3.12. Transfection efficiency of Lipofectamine 2000/pCMV-GFP (1/1 v/w) in C6 
cells in the presence of serum expressed as % cells transfected measured by flow 
cytometry (A) and relative gene expression with respect to 0 μM T904 based on mean 
fluorescence measured by flow cytometry (B). (*P<0.05 relative to 0 μM T904) 
3.4 Discussion 
 Recent efforts to enhance the transfection efficiency of nonviral vectors to 
improve their viability in vivo have resulted in the development of a number of new 
carrier formulations based primarily on chemical and physical iterations of existing 
successful polymers and lipids [38]. A majority of these new vectors seek to overcome 
existing extracellular barriers to gene delivery by substitution of protective or bioactive 
moieties onto popular reference carriers such as PEI [226–228]. However, complex 
chemical or physical modification of existing vectors often fails to address the 
intracellular barriers to nonviral delivery and largely only address problems associated 
with systemic bioavailability. With the advent and growth in popularity of scaffold-
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mediated gene delivery, the next generation of nonviral vectors must also be able to 
address the intracellular barriers to nonviral gene delivery in order to bring the efficiency 
of nonviral transfection on par with viral gene delivery. Biological response modifiers 
such as amphiphilic block copolymers that activate intracellular biochemical processes 
and facilitate transgene expression have recently emerged as potent compliments to 
nonviral gene carriers. Several Pluronic formulations have been shown to have broad 
effects on intracellular processes that contribute toward enhanced transgene expression 
such as cell uptake, nuclear localization, and transcriptional activation [145,147]. Despite 
similarities in chemical composition between triblock Pluronics and 4-arm Tetronics, no 
investigations have been made on the efficacy of the latter in polyplex or lipoplex 
transfection. 
We examine here for the first time how poloxamines can modify the behavior of 
cells to enhance the in vitro transfection efficiency of a widely used reference vector, 25 
kDa branched-PEI. The ability for T904 to enhance transfection efficiency was directly 
compared to P85 and P123 previously utilized in other in vitro studies to improve the 
transfection efficiency of polyplexes [147]. While both Pluronics were able to improve the 
transgene expression of PEI, T904 at the same concentration produced approximately 
3-5 fold higher levels of transgene expression compared to both P85 and P123. In 
addition, T904 was able to significantly increase polyplex-mediated transfection of C6, 
NHDF, and hMSC in a generally dose-dependent manner without substantially changing 
the physical/chemical characteristics of the polyplex itself. Overall gene expression 
levels as well as the impact of T904 on transfection efficiency were substantially higher 
in C6 cells compared to NHDF or hMSC, likely due to the inherently higher levels of 
gene expression observed in transformed and immortalized cell lines compared to 
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primary cells [39]. Cells were exposed to a maximum of 10 µM (0.0067% w/v) T904 for 
24 h in all transfection experiments due to a reduction in cell viability at higher T904 
concentrations. However, in the absence of polyplex, 10 µM T904 did not cause any 
toxicity in C6 cells, indicating that T904 alone does not have a significant impact on cell 
viability. Many previous studies have used considerably higher concentrations of 
Pluronics (0.03-1.0%), consistent with bolus delivery and subsequent diffusion in 
intramuscular gene transfer applications [145–147,221]. Because our long-term goal is 
to create T904-based hydrogels for local nonviral gene delivery, we used relatively lower 
concentrations of T904 and longer exposure times to more closely approximate release 
of T904 during hydrogel degradation. 
Many previous studies have observed that the ability of Pluronics to increase 
nonviral transfection and gene expression is dependent on the use of the CMV promoter 
that contains binding sites for the NF-κB transcription factor [138,146,229]. Pluronic P85 
has been shown to activate the NF-κB signaling pathway in cultured cells and inhibition 
of this pathway blocked Pluronic-mediated increases in transfection in intramuscular 
injection models [147,230]. The possibility that T904 may share this promoter-dependent 
activity with Pluronics was assessed by transfecting C6 cells using PEI/pSV40-β-gal. 
Beta-galactosidase expression increased significantly with T904 dosage, achieving 23-
fold higher expression. We have also qualitatively observed substantial increases in 
gene expression from another vector using the human EF-1α promoter (data not shown). 
These results suggest that unlike certain Pluronic formulations, T904 may act 
independent of promoter type and not rely on the NF-κB pathway to enhance 
transfection efficiency. 
 88 
 
In order to gain more insight into T904’s mechanism of action, we investigated its 
effect on several key steps in transfection. One potential explanation for the activity of 
T904 is increased cell uptake of polyplex due to membrane destabilization previously 
observed with some PEO/PPO block copolymers such as Lutrol® [223] and P123 [147]. 
We first tested this possibility indirectly by adding T904 to transfected cultures at varying 
time points after removal of polyplex. If T904 acts by facilitating vector internalization, 
this approach would be expected to significantly reduce transfection. However, 
transgene expression was enhanced significantly following addition of T904 at every 
time point, consistent with a previous in vivo test of delayed administration [230]. Next, 
we examined internalization of fluorescently labeled plasmid by flow cytometry following 
transfection with either T904 or P123. Neither block copolymer increased the 
internalization of plasmid, despite prior evidence suggesting that P123 may have a 
positive effect on polyplex uptake into cell [147]. However, the substantially reduced 
concentrations of T904 and P123 used in this study compared to prior work by Kabanov 
and coworkers make direct comparisons of mechanistic activity difficult. These results 
strongly suggest that in the present study, the primary mechanism of T904 and P123 
activity was modification of intracellular processes affecting transfection efficiency and 
not interactions with the cell membrane for increased uptake of polyplex. Recent work 
from Wasungu et al. also showed that Pluronic L64 increases gene expression without 
affecting membrane permeability or DNA transport in electroporation [231]. The 
difference in polyplex internalization activity between some poloxamers formulations 
such as Lutrol and Pluronic L64/ Tetronic T904 is likely a result of the difference in their 
composition, specifically hydrophilic / lipophilic balance [Lutrol: 24; L64/T904: 12-18] that 
influences their interactions will cellular membranes [133,232]. 
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In order to achieve transgene expression, vectors must ultimately reach the cell 
nucleus. The nuclear membrane is widely considered a critical barrier to efficient 
nonviral transfection, particularly in non-dividing cells [233]. Recently, Yang et al. 
demonstrated significant increases in nuclear localization of plasmid vectors containing a 
CMV promoter following polyplex transfection with P123 [147]. The proposed 
mechanism was that Pluronic-activated NF-κB binds to sites within the CMV promoter 
providing a nuclear localization signal that can facilitate association with importins and 
active transport across the nuclear membrane. Gonçalves recently reported similar 
results where a plasmid containing a minimal promoter modified with three NF-κB 
binding sites achieved significantly increased transgene expression and nuclear uptake 
in cells stimulated with the NF-κB activator TNF-α, while nuclear uptake was significantly 
reduced in the presence of an NF-κB inhibitor [234]. Similar DNA targeting sequences 
(DTS) capable of facilitating nuclear transport have been identified in other promoters as 
well [235]. In particular, specific regions of the SV40 viral promoter often used in plasmid 
design facilitates active transport of cytoplasmic DNA through the nuclear pore complex 
[111]. We observed that the addition of P123 had minimal effects on the nuclear 
localization of plasmid, likely due to the reduced concentrations used in the present 
study. While differences in localization due to the presence of P123 were not statistically 
significant, P123 was still able to somewhat enhance the nuclear uptake of CMV-
promoter plasmid in a dose dependent manner. In contrast, T904 did not have any effect 
on the amount of plasmid detected in the nucleus for either plasmid containing CMV or 
SV40 promoters. This may reflect the relatively rapid cell division rate of C6 cells since 
breakdown of the nuclear membrane during mitosis is a key mechanism of nuclear 
access in dividing cells [236]. One confounding variable in the analysis of plasmid within 
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the nucleus is potential interference from vectors bound to the exterior of the nuclear 
membrane [114]. However, we did not observe any aggregation of nuclei indicative of 
excessive membrane bound polyplexes as has been previously described [237] and 
attempts at decomplexation of nuclear bound polyplexes with anionic sodium 
tripolyphosphate or non-labeled pDNA and digestion with restriction enzymes for both 
plasmid types did not significantly alter any flow cytometric observations (data not 
shown). 
Since T904 did not affect the amount of plasmid within the nucleus, we 
considered potential changes in mRNA expression levels to be the most probable 
mechanism of action. qRT-PCR confirmed that mRNA transcript levels increased 
significantly with the addition of T904 in a dose-dependent manner with increasing T904 
concentration that closely paralleled gene expression levels. This response was 
consistent for transfection with both pCMV-GFP and pSV40-β-gal plasmids. These 
results demonstrate that the increases in gene expression observed following polyplex 
transfection with T904 results primarily from the higher availability of mRNA transcripts. 
This outcome is consistent with an earlier study from Kabanov’s group in which it was 
shown that Pluronics P85 and L64 increased mRNA levels and protein expression in 
stably transfected cell lines where internalization / nuclear import were not variables 
[145].  
In order to further investigate the potential role of transcription factor activity in 
T904-mediated increased transfection, we examined the expression levels of three 
endogenous genes associated with the NF- -6 known to be regulated 
primarily by AP-1 driven transcription and indirectly by NF-κB [238], IκB-α stimulated by 
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the activation of NF-κB as part of a negative feedback mechanism [239], and hsp70 
which is part of a family of stress inducible heat shock proteins previously examined by 
Sriadibhatla et al. for its activation by Pluronics in association with NF-κB activity [145]. If 
NF-κB activity played a critical role in transcriptional activation, all three endogenous 
genes would be expected to experience increased mRNA expression levels with 
increasing amounts of T904 during transfection with pCMV-GFP. However, neither IκB-α 
or hsp70 mRNA levels were substantially affected by T904. In contrast, IL-6 expression 
was significantly increased by both pCMV-GFP and pSV40-β-gal. The contrasting 
transcriptional response of IL-6 and the other two endogenous genes suggests that 
T904 may act through transcription factors other than NF-kB, possibly including AP-1.  
Due to our observations that T904 had no effect on cell or nuclear uptake of 
fluorescently labeled plasmid, we proceeded to examine whether it could also enhance 
the transfection efficiency of a lipoplex. Cohen et al. observed that even when similar 
amounts of fluorescently labeled plasmid were localized within the nucleus, lipoplex 
transfection displayed typically 10-fold higher transgene expression than polyplex 
transfection [237]. The reason for the disparity in transfection efficiency may have been 
a result of nuclear entry by plasmid still bound to the cationic polymer. Unpacking of 
polyplex in the nucleus represents a key rate-limiting step in polyplex-mediated 
transfection [240] and any effects of T904 on vector unpacking would ultimately go 
undetected by flow cytometric analysis of fluorescently labeled pDNA. In addition, 
improved vector unpacking within the nucleus as a result of T904-assisted polyplex 
transfection would also enhance the transcription of transgene mRNA due to the 
improved availability of plasmid copies. In order to assess whether vector unpacking 
lead to the observed increase in polyplex transfection efficiency following T904 addition, 
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the effect of T904 on lipoplex transfection was examined. Unlike polyplexes, lipoplexes 
dissociate following endosomal escape and only free pDNA is localized within the 
nucleus [237]. Therefore, any improvements in the transfection efficiency of lipoplex 
would likely be a result of transcriptional activation. We opted for the delayed 
transfection procedure and a very small dose of lipoplex to rule out possible effects of 
T904 on lipoplex cell uptake and to attempt to match the reference transfection efficiency 
of branched PEI. T904 was able to significantly enhance the transfection efficiency of 
Lipofectamine 2000 in a dose dependent manner, indicating that the activity of T904 was 
independent of the presence of the carrier in the nucleus and was more likely associated 
with the presence of plasmid.  
3.5 Conclusion 
The present studies demonstrate for the first time that like several poloxamers 
formulations, poloxamines such as T904 are capable of having a significant positive 
impact on the transfection efficiency of nonviral vectors. Unlike Pluronics whose activity 
may be closely linked to cell uptake or nuclear localization of polyplex or plasmid, T904 
had no effect on the trafficking of vector either into the cell or the nucleus. Instead, T904 
significantly increased the expression of transgene and endogenous IL-6 mRNA through 
a mechanism of enhanced transcription factor activity. We also found that T904 was 
capable of enhancing lipoplex transfection, indicating that its activity may be 
independent of intranuclear polyplex dissociation. Taken altogether, these findings 
suggest that enhanced transfection efficiency of branched PEI following the addition of 
T904 was primarily a result of increased transcription factor activity independent of both 
the NF-κB pathway and vector unpacking in the nucleus. 
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CHAPTER 4 
POLOXAMINE/FIBRIN HYBRID HYDROGELS FOR 
NONVIRAL GENE DELIVERY 
Abstract 
Hydrogels have been widely investigated for localized, sustained gene delivery 
due to the similarity of their physical properties to native extracellular matrix and their 
ability to be formed under mild conditions amenable to the incorporation of bioactive 
molecules. The objective of this study was to develop bioactive hydrogels composed of 
macromolecules capable of enhancing the efficiency of nonviral vectors. Hybrid 
hydrogels were prepared by simultaneous enzymatic and Michael-type addition 
crosslinking of reduced fibrinogen and an acrylated amphiphilic block copolymer, 
Tetronic T904, in the presence of dithiothreitol and thrombin. T904/fibrin hydrogels 
degraded by surface erosion in the presence of plasmin and provided sustained release 
of jetPEI/pGFP polyplex vectors up to an order of magnitude longer than pure fibrin gel 
control. In addition, the rate of gel degradation and time course of polyplex vector 
release were readily controlled by varying the T904/fibrinogen ratio in the gel 
composition. When added to transfected neuroblastoma (N2A) cells, both native T904 
itself and hydrogel degradation products significantly increased polyplex transfection 
efficiency with minimal effect on cell viability. Hybrid hydrogels were able to transfect 
N2A cells encapsulated within small fibrin clusters in three different gel transfection 
models. Cells progressively degraded and invaded the hybrid hydrogels, exhibiting 
increasing gene expression over two to three weeks and then diminishing but persistent 
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gene expression for over one month with overall expression levels greater than pure 
fibrin alone in the gel-on-gel model. In conclusion, these results demonstrate that 
T904/fibrin hybrid hydrogels can be promising tissue engineering scaffolds that provide 
local, controlled release of nonviral vectors in combination with the generation of 
bioactive gel degradation products that actively enhance vector efficiency. 
Keywords: nonviral, poloxamine, hydrogel, gene delivery, controlled release, 
biosynthetic 
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4.1 Introduction 
 As previously mentioned in chapter 1, Localized gene delivery from biomaterial 
scaffolds offers several crucial benefits over systemic delivery including controlled 
release, vector protection, and improved bioavailability [167]. In the context of rational 
nonviral vector design, localized scaffold-mediated delivery addresses many of the 
extracellular barriers associated with gene delivery. Incorporation of polyplex and 
lipoplexes into scaffolds reduces their exposure to serum and protects vectors from 
aggregation with negatively charged serum proteins by sequestering them near the 
target therapeutic site, reducing the need for long circulatory duration and eliminating 
concerns with first-pass organ accumulation. Hydrogels are particularly attractive as 
potential gene delivery scaffolds as they can be formed under mild conditions in order to 
preserve the activity of incorporated therapeutics and can be delivered by injection to 
minimize damage to surround tissue [165]. In addition, the physicochemical properties of 
many hydrogels can be modified to mimic the properties of native ECM and soft tissue 
[154,241]. 
Naturally-derived hydrogels intrinsically support cell adhesion and growth and 
can release entrapped vectors in response to cellular enzymatic activity [242]. Although 
effective in a variety of in vitro and in vivo models, their limitations include relatively low 
mechanical properties, difficulty in controlling degradation/release rates, and in some 
cases inefficient vector entrapment leading to burst release [170,197,201]. Fully 
synthetic hydrogels provide superior control over chemical and physical properties, but 
lack intrinsic bioactivity and responsiveness to cellular activity. Vector release occurs 
through a combination of diffusion and hydrolytic degradation, requiring careful tailoring 
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of network properties to obtain controlled release [181]. Recently, much attention has 
focused on hybrid or biosynthetic hydrogels composed of both naturally-derived and 
synthetic components with the goal of integrating the beneficial characteristics of each 
[243,244]. Examples investigated for gene delivery include polyethylene glycol (PEG) / 
hyaluronic acid interpenetrating networks and PEG crosslinked with protease-sensitive 
synthetic peptides derived from the sequence of natural extracellular matrix substrates 
[153,188–191]. Despite significant progress, controlling hydrogel degradation rate/ 
vector release kinetics and improving transfection efficiency remain challenges.  
The objective of this study was to investigate the potential for a hybrid 
biosynthetic hydrogel composed of fibrinogen (FgN) and T904 to simultaneously provide 
a provisional matrix for tissue regeneration as well as improve the transfection efficiency 
of encapsulated polyplex. Current variations of hybrid hydrogels for gene delivery focus 
on enhanced degradation of the synthetic component, usually PEG, with protein [153] or 
peptide [190] augmentations to provide substrates for cell infiltration or proteolysis.  In 
contrast to largely bio-inert synthetic polymers like PEG, T904 is uniquely positioned to 
improve on current gene delivery scaffold paradigms by providing additional functionality 
to the gene delivery scaffold. When released in is soluble form during degradation, T904 
addresses several intracellular barriers to nonviral gene delivery such as cell uptake of 
vector, nuclear import of exogenous DNA, and can enhance RNA transcript production. 
A purely synthetic T904 hydrogel degrades too slowly via hydrolysis in physiological 
conditions to provide adequate bioavailability of encapsulated vectors and T904 itself is 
not known to support cell adhesion. The incorporation FgN which can be converted by 
thrombin into fibrin as a complement to synthetic T904 provides much needed cell 
adhesive capabilities and enzymatic degradability to the hybrid hydrogel matrix. Fibrin as 
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a biomaterial has been used extensively as both a clinical sealant and as tissue 
engineering scaffolds for a wide variety of applications including gene delivery due to its 
innate support for cell adhesion and susceptibility to proteolysis [245,246]. However, 
stabilization with additional crosslinking may be required to reduce drawbacks of native 
fibrin hydrogels including severe shrinkage during gelation as well as unwanted burst 
release of incorporated therapeutic molecules [171]. In the context of the T904/fibrin 
hybrid hydrogel, T904 would act as the crucial crosslinker necessary for stabilizing the 
gel against rapid enzymatic degradation. 
In the present study, acrylated T904 and FgN were crosslinked in the presence 
of thrombin and dithiothreitol (DTT) by simultaneous enzymatic and Michael-type 
addition reactions. Polyplexes composed of commercially available jetPEI® and pDNA 
were incorporated into the hybrid hydrogels in order to facilitate efficient transgene 
expression. The resulting hydrogels were enzymatically degradable via surface erosion, 
provided sustained vector release at rates controlled by the balance between naturally-
derived and synthetic components, and generated degradation products capable of 
increasing polyplex transfection. Cells were able to invade polyplex-loaded 3D T904/FgN 
hydrogels, exhibiting transfection for up to four weeks in 3D culture. 
4.2 Methods 
4.2.1 Polyplex formation 
Plasmid nerve growth factor vector pBLAST44-hNGF (pNGF, Invivogen, San 
Diego, CA) and pCMV-GFP were prepared as previously described in chapter 3. To 
optimize particle size and complex stability after lyophilization, jetPEI (Polyplus-
transfection, Illkirch, France)/pDNA complexes were prepared using two different 
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solvents containing sucrose as a cryoprotectant. In method 1, complexes were prepared 
by adding 50 μL jetPEI solution (20 μL jetPEI diluted in 30 μL 150 mM NaCl containing 1 
% Sucrose) to 50 μL pDNA solution (10 μg pDNA diluted in 50 μL 150 mM NaCl 
containing 1% Sucrose).  In method 2, complexes were prepared by adding 50 μL jetPEI 
solution (20 μL jetPEI diluted in 30 μL 5 % Sucrose) to 50 μL pDNA solution (10 μg 
pDNA diluted in 50 μL 5% Sucrose). The complex solutions were thoroughly mixed by 
light vortexing and incubated at room temperature for 25 minutes. Naked pDNA was 
diluted in 100 μL 150 mM NaCl solution containing 1% sucrose or 100 μL 5% sucrose 
solution as controls for each method. The prepared complexes or naked pDNA solution 
were frozen overnight at -80°C and lyophilized for 24 hours. The lyophilized complexes 
and naked pDNA made by both method 1 and 2 were reconstituted with 100 μL water 
and used for evaluation of particle size, gel electrophoresis, or transfection. Lyophilized 
complexes prepared by method 2 were reconstituted with gel precursor solutions for 
incorporation into hydrogels and used for release study and transfection in hydrogel. 
4.2.2 Polyplex characterization 
The particle size of various jetPEI/pDNA complexes prepared as described 
above were determined by dynamic laser light scattering using ZetaPlus particle size 
analyzer (Brookhaven, Worcestershire, UK) and reported as effective mean diameter. 
The stability of complexes and integrity of DNA after lyophilization were evaluated by gel 
electrophoresis after decomplexation by STP. First, to optimize decomplexation by STP, 
fresh and lyophilized jetPEI/pDNA complexes prepared by method 1 and 2 as described 
above and treated with various concentrations (0-60 mg/mL) of STP for 4 hours. Naked 
pDNA treated with various concentration of STP were used as control.  The amount of 
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DNA recovered after decomplexation was quantified by Picogreen assay. DNA recovery 
was calculated as a percentage of naked DNA not exposed to STP. Polyplexes and 
pDNA with and without STP treatment (30 mg STP/μg DNA, 4 hours incubation) were 
electrophoresed on a 1% (w/v) agarose gel for 1.5 h at 80 V. The gel was stained with 
ethidium bromide (0.5 g/mL) for 30 min and imaged on a Fluorchem SP UV illuminator 
(ProteinSimple, Santa Clara, CA).  
4.2.3 Hydrogel preparation 
 
 
Figure 4.1. Preparation of T904/fibrin hybrid hydrogel containing jetPEI/pGFP 
polyplexes by dual enzymatic and Michael addition reactions. Fibrinogen (FgN) was first 
reduced with DTT and then combined with a solution containing T904-acrylate, thrombin, 
calcium chloride, and lyophilized polyplex. For the 2D transfection model, polyplex-
loaded hydrogels were formed on top of the fibrin/cell clusters. For 3D cell transfection, 
fibrin/cell clusters were positioned at the center of polyplex-loaded hydrogel.  
Tetronic® 904 (T904) was generously donated by BASF (Florham Park, NJ). 
Human fibrinogen (FgN), human alpha thrombin, and human plasmin were purchased 
from Enzyme Research Laboratories (South Bend, IN). T904 was reacted with acryloyl 
chloride as previously described [247] and 91% acrylation was determined by 1H-NMR. 
Varying compositions of T904/fibrin hybrid hydrogels were prepared by dual enzymatic 
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and Michael-type addition crosslinking (Figure 4.1). Fibrinogen (FgN) was first reduced 
by mixing for 1 hour with varying amounts of DTT required to give a final 1:1 
acrylate:thiol ratio within the hydrogel. Lyophilized polyplex or pDNA was reconstituted in 
a solution of T904-acrylate, 2.5 mM CaCl2, and 0.1U thrombin in 20 mM sodium citrate 
buffer. The reduced FgN/DTT solution was added to the acrylated T904 solution, mixed 
by gentle micropipetting, and 25 μL aliquots (2.5 μg DNA/gel) added to decapitated 1 mL 
syringes or 12 well plates. Samples were incubated at room temperature for 2 hours 
followed by 37°C for 2 hours for crosslinking. 
4.2.4 Hydrogel characterization 
Scanning electron microscopy was performed to determine the inner physical 
structure of the hybrid hydrogel. 3% fibrin, 3% T904/2% FgN, and 5% T904/2% FgN gels 
containing lyophilized jetPEI/pGFP were prepared as described above. Hydrogels were 
flash frozen with liquid nitrogen, bisected vertically to expose the inside of the hydrogel, 
and imaged with a Hitachi S-3400N Fully Automated VP SEM.  
Swelling ratio and mass loss of hybrid hydrogels during degradation were 
determined in order to assess the possible mechanisms involved in gel degradation. 3% 
T904/2% FgN hydrogels (25 μL) with pGFP or polyplex were crosslinked and incubated 
in 1 mL 50 mM PBS (pH 7.2) containing 100 nM plasmin. At 4 (pCMV-GFP) and 24 
(polyplex) hour intervals, samples were collected, photographed, and wet/dry weights 
measured. Mass swelling ratio was calculated as the ratio of wet weight to dry weight. 
Percent mass loss was calculated using the following equation. 
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4.2.5 Hydrogel cytocompatibility 
Cytocompatibility testing was performed for 3% fibrin gels and 3% T904/2% FgN 
gels. Gel extracts were prepared by incubating 25 µL gels in 1 ml media for 24 hours at 
37°C while shaking at 300 RPM. Gel degradation products were prepared from 25 µL 
gels by incubating gels in 100 µL media with 100 nM plasmin for 24 hours at 37°C on a 
plate mixer at 300 rpm. Both gel extract and gel degradation product solutions were 
filtered through 0.2 µm membrane filter to remove large particles. N2A neuroblastoma 
cells (N2A) (ATCC, Manassas, VA) were routinely cultured in Eagle’s Minimum Essential 
Medium (EMEM, ATCC) with 10% FCS (Hyclone, Logan, UT) and 1% penicillin and 
streptomycin (Mediatech, Manassas, VA). B35 neuroblastoma (B35) (ATCC) were 
routinely cultured in Dulbecco’s Modification of Eagle’s Medium/Ham’s F-12 50/50 mix 
with L-glutamine (DMEM/F12, Mediatech) with 5% bovine growth serum (BGS) 
(Hyclone) and 1% penicillin and streptomycin. N2A and B35 cells were plated at a 
density of 1 x 105 cells/mL in 12 well plates and cultured overnight. 100 µL of gel 
extracts, gel degradation products, or fresh medium (control) was added to each well. 
Cells were incubated an additional 48 hours and viability was assessed by MTT assay. 
4.2.6 Vector loading and release from hybrid hydrogels 
Polyplexes and pCMV-GFP (2.5 μg DNA) were lyophilized and incorporated 
within 3% fibrin gels or hybrid hydrogels (25 μL) composed of 2% FgN and varying 
concentrations of acrylated T904 and DTT. To measure initial loading efficiency, gels 
were incubated in PBS containing 0.01% trypsin for 2 days and then pH 12 TE buffer for 
1 day at 37°C on a 300 rpm plate mixer for complete degradation. To measure release 
kinetics, gels were incubated in 1mL 50 mM PBS containing 100nM plasmin, which was 
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collected and replenished at 4, 8, 24 hours and every other day for 2 weeks. Solutions 
from both loading and release studies were treated with 15 mg/ml STP for 30 minutes 
and recovered DNA quantitated by Picogreen assay. Loading efficiency was calculated 
as the percentage of initial DNA recovered during accelerated degradation. DNA release 
was calculated as a percentage of loaded DNA determined by loading efficiency. 
4.2.7 Transfection with hydrogel degradation products 
The effect of gel degradation products on transfection efficiency and cytotoxicity 
was assessed by conventional 2D transfection. Hydrogels (3% T904/2% FgN) were 
made as previously described in 1 mL syringes with 25 µL aliquots and rapidly degraded 
by 48 hours total incubation in 50 µL PBS containing 2 µM plasmin supplemented by an 
additional 50 µL pH 12 TE buffer for the second 24 hours. N2A cells were seeded in 12 
well plates (1.5 X 105 cells, n=3) and cultured for 24 hours to reach 70-80% confluence. 
Cells were then transfected with jetPEI/pCMV-GFP (N/P = 5/1) using 0.5 µg DNA per 
well in fresh medium containing 5% FCS.  After 4 hours, media was replaced again and 
cells were incubated with soluble T904 (10 µM), 10 kDa 4-arm PEG (Nektar, San 
Francisco, CA) (10 µM), or gel degradation products containing 10-50 µM T904. After 48 
hours, cells were washed with PBS, trypsinized, centrifuged at 1500 rpm for 3 minutes, 
and fixed with 1% formaldehyde, and assayed by flow cytometry in a Guava easyCyte 
flow cytometer (Millipore, Billerica, MA) with 5000 counts per sample. Cell viability in 
parallel cultures was determined by MTT assay. 
4.2.8 Qualitative assessment of hydrogel-mediated transfection 
A gel-within-gel cell culture model (Figure 4.1) was used to qualitatively 
investigate and image the bioactivity of released polyplexes and duration of transfection 
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of invading cells. N2A cells (1 X 105 cells) were first entrapped within 4 µL fibrin clots 
(3% FgN, 0.1 U thrombin, 2.5 mM CaCl2 in 20mM sodium citrate buffer, 15 minutes for 
crosslinking). In the 2D model, 3.5% T904/2% FgN hybrid hydrogels (3 µg pCMV-
GFP/30 µL) were crosslinked on top of N2A-containing fibrin clots on the surface of 
tissue culture plates for 15 minutes at room temperature and 15 minutes at 37 °C. For 
the 3D model, identical gels were crosslinked in decapitated 1 mL syringes after N2A-
containing fibrin clots were positioned in the center of the solution volume. Hybrid 
hydrogels were cultured in 2 mL media containing 5% FCS and digitally imaged using an 
inverted epifluorescent microscope (Zeiss Axiovert 200) at predetermined time points. 
4.2.9 Quantitative assessment of hydrogel-mediated transfection 
 The effect of T904 on pNGF in conventional transfection with jetPEI was 
assessed. N2A cells were seeded in 12 well plates (1.5 X 105 cells, n=3) and cultured for 
24 hours to reach 70-80% confluence. Cells were then transfected with jetPEI/pNGF 
(N/P = 5/1) using 0.5 µg DNA per well in fresh medium containing 5% FCS. After 4 
hours, media was replaced again and cells were incubated with soluble T904 (0-10 µM) 
an additional 24 hours. At 48 hours following transfection, media was collected from 
each well and transfection was assessed by enzyme-linked immunosorbent assay 
(ELISA) using the DuoSet ELISA Development kit for human β-NGF (R&D Systems, 
Minneapolis, MN) and QuantaBlu Fluorogenic Peroxidase Substrate (Thermo Fisher 
Scientific Inc., Rockford, IL). Transfection efficiency was determined by fluorimetry in a 
Synergy HT microplate reader (Biotek, Winooski, VT) and expressed as concentration of 
NGF (ng/mL). Transfection efficiency for jetPEI/pNGF at each T904 concentration was 
 104 
 
expressed as transfection efficiency relative to jetPEI/pNGF with 0 µM T904 using NGF 
concentration with sample size n=6. 
 
 
 
Figure 4.2. The gel-on-gel (pancake) model for gel-mediated transfection. Polyplex-
loaded hydrogels were formed directly on culture plates with fibrin cell clusters seeded 
on top. 
 Quantitative assessment of hydrogel-mediated transfection was examined using 
jetPEI/pNGF and either the gel-within-gel model for 3D transfection or a third gel 
transfection method (the pancake method) outlined in Figure 4.2. In the pancake 
method, a 30 μL 2% fibrin hydrogels or 1-3 % T904/2% FgN hybrid gels containing 3 μg 
pNGF/30 μL were polymerized directly on well plates and allowed to spread until 
relatively flat and incubated for 1 h at room temperature and 37°C respectively. Four 
fibrin clots (4 μL) containing 2.5 X 104 cells each were incubated for 15 min at 37°C and 
subsequently placed equidistant from each other and the edge of each circular polyplex 
containing hydrogel. Hydrogels were incubated for 37 days in 1 mL media containing 5% 
FCS. Media was replenished and stored for assay every other day starting 2 days after 
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initial gelation. Cumulative levels of NGF expression from each well were assayed by 
ELISA as previously described and expressed as cumulative NGF expression (pg).  
4.2.10 Statistical analysis 
Results were analyzed using one-way ANOVA with Tukey’s test for mean 
differences (significance p<0.05). Sample sizes were n=3/group and all experiments 
were performed in triplicate unless otherwise stated. 
4.3 Results 
4.3.1 Particle size and zeta potential 
The mean particle sizes measured by dynamic light scattering of both fresh and 
lyophilized polyplexes prepared by each method 1 and method 2 are shown in Table 4.1. 
Polyplexes formed with the 25 kDa branched PEI were included as a reference. 
Polyplexes formed in the presence of NaCl were found to have significantly larger 
hydrodynamic diameters (μm-scale) than those prepared in 5% sucrose (<200 nm). 
Lyophilization significantly reduced the hydrodynamic diameter of polyplexes prepared 
by both methods. Lyophilized polyplexes prepared in 5% sucrose attained final particle 
sizes that were not significantly different from fresh polyplexes prepared with branched 
PEI. 
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Table 4.1.  Particle size and hydrodynamic diameter (nm) of fresh and lyophilized 
complex 
Polycation N/P ratio Complex Solution Particle Size 
   
Fresh Lyophilized 
JetPEI 5/1 150 mM NaCla 3295.5±712.5 1793.4±245.6 
JetPEI 5/1 5% Sucrose 182.2±6.7 123.8±5.3 
b-PEI (25 kDa) 5/1 Distilled water 118.3±3.7 
  
     a150mM NaCl contains 1% sucrose as a cryoprotectant. 
 
4.3.2 STP dissociation Picogreen and gel electrophoresis 
Fresh and lyophilized naked pCMV-GFP and polyplexes prepared by both 
methods were exposed to varying concentrations of STP (Figure 4.3). In the absence of 
STP treatment (black bars), negligible Picogreen signal was detected for all polyplex 
groups, indicating that pCMV-GFP was stably complexed with PEI and inaccessible to 
the DNA binding dye. Polyplexes were incubated with varying concentrations of STP 
based on the expectation that the efficiency of decomplexation and DNA recovery would 
increase at higher concentrations. In contrast, 15 mg/mL STP produced maximum 
recovery while higher STP concentrations resulted in significantly reduced DNA recovery 
from both fresh and lyophilized polyplexes prepared in 5% sucrose, as well as pGFP 
alone (P<0.05). 
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Figure 4.3. Recovery of DNA from jetPEI/pGFP polyplexes prepared in 150 mM 
NaCl containing 1% sucrose (Method 1) and 5% Sucrose (Method 2) after treatment with 
varying concentrations of sodium tripolyphosphate (STP). DNA recovery was expressed 
as a percentage of the signal detected for naked pDNA not exposed to STP. (F. pDNA: 
fresh naked pDNA, L. pDNA : lyophilized naked pDNA, FC NaCl: Freshly prepared 
complex in 150 mM NaCl containing 1% sucrose,  LC  NaCl: lyophilized complex 
prepared in 150 mM NaCl containing 1% sucrose, FC Suc: Freshly prepared complex in 
5 % sucrose, LC Suc: lyophilized complex prepared in 5% sucrose) (*P<0.05, #P<0.05 
compared to F. pDNA w/o STP) 
Similar results were observed by gel electrophoresis (Figure 4.4). Plasmid 
prepared in both sucrose and water was stable after exposure to STP and migrated as a 
single intact band (lanes 9-12). Complete gel retardation was observed for all untreated 
polyplexes (1-7 odd lanes). After treatment with STP, intact pCMV-GFP was recovered 
from all groups (4-8, even lanes) except lyophilized polyplexes prepared in the presence 
of NaCl by method 1 (lane 2). 
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Figure 4.4. Complex stability and integrity of DNA after decomplexation by STP were 
evaluated by agarose gel electrophoresis. Odd numbered lanes are untreated 
polyplexes or pDNA. Even numbered lanes are polyplexes or pDNA treated with 15 
mg/ml STP. (pDNA: fresh naked pDNA, FC NaCl: freshly prepared complex in 150 mM 
NaCl containing 1% sucrose,  LC  NaCl: lyophilized complex prepared in 150 mM NaCl 
containing 1% sucrose, FC Suc: freshly prepared complex in 5 % sucrose, LC Suc: 
lyophilized complex prepared in 5% sucrose. The gel is flanked by 10 kb DNA ladder.  
4.3.3 Hydrogel preparation and characterization 
Scanning electron micrographs showed that T904/fibrin hydrogels exhibited an 
overall fibrillar structure, although the fibril thickness and pore size were much larger 
than that of the pure enzymatically crosslinked fibrin hydrogel (Figure 4.5). Increasing 
the T904 content from 3 to 5% did not substantially affect gel structure.  
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Figure 4.5. SEM micrographs of 3% fibrin hydrogel (A), 3% T904/2% FgN hydrogel (B), 
and 5% T904/2% FgN hydrogel (C). All hydrogels contained lyophilized jetPEI/pGFP 
polyplexes prepared in 5% sucrose. Gel cross-sections were imaged at 500X 
magnification. Scale bar = 100 µm. 
The mass loss of polyplex-loaded 3% T904/2% FgN hydrogels incubated in 100 
nM plasmin was much slower than hydrogels with pGFP (Figure 4.6A). pCMV-GFP-
loaded hydrogels lost 38% of original mass after 8 hours while those with polyplex only 
achieved 32.7% mass loss after 2 days. The mass swelling ratio of pGFP- and polyplex-
loaded 3% T904/2% FgN hybrid hydrogels was monitored during degradation (Figure 
4.6B). Swelling was plotted as a function of mass loss rather than time due to the 
substantial difference in degradation rate. The initial swelling ratio did not significantly 
differ between the two gel types and remained stable for both during mass loss. Figure 
4.6C shows representative images of 100 µl 3% T904/2% FgN gels prepared using the 
syringe method at 0, 1, 2, and 3 days incubation in 100 nM plasmin. Gels maintained 
their cylindrical geometry as their volume decreased. 
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Figure 4.6. The mass loss (A) and mass swelling ratio (B) of  3% T904/2% FgN 
hydrogels containing pGFP or jetPEI/pGFP polyplexes. Degradation of 3% T904/2% 
FgN hydrogel after 0, 1, 2, and 3 days incubation in PBS containing 100 nM plasmin (C).  
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4.3.4 Hydrogel cytocompatibility  
To evaluate toxicity of gel components, gel extracts and gel degradation products 
were prepared from fibrin gels and 3% T904/2% FgN gels.  Figure 4.7 shows cell 
viability measured by the MTT assay for N2A and B35 cells cultured in the presence of 
gel extracts and degradation products relative to controls maintained in routine culture 
medium. Consistently high (>95%) viability comparable to the native fibrin control was 
observed for both cell types, demonstrating good cytocompatibility of the hybrid 
hydrogels. 
 
Figure 4.7. Cytotoxicity of 3% FgN and 3%T904/2%FgN gel extracts and plasmin 
degradation products in B35 and N2A cells measured by MTT assay.  
 EX: Gel extracts, DG: Gel degradation products 
4.3.5 Vector loading and release from hybrid hydrogels 
Loading efficiencies for pGFP and polyplex vectors (Figures 4.8 A and B, 
respectively) were determined after accelerated enzymatic (trypsin) and hydrolytic (pH 
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12 TE) degradation. All gels displayed high total loading efficiency (approximately 80% 
or greater). For pGFP-loaded gels, high levels of DNA recovery (>80%) were achieved 
by enzymatic degradation for fibrin gels and hybrid gels with lower range of T904 
concentration (3-7.5%). At 10 and 12.5% T904, the vast majority of DNA was only 
recoverable after hydrolytic degradation. Polyplex-loaded gels exhibited a similar pattern 
of decreasing fraction of enzymatically recoverable DNA with increasing T904 
concentration; although the range of T904 concentration tested (3-5%) was narrower 
due to the reduced degradation relative to pGFP-loaded gels. In addition, the fraction of 
enzymatically recoverable DNA from hybrid hydrogels was substantially lower for 
polyplexes than pGFP.  
 113 
 
 
Figure 4.8. Loading efficiency of pGFP (A) and jetPEI/pGFP polyplexes (B) in 3% fibrin 
and hybrid hydrogels containing 2% fibrinogen with varying concentrations of T904-
acrylate. The total loading efficiency was obtained from combining the amounts of pDNA 
recovered by enzymatic degradation (0.01% trypsin) and hydrolytic degradation (pH 12 
TE buffer). Release of pGFP (C) and jetPEI/pGFP polyplexes (D) from 3% fibrin and 
hybrid hydrogels containing 2% fibrinogen and varying concentrations of T904-acrylate 
during incubation in 100 nM plasmin. 
Release profiles for pGFP- and polyplex-loaded fibrin and various hybrid 
hydrogels during incubation in 100 nM plasmin are shown in Figure 4.8 C and D, 
respectively. Complete degradation and vector release from fibrin only gels occurred 
within 1 day. The release profiles for both vectors from hybrid hydrogels were varied 
over a broad time scale by changing the balance between synthetic and naturally-
 114 
 
derived components within the gels, with increasing T904 concentration slowing gel 
degradation and vector release. Approximately linear release profiles and 100% total 
release were obtained at relatively lower T904 concentrations (3 and 5% for pGFP and 
3-4% for polyplex). At higher T904 concentrations, release was substantially reduced 
during the first week of incubation, and then increased during the second week. Gels 
with relatively high T904 concentrations were still present at the end of 2 weeks and had 
not reached complete degradation / release. In contrast to release in the presence of 
plasmin, very little release of pGFP (<2%) from 5% T904/2% FgN gels was observed 
during incubation in PBS for up to 7 days (data not shown). 
4.3.6 Transfection with hydrogel degradation products 
The ability of hydrogel degradation products to increase the transfection 
efficiency of the polyplex was assessed by in vitro transfection using freshly prepared 
jetPEI/pGFP and rapidly degraded 3% T904/ 2% FgN hydrogels (Figure 4.9A). A 
relatively low amount of DNA (0.5 µg) was used per well in order to approximate the 
limited amount of vector accessible to cells when homogeneously dispersed in a 3D 
network, as opposed to 2D transfection where sedimentation effectively concentrates 
vectors at the cell surface. Exposure to 10 µM unmodified T904 significantly increased 
transfection efficiency, while 4-arm PEG at comparable concentration had no significant 
effect. Cells cultured with gel degradation products displayed a dose-dependent 
increase in transfection efficiency with increasing T904 concentration, with all groups 
showing significantly increased expression relative to jetPEI transfection alone. High cell 
viability was maintained in all groups, with only 10 µM native T904 showing a significant 
decrease relative to jetPEI transfection alone (Figure 4.9B). 
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Figure 4.9. Transfection efficiency (A) of jetPEI/pGFP complexes alone and with 10 µM 
T904 or 4-arm PEG and gel degradation products containing 10-50 µM T904 was 
assessed by flow cytometry and expressed as % cells transfected. Corresponding cell 
viability (B) was measured by MTT assay. (*P<0.05 relative to jetPEI/pGFP alone) 
4.3.7 Qualitative assessment of hydrogel-mediated transfection 
In the 2D transfection model, fibrin clots containing N2A cells in tissue culture 
plates were overlaid with polyplex-loaded hybrid hydrogels. The fibrin clots were initially 
visible as opaque regions within the gel. By 3 days, a region of gel degradation was 
visible surrounding the clots as N2A cells began to proliferate and migrate through the 
surrounding gel (Figure 4.10). GFP expression by transfected cells was clearly visible at 
3 days and substantially increased by 7 days. N2A cells were able to eventually fully 
degrade the hybrid hydrogels and reach confluence upon the tissue culture plate.  
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Figure 4.10. GFP expression by transfected N2A cells in 3.5% T904/2% FgN hydrogels 
in 2D model. Transfected cells were visualized at 1 day (A,D), 3 days (B,E), and 7 days 
(C,F) with phase contrast (A-C) and fluorescence microscopy (D-E). Original 
magnifications, 200X. Scale bar represents 200 µm. C: Fibrin cluster, G: 3.5% T904/2% 
FgN hydrogels (3 µg pGFP/gel). 
 In the 3D model, N2A cells entrapped within fibrin clots were suspended within 
polyplex-loaded hydrogels. In contrast to the 2D transfection model, no zone of 
degradation was observed in the 3D transfection model between the expanding cell 
cluster and the surrounding hybrid hydrogel (Figure 4.11). Instead, N2A cells appeared 
to individually migrate through the hydrogels. GFP transfection was clearly visible at 7 
days and progressively increased up to 15 days, at which point the gels fragmented from 
extensive degradation. After 15 days, cells migrating out of the degrading gels adhered 
and grew on the underlying well plate, continuing to exhibit transfection up to 27 days.  
 
 
 
 117 
 
 
Figure 4.11. GFP expression by transfected N2A cells in 3.5% T904/2% FgN hydrogels 
in 3D model. Transfected cells were visualized at 3 days (A,F), 7 days (B,G), 11 days 
(C,H), 15 days (D,I), and 27 days (E,J) with phase contrast (A-E) and fluorescence 
microscopy (F-J)). Original magnifications, 200X. Scale bar represents 200 µm. C: Fibrin 
cluster, G: 3.5% T904/2% FgN hydrogels (3 µg pGFP/gel). 
4.3.8 Quantitative assessment of hydrogel-mediated transfection 
 First, the ability for soluble T904 to enhance the transfection efficiency of 
jetPEI/pNGF was assessed via conventional in vitro transfection. Figure 4.12 shows that 
T904 (2.5-10 μM) significantly enhanced the transfection efficiency of the jetPEI/pNGF 
compared to transfection with 0 μM T904 (P<0.05).  
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Figure 4.12. Transfection efficiency of jetPEI/pNGF complexes with 0-10 μM T904 in 
N2A cells in serum measured by flow cytometry and expressed as mean fluorescence 
relative to 0 μM T904. (*P<0.05 relative to 0 μM T904) 
After confirmation that the activity of T904 in polyplex transfection was preserved 
using the pNGF vector, the ability for jetPEI/pNGF incorporated within hybrid hydrogels 
to facilitate hydrogel-mediated transfection was assessed using ELISA to quantify NGF 
expression. In the 3D gel-within-gel model, N2A cells entrapped within fibrin clots were 
successfully transfected and expressed NGF. However, the cumulative expression of 
NGF from cells in all three T904/FgN hybrids never reached levels detected from cells 
encapsulated within pure fibrin (Figure 4.13A). Increase in NGF expression was 
relatively linear in the first three weeks for all gel types and subsequently plateaued after 
the fourth week. Conversely, in the pancake model cumulative expression of NGF from 
all three variations of hybrid hydrogel surpassed expression levels from the fibrin gel in 
the fourth week of incubation (Figure 4.13B). Increase in NGF expression in the pancake 
model was relatively linear for four weeks in all gel conditions and only plateaued in the 
final week of data collection. 
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Figure 4.13. Cumulative NGF expression by cells transfected by 2% fibrin and 1-3% 
T904/2% FgN hydrogels via the 3D model (A) or the pancake model (B) with sampling 
every other day. 
4.4 Discussion 
Localized transfection through scaffold-mediated release of nonviral vectors 
provides an attractive alternative to the delivery of recombinant growth factors, which 
have a short half-life in situ and often require super-physiological doses for therapeutic 
efficacy [2,248]. Hydrogels are particularly favored for this application because they can 
be formed under mild conditions to protect incorporated vectors and are amenable to 
delivery by injection to minimize damage to surrounding tissue [165,249]. A relatively 
new development is the creation of hybrid hydrogels that incorporate both naturally-
derived and synthetic components in order to integrate cellular responsiveness with 
improved control over physical and chemical properties [243,244]. Although successful 
gene delivery from hybrid hydrogels has been achieved both in vitro and in vivo, the 
hydrogel compositions used have generally been adapted from other tissue engineering 
applications on the basis of their biocompatibility and/or favorable cellular interactions 
rather than specifically selected/designed for gene delivery [169,170]. Several recent 
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studies have highlighted the potential impact of scaffold properties such as mechanics 
and degradation rate on nonviral gene delivery [191,213,250]. However, few studies 
have examined the potential opportunity to enhance the effectiveness of scaffold-
mediated gene delivery through incorporating materials that when released in their 
soluble form during degradation can actively enhance the efficacy of released nonviral 
vectors.   
In this study we investigated the development of a novel hybrid hydrogel formed 
from an acrylated derivative of the amphiphilic block copolymer Tetronic T904 and the 
native macromolecule fibrinogen for nonviral vector delivery. T904 was selected as the 
synthetic component instead of a more commonly used hydrophilic polymer such as 
PEG based on the ability of amphiphilic block copolymers to act as biological response 
modifiers capable of increasing nonviral gene expression through increased vector 
internalization, nuclear uptake, and transcriptional activity [139,145,147,221,223]. 
Fibrinogen was selected as the naturally-derived component to convey support for cell 
adhesion, growth, and proteolytic degradation [245].  We performed gel characterization 
and release studies using both pDNA and polyplexes. Although naked pDNA exhibits 
negligible transfection efficiency in vitro, it has shown in vivo efficacy when loaded at 
high doses in various naturally-derived hydrogels [29,251]. 
Retention of vector activity after lyophilization remains a challenging problem, 
and concentration of nonviral vectors by lyophilization is usually required in order to load 
sufficient amounts of DNA within hydrogel scaffolds [190].Polyplex vector using jetPEI 
was used to facilitate high in vitro gene expression. However, jetPEI/pDNA is normally 
prepared in the presence of 150 mM NaCl buffer that when concentrated following 
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lyophilization may interfere with vector activity, Picogreen assay, or adversely increase 
ionic strength during hydrogel polymerization. Therefore, activity of polyplexes following 
lyophilization was assessed using first manufacturer recommended complexation in 150 
mM NaCl with 1% sucrose as well as a second separate method using only 5% sucrose. 
Lyophilized polyplexes prepared in 5% sucrose attained particle sizes under 200 nm and 
not significantly different from fresh polyplexes prepared with 25 kDa branched PEI. 
Thus, 5% sucrose effectively prevented aggregation commonly observed during 
lyophilization without adequate cyroprotection and yielded particles with nm-scale size 
amenable to cellular uptake by endocytosis [51,252]. In contrast, polyplexes prepared in 
the presence of NaCl had particle sizes well above 1 µm. This observation is consistent 
with a previous report examining another linear PEI derivative, ExGen 500 [253].This 
suggests that STP can interfere with the Picogreen assay in a concentration-dependent 
manner and 15 mg/ml was used for all subsequent studies 
Hybrid hydrogels were successfully formed through dual enzymatic and covalent 
crosslinking creating interpenetrating polymer network hydrogels of fibrin and T904. In 
contrast to pure fibrin gels prepared solely by enzymatic crosslinking that exhibit 
contraction and a residual sol fraction not tightly associated with the gel, hybrid networks 
formed with the same volume and geometry as the original precursor solution (data not 
shown). Two important observations support the critical role of dual enzymatic/covalent 
crosslinking. First, in the absence of thrombin, a minimum 12.5% w/v T904 concentration 
was required to achieve stable gelation, whereas inclusion of thrombin allowed efficient 
gelation with as little as 0.5% T904. Second, enzymatically crosslinked fibrin gels 
completely degraded after 24 hours exposure to 100 nM plasmin, while incorporation of 
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acrylated T904 and DTT decreased degradation rate in a dose-dependent manner as 
shown in our release studies.  
Hybrid gels exhibited a fibrillar structure more macroporous than native fibrin, 
likely due to protein/polymer interactions. For example, addition of soluble polyethylene 
glycol to protein solutions is a well-known method to induce protein precipitation [254]. 
The rapid crosslinking in our hybrid hydrogels prevents such macroscopic precipitation, 
instead likely producing micro-scale phase separation that results in increased fibril size 
and gel porosity. Unlike pure Tetronic hydrogels [247] and most other purely synthetic 
hydrogels containing ester linkages that undergo bulk degradation and exhibit increased 
swelling during degradation [255], the maintenance of stable swelling ratio by the 
T904/fibrin hydrogel during degradation is most consistent with degradation by surface 
erosion [256]. While both polyplex and plasmid incorporated hydrogels were 
enzymatically degradable, incorporation of polyplex reduced the rate of mass loss in 
hybrid gels, suggesting that polyplexes interact with the hydrogel network in a manner 
that decreases its susceptibility to enzymatic degradation. One potential explanation is 
that fibrinogen possesses a net negative charge in physiological buffer [257] and may 
participate in noncovalent, electrostatic interactions with positively charged polyplexes 
that reduce its accessibility to the enzyme.  
While not specifically tailored for gene delivery, the Seliktar and Suggs research 
groups have extensively investigated similar hybrid materials formed by photo-initiated 
or thrombin-mediated crosslinking of different PEGylated fibrinogen derivatives [11,258]. 
In both cases, the PEG/fibrinogen ratio was a critical variable in controlling enzymatic 
degradation, cell-mediated remodeling, and release of incorporated growth factors [259–
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261]. We hypothesized that our hybrid hydrogel may behave in a similar manner, 
allowing control over the release kinetics of incorporated nonviral vectors through 
variation of T904/fibrinogen ratio. Degradation and vector release from these hybrid gels 
are likely attributable to a combination of the enzymatic degradation of fibrin and the 
hydrolysis of degradable ester linkages resulting from covalent reactions between T904 
acrylate groups and thiols in fibrinogen and DTT. A noticeable inflection point occurs in 
both the loading efficiency data for trypsin recovery and the release data around 7.5-
10% T904 for pGFP-loaded hydrogels and 4.5% T904 for polyplex-loaded hydrogels. 
These particular compositions likely represent a critical ratio between the naturally-
derived and synthetic components, below which their release behavior is primarily 
governed by enzymatic degradation of the fibrin component and above which the 
synthetic component begins to predominate and release becomes increasingly 
dependent on at least partial hydrolytic degradation. T904/fibrin hydrogels demonstrated 
several advantages as matrices for gene delivery including high loading efficiency, the 
absence of initial burst release, and extended release up to an order of magnitude 
longer than pure fibrin controls, which was less than 1 day under the conditions used in 
this study. In addition, the rate of gel degradation and time course of vector release were 
readily controlled by varying the ratio of naturally derived to synthetic components, 
increasing as the ratio of synthetic/natural-derived composition increased.  
After proteolytic degradation of fibrin and cleavage of ester linkages formed 
during thiol/acrylate crosslinking by hydrolysis or esterase enzymes, one of the expected 
degradation products of T904/fibrin gels will be native T904. When added to transfected 
cells, both native T904 and gel degradation products significantly increased polyplex 
transfection efficiency with minimal effects on cell viability. This outcome, previously 
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reported with Pluronics [145,147], appears to be unique to amphiphilic copolymers as 
multi-arm PEG that was also tested did not affect transfection. Therefore, while the 
degradation products of most hydrogels are generally regarded as bio-inert with respect 
to vector activity, these studies suggest that T904/fibrin hydrogels offer a new approach 
to increasing the effectiveness of nonviral gene delivery by generating soluble 
degradation products that can actively increase the bioactivity of released vectors.  
Transfection of cells in 3D using polyplex-loaded hydrogels is critical to validate 
the activity of polyplexes following lyophilization, reconstitution in gel precursors, and 
distribution in the 3D environment of the hydrogel. Two primary models exist for in vitro 
transfection using hydrogel matrices: co-encapsulation of cells with vector in the gel 
precursor and initial separation of cells from the vector prior to gelation by using a gel-
within-gel procedure that more closely mimics invasion of hydrogels in vivo by 
endogenous cells from surrounding tissue [262,263]. While co-encapsulation of cells and 
polyplex in gel precursors provides a means for fast detection of transfection [153], 
results may be confounded by internalization of polyplex by cells prior to gelation. In 
addition, homogenously dispersed cells may demonstrate limited migration and only 
have access to polyplexes initially distributed in close proximity to the cells [188]. In 
contrast, separation of polyplex from cells prior to hydrogel polymerization ensures that 
all vector internalization occurs as a result of cell invasion or hydrogel degradation 
[208,264]. For the T904/fibrin hydrogels used here, cells seeded in fibrin clots gained 
access to jetPEI/pGFP incorporated within surrounding hybrid gels by release through 
enzyme mediated surface erosion or coming into contact with encapsulated polyplexes 
during cell migration. Proteolytic activity of N2A cells was confirmed by the ability of 
conditioned media from N2A cells to fully degrade fibrin hydrogels, which was inhibited 
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by addition of aprotinin, suggesting a key role for plasmin in cell-mediated gel 
degradation (data not shown). Previous reports from Shea’s lab indicated a critical role 
of cell migration and matrix degradation for in vitro hydrogel transfection, particularly in 
the case of gel-within-gel models [191]. Transection of N2A cells by gel degradation as 
well as cell invasion were both observed in the current study, the former more prominent 
in the 2D model and the latter in the 3D model. Qualitative observations of transfection 
efficiency of cells in 3D were comparable or superior to other investigations using similar 
gel-in-gel models (Shepard et al., 2010; Lei and Segura, 2009). 
 The previous chapter established that T904 enhanced the transfection efficiency 
of both CMV and SV40 promoter plasmids. However, pNGF used in this study contains 
the EF1-α promoter. Therefore, the activity of T904 with the NGF vector was first 
confirmed using traditional plate transfection where T904 significantly enhanced the 
transfection efficiency of jetPEI/pNGF in a dose-dependent manner. Hydrogel-mediated 
transfection of cells in vitro was assessed by quantitation of NGF production following 
transfection with jetPEI/pNGF using both the 3D gel-in-gel model previously used for 
qualitative assessment and a pancake model where cells were seeded in fibrin clots on 
top of a flat gel layer with incorporated polyplexes. The primary reasoning for using the 
pancake model for in vitro gel transfection as opposed to relying on the 3D gel-in-gel 
model was the high dependency of NGF production and recovery on cell proliferation in 
gel-mediated cultures. In general, cells encapsulated and constrained within fibrin clots 
surrounded by pure fibrin gels proliferated much faster than cells encapsulated within 
hybrid gels, leading to rapid proliferation and high expression of transgene as a function 
of cell number. As a result, we opted to include both a gel transfection condition with 
physically constrained cells (the 3D gel-in-gel model) as well as a model where cells 
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would be allowed to freely proliferate over roughly the same surface area regardless of 
gel degradation rate (pancake model). Therefore, the main benefit of the pancake model 
would be eliminating a large portion of the bias from cell number on the production of 
NGF from each hydrogel condition. Unsurprisingly, we found that the production of NGF 
in the 3D model was severely limited in the hybrid hydrogel conditions with less %T904 
content resulting in higher cumulative levels of NGF expression. As previously 
explained, this was likely due to slower rates of cell proliferation and migration within the 
hybrid hydrogels due to increased concentration of T904-acrylate. On the other hand, 
while the initial levels of NGF expression in the first three weeks were higher in the fibrin 
gel condition in the pancake model, an inflection point was reached at the end of the 
third week wherein the cumulative expression of NGF from the hybrid gel containing 1% 
T904 surpassed that of pure fibrin. Ultimately, cumulative levels of NGF expression were 
greater in all hybrid gel conditions compared to pure fibrin using the pancake model, 
indicating an overall benefit of T904 incorporation not only in delaying and extending 
transfection, but also providing higher cumulative expression of transgene. Our 
observations were consistent with previous work from Holladay and coworkers who 
demonstrated that although incorporation of vector into a scaffold delayed the 
expression of transgene compared to conventional transfection, levels of expression 
were significantly higher in the second week of incubation with the scaffold compared to 
conventional 2D transfection [151]. 
4.5 Conclusion 
Improving control of release kinetics and transfection efficiency are critical 
hurdles to the successful application of nonviral gene delivery in tissue engineering. By 
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crosslinking fibrin with Tetronic T904, hybrid hydrogels were created that possess 
variable susceptibility to proteolytic degradation and provide controlled release of 
nonviral vectors over varying time frames through manipulation of the ratio of 
T904/fibrinogen composition. Unlike other relatively inert synthetic polymers such as 
PEG, the incorporation of amphiphilic T904 allowed the gels to degrade into soluble 
products that significantly increase polyplex transfection efficiency. T904/fibrin hydrogels 
efficiently transfected invading cells with expression extending to approximately one 
month, suggesting these matrices may be applicable for gene delivery in a variety of soft 
tissue applications. 
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CHAPTER 5 
IN VIVO TRANSFECTION WITH THE T904/FIBRIN HYBRID 
HYDROGEL  
Abstract 
 The transition of a nonviral vector-based therapeutic from established in vitro 
transfection protocols to an in vivo gene delivery model represents its most difficult 
challenge in the path toward clinical efficacy. The objective of this study was to 
investigate the potential of the T904/fibrin hydrogel for scaffold-mediated nonviral gene 
delivery in vivo. Toward this end, we employed a common excisional cutaneous wound 
model to assess the transfection of invading macrophages and fibroblasts during the 
inflammation and re-epithelialization stages of wound healing. Fibroblasts were able to 
migrate within and degrade low %T904 content hydrogels in vitro, alleviating concerns 
with the ability for cells with nominal protease activity to migrate within complex-
containing high %T904 content hybrid gels. Despite the adverse effects of ionic strength 
on the degradability of fibrin-based gels and polyplex aggregation due to high initial DNA 
load, both branched- and linear-PEI incorporated T904/fibrin hydrogels loaded with as 
much as 1 μg DNA/μL gel successfully transfected cells in the cutaneous wound site. 
This study demonstrates that polyplex-loaded T904/fibrin hydrogels are capable of 
providing in vivo transgene expression through both enzymatic degradation and cell 
infiltration. 
Key words: wound healing, in vivo, scaffold, gene delivery, amphiphilic block 
copolymer, fibrin 
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5.1 Introduction 
The dynamic, interdependent processes involved in wound healing represent one 
of the foremost areas where tissue engineering may aid in the regeneration of lost tissue 
and/or function. In addition to trauma from burns or other injury, wounds formed from 
chronic diseases, pressure, venous stasis, and diabetes mellitus are all candidates for 
treatment by tissue engineering [265]. A variety of soluble growth factors, serum 
proteins, ECM biomolecules, and cells are involved in the three states of the wound 
healing process: inflammation, tissue formation, and tissue remodeling [266]. These 
biomacromolecules and cells contribute to a dynamic environment in which the transient 
availability of key signaling molecules may ultimately determine the success or failure of 
functional tissue restoration. Gene therapy can provide significant benefit to wound 
healing by increasing the availability of these soluble signaling molecules including 
growth factors (FGF, platelet-derived growth factor (PDGF), VEGF, NGF) that promote 
healing and angiogenesis [3] as well as cytokines (transforming growth factor α, 
transforming growth factor β, insulin-like growth factor I) critical in the inflammatory 
process and transition toward epithelialization [267]. 
Viral gene delivery in wound healing offers long-term availability of therapeutic 
growth factors for chronic wound healing [268]. However, significant risk is associated 
with viral gene delivery in wound healing as application of the virus itself may exacerbate 
the inflammatory response and impair the regeneration of epithelial tissue. Liechty et al. 
were able to induce epithelialization of ischemic rabbit ears with PDGF transferred via 
adenovirus [269]. The positive impact of PDGF on wound healing was sufficient to 
overcome the adverse inflammatory effects of adenovirus. In addition, viral gene delivery 
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using VEGF has shown significant benefit in promoting angiogenesis in diabetic wound 
healing models [30,270,271]. Nonviral vectors may be an attractive alternative to viral 
gene delivery for wound healing applications due to the combination of controlled 
release and transient gene expression in aiding regeneration in the dynamic wound 
healing environment by providing time-sensitive biological cues. The earliest form of 
nonviral delivery in wound healing involved the direct injection of naked plasmid coding 
for interleukin-8 [272]. However, injection of naked DNA into the skin was shown to be 
highly inefficient as the protective hydrophobic stratum corneum on the outer layer of the 
dermis represents a difficult to penetrate layer for negatively charged DNA. Both 
physical and chemical means have been explored to overcome the limitations of naked 
DNA delivery in wound healing [268]. Despite their low in vivo efficacy, cationic 
liposomes have emerged as viable gene carriers for the delivery of cDNA and pDNA in 
wound healing. Strategies such as incorporation of the CMV promoter [273] and using 
monovalent cationic lipids have been shown to improve lipoplex transfection efficiency in 
the delivery of DNA and oligonucleotides coding for both growth factors and cytokines 
[274]. Despite incremental improvements in nonviral vectors for wound healing and 
nonviral transfection in general, the efficiency of cationic liposomes and polymers 
remains their largest weakness in wound healing applications. 
Several prior studies have examined the effect of nonviral gene delivery using 
naked DNA on excisional skin wounds for wound closure [275], re-epithelialization [276], 
and angiogenesis [277] with moderate success. In the present study, similar full 
thickness excisional skin wounds were used in mice to investigate the potential for 
polyplex delivery from T904/fibrin hydrogels to facilitate transgene expression in wound 
healing. First, the ability for fibroblasts to migrate within polyplex-containing hydrogels 
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was confirmed in vitro using gel encapsulation models from chapter 3. Polyplex-
containing hydrogels were subsequently implanted in excisional wounds and the 
transfection of cells in the vicinity of explanted tissue was confirmed using 
immunohistochemistry (IHC).  
5.2 Methods 
5.2.1 Polyplex formation and lyophilization 
 Plasmid encoding green fluorescence protein under a CMV promoter (pGFP, 
Genlantis, San Diego, CA) was transformed into Escherichia coli DH5α (Life 
Technologies), amplified in the presence of kanamycin and purified using the Qiagen 
Mega Plus Prep kit (Qiagen, Valencia, CA). Plasmid concentrations were determined by 
UV spectrophotometry with Take 3 (Biotek, Winooski, VT). Two different methods for 
polyplex incorporation into hydrogels were used: low polyplex concentration (0.1 μg 
DNA/μL gel) or high polyplex concentration (1 μg DNA/μL gel). The lyophilization and 
reconstitution of low concentration polyplex was described previously in chapter 3. For 
high polyplex concentration, jetPEI complexes were prepared by mixing 200 μL jetPEI 
solutions (Polyplus-transfection, Illkirch, France) with equal volume of 100 μg pDNA in 
5% sucrose solution and incubating for 25 minutes at room temperature. High polyplex 
concentration 25 kDa branched PEI (bPEI, Sigma-Aldrich, St. Louis, MO) complexes 
were prepared by mixing equal volumes of bPEI diluted in 5% sucrose solution with 100 
μg pDNA in 5% sucrose at bPEI nitrogen to pDNA phosphate ratio (N/P) of 7.5/1 and 
incubated for 30 minutes at 37°C. Complexes were subsequently transferred to -80°C 
overnight and lyophilized for approximately 6 hours. Lyophilized complexes were then 
reconstituted with gel precursors for incorporation into hydrogels. 
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5.2.2 In vitro fibroblast encapsulation and migration 
Normal human dermal fibroblasts (NHDF, Lonza, Walkersville, MD) were 
cultured in DMEM/F12 with 10% BGS and 1% penicillin and streptomycin. Human 
mesenchymal stem cells (hMSC, Lonza) were cultured in low glucose DMEM (Life 
Technologies, Carlsbad, CA). The 2D model for hydrogel encapsulation previously 
described in chapter 3 was used to assess the ability for NHDF to migrate through 
polyplex containing hydrogels. 0.25% fibrin clots (10 μL) containing 9.1X105 NHDF were 
seeded at the center of 12 well culture plates. Hydrogels (30 μL) composed of 1% 
T904/2% fibrin with or without low concentrations of both types of polyplex were then 
seeded on top of the fibrin clots. Live/dead staining was performed using fluorescein 
diacetate to stain for live cells and propidium iodide to stain for dead cells. Images were 
captured at 10x original magnification using epifluorescent microscopy (Zeiss Axiovert 
200) 4 and 10 days following initial gelation. 
5.2.3 In vivo implantation and retrieval 
All animal procedures were performed with the approval and supervision of 
Clemson University Institute of Animal Care and Use Committee. Full thickness 
excisional wounds were created through the skin on the back of anesthetized adult male 
BALB/c mice using 5mm standard biopsy punches (Integra, Plainsboro, NJ) (Figure 5.1A 
and C). Hydrogels (25 μL) made using the syringe method previously described in 
chapter 3 composed of 2% fibrin or 1% T904/2% fibrin (hybrid) with or without high 
concentrations of both types of polyplex were then placed in the wound cavity (Figure 
5.1B and D).  
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Figure 5.1. Wounds created using 5 mm biopsy punches on the dorsum of mice (A, C). 
1% T904/2% fibrin (hybrid) gel without complex and 2% fibrin gel with jetPEI/pGFP (1 μg 
DNA/μL gel) implanted within the wound cavity (B). Hybrid gels with bPEI/pGFP (1 μg 
DNA/μL gel) or jetPEI/pGFP (1 μg DNA/μL gel) implanted within the wound cavity. 
Open excisional wounds were subsequently covered by sterile gauze (Figure 
5.2A) and secured tightly by surgical wrap wrapped around the body of the animal 
(Figure 5.2B). Explants were taken five days following initial implantation by removing 
both the fibrous capsule formation at the hydrogel implantation site as well as additional 
2-3mm of tissue around the site. Explants were flash frozen by dry ice and ethanol in 
Tissue-Tek O.C.T. compound (Sakura Finetek USA, Torrance, CA) and stored at -80°C 
for 24 h prior to sectioning. 
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Figure 5.2. Hydrogels secured within the wound site with a layer of sterile gauze (A) 
subsequently secured by surgical wrap (B). 
5.2.4 Immunohistochemistry 
 Cryosectioning was performed on frozen tissue samples and sections were 
transferred to charged microscope slides (C & A Scientific, Manassas, VA) with 10 μm 
thickness and fixed in 4% paraformaldehyde. The expression of green fluorescence 
protein (GFP) was observed via epifluorescent microscopy with DAPI counterstain for 
nuclei. IHC for GFP was performed using anti-GFP (Life Technologies, Carlsbad, CA) 
primary antibody and DyLight 550 (Thermo Fisher Scientific Inc., Rockford, IL) 
secondary antibody with 562nm / 576nm excitation / emission maxima. 
5.3 Results 
5.3.1 Fibroblast cell spreading and migration 
 We examined the encapsulation of fibroblasts within fibrin clots surrounded by 
hybrid hydrogels with incorporated polyplex in order to confirm whether the reduced 
proteolytic activity of NHDF compared to N2A was enough to migrate and/or degrade the 
hybrid hydrogel. At 4 days after initial gelation a majority of encapsulated NHDF in all gel 
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conditions remained viable (Figure 5.3). The migration of NHDF from the fibrin clot (C-
side of yellow line) into the 1%T904/2% fibrin hybrid hydrogel (G-side of yellow line) 
appeared to have been slowed by the presence of both bPEI (Figure 5.3B) and the 
linear jetPEI (Figure 5.3C) with bPEI appearing to have a larger inhibitory effect on cell 
migration. These results corroborated earlier findings in chapter 3 that showed the 
incorporation of jetPEI/pCMV-GFP resulted in slower hydrogel degradation rate and 
release rate of incorporated DNA. Following 10 days of incubation, large numbers of 
cells stained green by FDI had migrated into both complex-containing and no-complex 
hybrid gels. In addition, cell populations were virtually completely viable with very few 
cells stained red by PI. 
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Figure 5.3. NHDF cell migration from fibrin cell cluster into surrounding 1% T904/2% 
fibrin hydrogels without complex (A), 1% T904/2% fibrin hydrogels with bPEI/pGFP (B), 
and 1% T904/2% fibrin hydrogels with jetPEI/pGFP (C) at 4 days and 10 days following 
initial gelation. Live cells (green, FDA) and dead cells (red, PI) visualized by 
fluorescence microscopy with the boundary between cell cluster and hybrid hydrogel 
visualized by phase contrast (brightfield) and denoted by the curved yellow line. Original 
magnification, 40x. 
C: Fibrin cell cluster, G: 1% T904/2% fibrin hydrogels 
5.3.2 Implant retrieval 
 We examined the superficial wound healing response to the presence of the 
polyplex-incorporated hydrogel prior to removing tissue for cryosectioning. Evidence of 
significant re-epithelialization was detected in wounds with implanted fibrin+jetPEI/pGFP 
and hybrid+bPEI/pGFP despite the lack of biomolecules designed to address wound 
healing (Figure 5.3A and B). The fibrin implant exhibited the poorest superficial wound 
healing. Figure 5.3C shows explanted tissue sections from the wound site which 
displayed significant reduction in hydrogel size and alteration in hydrogel structure 
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compared to the fresh implants shown in Figure 5.1. The morphology of the hydrogel 
explant and the formation of fibrous capsule suggested that significant degradation 
and/or migration of cells within the hydrogel implants had occurred during incubation 
within the wound site. 
 
Figure 5.4. Wound site 5 days following implantation with 1% T904/2% fibrin (hybrid) gel 
without complex and 2% fibrin gel with jetPEI/pGFP (1 μg DNA/μL gel) (A). Hybrid gels 
with bPEI/pGFP (1 μg DNA/μL gel) or jetPEI/pGFP (1 μg DNA/μL gel) (B) accompanied 
by explanted tissue and gel remnants (C). 
5.3.3 GFP expression in recovered tissue 
 Figure 5.5 shows representative fluorescence microscopy images of recovered 
tissue sections from the excisional cutaneous wound. After 5 days of implantation within 
the wound site, hydrogels were largely resorbed and only small fragments of complex-
containing hydrogels remained. As a result, sections of the wound site consisted 
primarily of native tissue or recapitulated gel fragments with only small, heavily degraded 
remnants of hydrogel at the center of some explants. DAPI counterstaining revealed that 
all explants displayed high degrees of cell migration toward the center of hydrogels and 
no hydrogel showed any significant resistance toward degradation or cell invasion. No 
green fluorescence as a result of transfection was detected in tissue sections from 1% 
T904/2% fibrin implants without jetPEI/pGFP (Figure 5.5A). However, some anomalous 
circular patterns of green auto-fluorescence likely due to the presence of hair follicles 
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were present toward the outer edges of each tissue section. Large isolated regions of 
transfection were observed in explant sections from 2% fibrin hydrogels containing 
jetPEI/pGFP with GFP expression positively identified by IHC with anti-GFP and DyLight 
550 (Figure 5.5B). In contrast to pure fibrin, transfection observed in explants of 1% 
T904/2% fibrin hydrogels containing either bPEI/pGFP or jetPEI/pGFP was dispersed 
intermittently across both the hydrogel remnants and adjacent to tissue of each section 
(Figure 5.5C and D). 
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Figure 5.5. GFP expression, anti-GFP staining, and nuclei counterstained by DAPI in 10 
μM cryosections from explants containing surrounding tissue and remnants of 1% 
T904/2% fibrin (hybrid) gel without complex (A), 2% fibrin gel with jetPEI/pGFP (1 μg 
DNA/μL gel), hybrid gel with bPEI/pGFP (1 μg DNA/μL gel) (C), and hybrid gel with 
jetPEI/pGFP (1 μg DNA/μL gel) (D). Original magnification, 100X. 
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5.4 Discussion 
The primary objective of this study was to assess the capability for T904/fibrin 
hybrid hydrogel scaffolds to deliver transgene in vivo. Nonviral vectors delivered via 
bolus injection or in tissue engineering scaffolds typically elicit short-lived, transient gene 
expression. Scaffolds extend the expression of transgene by varying the time-course of 
vector availability through the controlled release of incorporated DNA. An array of tissue 
engineering scaffolds made from synthetic materials such as PEG [278] and natural 
proteins such as collagen [279] have been utilized for nonviral vector delivery. However, 
the primary considerations involved in selecting scaffold components for gene delivery 
are cytocompatibility and controlled release with relatively little attention toward the 
possible effects of scaffold degradation products on transgene expression. In the 
present study, we employed a novel approach toward scaffold-mediated gene delivery 
by utilizing a hybrid hydrogel scaffold composed of a natural serum protein, fibrinogen 
and a bioactive amphiphilic block copolymer, Tetronic T904 to provide transgene 
delivery in an in vivo cutaneous wound model. 
Fibrin has been widely used in tissue engineering in a variety of applications and 
is favorably positioned for gene delivery due to its ability to be formed under mild 
conditions via enzymatic crosslinking of fibrinogen mediated by thrombin [280,281]. 
However, fibrin gels are highly susceptible to rapid proteolytic degradation and 
necessitate crosslinking to stabilize the gel against plasmin and other serum proteases. 
The incorporation of acrylated synthetic polymer as a crosslinker to reduce the rate of 
fibrin degradation has been utilized previously in a variety of tissue engineering 
applications [282,283]. However, among the various synthetic polymers considered for 
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gene delivery scaffolds, T904 is unique in its functionality as it not only provides the 
means to slow the enzymatic degradation of fibrin, but also has the potential to enhance 
the efficiency of scaffold-mediated transfection. Soluble T904 released during gel 
degradation acts as biological response modifiers to enhance the transgene expression 
of vectors incorporated within the scaffold. 
In the previous chapter, we established the effectiveness of the T904/fibrin hybrid 
hydrogel in promoting the controlled release of incorporated DNA and the in vitro 
transfection of N2A neuroblastoma. The N2A were able to rapidly proliferate and migrate 
through hybrid hydrogels with 3% T904 content and gain access to incorporated 
polyplex resulting in extended transgene expression. The ability for N2A to degrade 
fibrin-based hydrogels is a result of the high amount of tissue plasminogen activator 
(tPa) and plasmin expressed by N2A [284,285]. The strong proteolytic activity of N2A is 
mirrored by the in vivo environment in regions of the CNS that display high degrees of 
plasticity such as the hippocampus [286]. In contrast to the neuronal cell phenotypes, 
initial investigations in the encapsulation of fibroblasts indicated much reduced 
proteolytic activity. While NHDF were capable of degrading and migrating within hybrid 
hydrogels with 3% T904 content (no complex), the same cells were virtually incapable of 
cell migration in vitro in the same time frames when jetPEI/DNA was subsequently 
incorporated into the same gel formulations (<2 weeks, data not shown). While, the 
inability for NHDF to migrate within complex-containing T904/fibrin gels represents a 
major concern for the application of the hybrid hydrogel in wound healing, the slow rate 
of fibroblast migration could be compensated for by the fibrinolytic activity of 
macrophages recruited by the initial inflammatory response [287,288]. Fibroblasts are 
among the most critical cell types in the scaffold remodeling process and despite the 
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presence of macrophages and other immune cells with high levels of tPa activity, the 
ability for fibroblasts to migrate within the scaffold in vivo is crucial for both gel resorption 
and transgene expression in newly formed dermal tissue. Therefore, we first assessed 
the migration of NHDF in complex-incorporated hydrogels with low T904 content (1%) 
prior to in vivo implantation in the excisional cutaneous wound model. As expected, 
decreasing the amount of T904 from 3% to 1% allowed the migration of NHDF in both 
bPEI/pGFP and jetPEI/pGFP incorporated hydrogels as early as 4 days following initial 
implantation, although some inhibition of cell migration was observed in bPEI-
incorporated gels compared to both no-complex controls and jetPEI-incorporated gels. 
After 10 days of incubation, significant cell migration had occurred in all gel conditions, 
indicating that 1% T904/2% fibrin represented a favorable gel configuration for the 
wound healing model. 
In the previous chapter, a relatively low concentration of DNA in hydrogel (0.1 μg 
DNA/μL gel) was sufficient to promote gel-mediated transfection in vitro with N2A. 
However, the generally low transfection efficiency of polyplex in fibroblasts such as 
NHDF and the significantly higher doses of DNA required for in vivo transfection 
necessitated much higher concentrations of DNA in hydrogel implants [169]. We raised 
the concentration of DNA 10-fold in the hydrogel while maintaining the same 
polymer/DNA ratio. The activity of highly concentrated polyplex following lyophilization 
was confirmed by conventional plate transfection (data not shown), although concerns 
with hydrogel morphology remained. A 10-fold increase in polyplex concentration would 
be expected to greatly affect the ionic strength of hydrogel precursor solution and the 
resulting fibrin-based gel. Eyrich et al. were able to create fibrin hydrogels with long-term 
stability in cell culture medium by indirectly increasing the ionic strength of the gel 
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precursor solution through increased concentrations of CaCl2 [289]. Davis et al. also 
observed similar increase in hydrogel physical properties and stability against 
degradation by increasing the ionic strength of fibrin gel precursor solution through the 
addition of NaCl [290]. Gels fabricated at higher ionic strength exhibited overall increase 
in optical density and higher ionic strengths in pre-gel solutions acted similarly as high 
concentrations of thrombin by increasing the mechanical properties of the gel and 
stabilizing gel morphology. Qualitative observation of the T904/fibrin hydrogel with 10-
fold increase in incorporated vector revealed no changes in overall morphology. In 
addition, gel explants and observations of tissue sections revealed that the in vivo 
migration of cells within the gels and the proteolytic degradation of the gels were not 
inhibited by the presence of high concentrations of polyplex. Despite the minimal effect 
of increased DNA concentration on gel morphology, polyplex precipitation due to high 
concentrations of cationic polymer in low volumes of gel precursors remains a concern. 
However, no major observations of precipitation were made following the reconstitution 
of lyophilized polyplex, although this does not eliminate the possibility that high 
concentrations of cationic polymer released from the gel during degradation may 
aggregate with negatively charged ECM or serum proteins. Though the present work 
does not directly address the implications of polyplex aggregation pre- and post-scaffold 
incorporation, future studies involving polyplex incorporation in the T904/fibrin hydrogel 
may need to consider the possibility that polyplex aggregation may reduce the 
effectiveness of vectors delivered from the scaffold. 
While efforts have been made to characterize the delivery of non-viral vectors 
from fibrin-based scaffolds in vitro [170,206], there have been no reports on the in vivo 
efficacy of fibrin-based scaffolds for non-viral vector delivery in wound healing. A full-
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thickness excisional wound model previously used extensively in the literature to 
demonstrate gene delivery in diabetic wound healing [183,277] was used to gauge the 
effectiveness of the T904/fibrin hybrid hydrogel in delivering its genetic payload. Prior to 
examining the expression of the GFP reporter gene, the superficial wound healing 
response to the presence of the hybrid hydrogel was assessed to qualitatively evaluate 
the presence of any major adverse inflammatory responses to the presence of the gel. 
Evidence of significant re-epithelialization and wound closure within five days was 
observed, particularly in the 1% T904/2% fibrin hydrogel without complex. The 
observations were consistent with previous reports where the presence of a hydrogel 
alone within the wound was beneficial to early stage healing [276]. Explanted tissue 
sections from the wound site showed significant reduction in hydrogel structure and size, 
indicating at the minimum some partial resorption and/or degradation of the hydrogel. No 
GFP expression was detected in cryosections of tissue explants from T904/fibrin control 
gels without complex. However, green autofluorescence was present and visualized as 
small, bright green circular rings accompanied by rings of DAPI-stained nuclei. We 
hypothesized that these auto fluorescent structures found only on the periphery of each 
cryosection was primarily a result of hair follicles removed with the explant as part of the 
native dermal tissue. The initial size of 2% fibrin gel implants was small compared to the 
1% T904/2% fibrin hybrid hydrogel due to gel shrinkage that may have occurred during 
fibrin gelation [291]. Further reduction in overall gel structure and size may have 
transpired over the course of the five day implant period due to contraction of the fibrin 
gel from dehydration [262] or remodeling by cells [172]. As a result, explant tissue 
sections from wound sites containing fibrin hydrogels with jetPEI/pGFP showed 
evidence of complete gel resorption and only exhibited few isolated regions of 
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transfection. In contrast, both bPEI/pGFP and jetPEI/pGFP incorporated hydrogels 
retained small fragments of hydrogel located toward the center of the explant. Circular 
regions with central cavities void of both nuclei as well as transfection resembling the 
honeycombed structure of fresh hybrid hydrogels were present in each cryosection, 
suggesting that although the implant likely experienced size reduction due to 
degradation, significant portions of the overall gel structure remained within the wound. 
Transfected cells were found scattered around the region between the gel fragments at 
the center of the explant and the native dermal tissue at the edge of each cryosection 
where rapidly proliferating cells engaging in re-epithelialization as well as invading 
macrophages and other immune cells were likely present. Overall observations of 
transfection revealed that polyplexes incorporated within hybrid hydrogels remained 
bioactive and that the elevation of ionic strength and DNA dose in the gels did not 
negatively impact the ability for cells to degrade and migrate within the gels. 
5.5 Conclusion 
The transition of nonviral gene delivery from established in vitro transfection 
models to an in vivo model remains one of the most critical challenges in the design of 
novel nonviral vectors. In this study, we assessed ability for the T904/fibrin hydrogel to 
allow fibroblast cell migration/degradation and provide a reservoir for in vivo polyplex 
delivery to a full-thickness excisional cutaneous wound model. Concerns with the 
inability for fibroblasts with reduced proteolytic activity compared to neuroblastoma to 
degrade the T904/fibrin hydrogel were mitigated by decreasing %T904 content. The 
adverse effects of increased ionic strength and polyplex load on hydrogel degradability 
and vector activity were minimal as both branched- and linear-PEI based polyplex 
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delivered from the T904/fibrin hybrid gel successfully transfected cells in and around the 
wound site in vivo. 
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CHAPTER 6 
CONCLUSIONS AND FUTURE DIRECTIONS 
6.1 Conclusions 
 The overall goal of this dissertation as outlined in chapter 2 was to demonstrate 
the efficacy of T904 in gene delivery and its utility as a hydrogel component for scaffold-
mediated gene delivery. The hypothesis was made that amphiphilic block copolymers 
previously shown to exhibit positive effects on transgene expression in nonviral delivery 
both in vivo and in vitro would allow the creation of hydrogel scaffolds with bioactive 
properties tailored for gene delivery. Toward this end, several criteria needed to be met 
in order to validate the hypothesized competitive advantage of T904 over currently 
popular bio-inert polymers used for tissue engineering such as PEG. Although 
amphiphilic block copolymers have been used successfully in both in vivo intramuscular 
plasmid delivery as well as in vitro polyplex transfection, studies focused primarily on 
polyplex delivery are limited to triblock Pluronics with no information available on the 
effect of poloxamines/Tetronics on in vitro or in vivo nonviral transfection with carriers 
(polyplex or lipoplex). Therefore, the first objective of this dissertation was to assess the 
capabilities of T904 in conventional in vitro transfection to establish the ability of T904 to 
enhance nonviral transfection and assess whether or not Tetronics function similarly as 
Pluronics in polyplex transfection. 
 In chapter 3, T904 was used as an additive in established in vitro transfection 
protocols with commonly used 25 kDa bPEI and plasmid DNAs (pCMV-GFP, pSV40-β-
gal) as the reference carrier/vector combinations. The addition of T904 significantly 
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enhanced the transfection efficiency of bPEI/pDNA in 3 separate cell lines including 
hMSC, indicating that the poloxamine was capable of providing significant benefit to 
polyplex gene delivery. In order to better understand the activity of T904 in transfection, 
the mechanisms and pathways involved in T904-assisted bPEI/pDNA transfection was 
examined using flow cytometry and RT-PCR. Previous efforts by other groups to 
elucidate the mechanism of Pluronics in polyplex transfection revealed a critical role of 
the NF-κB pathway with effects on cell internalization [223], nuclear import [147], and 
mRNA transcript production [145]. It was found that Pluronic activity was largely 
promoter-dependent, relying on the interaction between NF-κB response elements and 
the CMV promoter located in the plasmid. Increased transfection efficiency as a result of 
Pluronic-assisted polyplex transfection was largely attributed to interactions between 
these NF-κB response elements and the NF-κB transcription factor or NF-κB associated 
pathways. As a starting point in the investigations toward understanding the activity of 
T904, it was hypothesized that the poloxamine would behave in the same manner as the 
poloxamers in polyplex transfection, relying on the NF-κB pathway to facilitate enhanced 
transgene expression. This hypothesis was not without merit as previous studies on the 
in vivo intramuscular delivery of pDNA using both poloxamers and poloxamines revealed 
similar degrees of competency [121,146,292]. In contrast to expectations, transfection 
using the SV40 promoter plasmid, as well as the EF1-α promoter pNGF in chapter 4, 
revealed that NF-κB responsive CMV promoter was not required for enhanced 
transfection efficiency in T904-assisted polyplex transfection. In addition, subsequent 
studies assessing both cell and nuclear uptake of vector revealed that T904 acted 
independently of both mechanisms previously proposed as the primary ways in which 
Pluronics enhanced the transfection efficiency of polyplexes. Finally, RT-PCR was 
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performed to reveal the effect of T904 on mRNA transcript production. Both the levels of 
transgene transcripts as well as endogenous genes related to the NF-κB pathway were 
quantified. Unexpectedly, T904 had no effect on IκB-α and hsp70 transcript levels known 
to be downstream targets of the NF-κB pathway, but enhanced the levels of endogenous 
IL-6 transcript at similar magnitudes as the increases in exogenous GFP and β-gal 
reporters. One possible explanation for this observation was that unlike IκB-α and hsp70, 
IL-6 activation is known to be closely related to the activity of other general transcription 
factors, specifically AP-1. Coincidentally, both pCMV-GFP and pSV40-β-gal have known 
affinity with the AP-1 transcription factor, indicating that upregulation of AP-1 
transcription factor activity may have led to the observed increases in transcript 
production of both the endogenous IL-6 gene as well as the two exogenous reporters. 
Taken altogether, the results of experiments in chapter 3 suggested that although T904 
was capable of enhancing the transfection efficiency of polyplexes in a dose-dependent 
manner, the mechanism of its activity was different from that of Pluronics. 
 Transitioning from established 2D transfection models to a 3D scaffold-mediated 
gene delivery environment necessitates careful consideration in the ability for cells to 
degrade the scaffold and gain access to encapsulated gene carriers. Due to the inability 
for purely synthetic hydrogels (like T904) to support cell adhesion and enzymatic 
degradation, a natural serum protein susceptible to proteolysis was incorporated into the 
hydrogel. The result was the development of a hybrid biosynthetic hydrogel scaffold 
capable of both the controlled release of incorporated DNA or polyplex through 
enzymatic degradation that also supported the migration of cells within the gel itself. Due 
to their high tissue plasminogen activator (tPa) and plasmin activity, N2A cells were 
chosen as a model cell type for assessing the 3D transfection capabilities of polyplex-
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incorporated T904/fibrin hybrid hydrogels. Cells were observed to migrate freely in 3D 
within the hybrid hydrogel and expressed transgene for one month. Quantitative 
evaluation of hydrogel-mediated transfection revealed that in a gel-on-gel model where 
cells were allowed to freely proliferate on the surface of the complex-containing 
hydrogel, the cumulative gene expression of cells transfected by T904/fibrin hybrid 
hydrogels exceeded that of fibrin alone. In addition, degradation products from complex-
incorporated T904/fibrin hydrogels were able to significantly enhance the transfection 
efficiency of cells in conventional cell culture, indicating that hydrogel polymerization did 
not negatively impact the ability for soluble T904 degradation products to enhance 
polyplex transfection. 
 The final objective of the dissertation was to investigate whether the T904/fibrin 
hybrid hydrogel could maintain the bioactivity of incorporated polyplex for in vivo 
transfection in a cutaneous wound model. One critical aspect of gene delivery in the 
dermis relative to the components used in the hybrid hydrogel was whether cells with 
substantially lower plasmin/protease activity (fibroblasts) could degrade and/or migrate 
within the hydrogel. In chapter 4, neuroblastoma with high tPa efficiently degraded the 
gels and gained access to encapsulated polyplex, but early pilot experiments using 
hydrogels with incorporated polyplex and 3+% T904 revealed that fibroblasts such as 
NHDF would likely struggle to access transgene in the same time frames. Therefore, the 
amount of T904 in each gel was lowered to 1% and the amount of incorporated polyplex 
increased 10-fold. Neither proved detrimental to the T904/fibrin hydrogel for in vivo gene 
delivery as both bPEI/pGFP and jetPEI/pGFP incorporated hybrid hydrogels were able 
to facilitate transfection of cells in the cutaneous wound model and neither gel type 
inhibited cell migration. 
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6.2 Recommendations for future directions 
 One of the major aims of chapter 3 was to demonstrate the effect of poloxamines 
in nonviral transfection as well as any apparent differences in polyplex transfection 
between poloxamines and poloxamers. Toward this end, T904 was chosen as the 
poloxamine representative following initial pilot experiments in which T904 demonstrated 
a great affinity for transfection than Tetronics T304, T1107, and T90R4. Tetronics are 
classified according to their molecular weight and hydrophilic/lipophilic balance (HLB). 
T904 represents an average Tetronic with MW=6.7 kDa and HLB values from 12-18. No 
other Tetronic has this particular cross-section of size and HLB. For example, while 4.7 
kDa T901 may be similar in size to T904, it is considerably more lipophilic with HLB 
values from 1-7 and although T304 has a similar HLB values as T904 from 12-18, it is 
substantially smaller in size with MW=1.65 kDa. Future investigations into the efficacy of 
poloxamines in nonviral transfection should definitely encompass a wider range of 
formulations and systemic synthesis of novel poloxamine formulations with size and HLB 
similar to T904. Of particular interest is how the copolymer HLB value affects copolymer 
activity in transcript production and how reverse poloxamines where the PEO and PPO 
blocks are switched (e.g. T90R4) behave in nonviral transfection. It may also be possible 
that certain Tetronics behave mechanistically similar as Pluronics in the literature, so 
potential investigations into other poloxamines for nonviral transfection should include 
studies on mechanism such as nuclear import and transcript production. The significant 
effect of T904 on the production of endogenous IL-6 gene transcripts suggests that more 
thorough analysis of T904 on the up-regulation of endogenous, off-target genes would 
provide insight on the effect of T904 on other cellular pathways. Gene array analysis 
previously used by Kabanov and coworkers to examine NF-κB pathway activation [147] 
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would be a good assay to use for higher throughput studies. Any in vitro transfection 
screenings should also include investigations with lipoplexes in order to expand the 
potential applications of amphiphilic block copolymers for nonviral vector delivery. 
 Relatively few physicochemical characterization assays were made on 
T904/fibrin hydrogels. As a scaffold destined for soft-tissue applications where it would 
eventually be degraded, the actual physical strength of the gel itself was secondary to its 
degradation mechanics and swelling behavior. However, future investigations in the 
potential uses of the T904/fibrin hybrid hydrogel in gene deliver or other tissue 
engineering applications should include in depth studies on the physical characteristics 
of the hydrogel. In particular, rheology should be used to gauge the rate of hydrogel 
formation which would be useful in determining whether in situ polymerization would be 
viable for T904/fibrin. For all hydrogel studies related to degradation including controlled 
release of incorporated DNA or polyplex, 100 nM plasmin was used to model the in vivo 
environment. Future investigations on the release of vector from the T904/fibrin hybrid 
hydrogel should include additional degradation models to tailor the ratio of synthetic to 
natural components in the hydrogel for specific applications. As mentioned in chapter 5, 
complex-incorporated hydrogels with medium to high %T904 content were somewhat 
resistant to fibroblast migration. Although a significant literature exists on the effect of 
ionic strength and other factors (thrombin concentration, Ca2+ concentration, 
temperature, pH) on fibrin formation, some investigations on the effect of polyplexes on 
fibrin and hybrid hydrogel physicochemical structure should be made including gel 
degradation rate, hydrogel porosity, fibril density, and fibril size. 
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 Although the ability for polyplex-incorporated T904/fibrin hybrid hydrogels to 
transfect cells in vivo was established in chapter 5, only the expression of a GFP 
reporter gene was confirmed and the primary advantage of T904 over other synthetic 
materials, its ability to enhance transgene expression, was not tested. Isolating the 
composition of the scaffold as the only variable affecting transfection efficiency 
represented a significant challenge over similar assessment of T904 versus other 
synthetic polymers in vitro. The rate of hydrogel degradation and ability for cells to 
migrate through a gene-incorporated scaffold was previously studied by Shepard et al. 
and established as critical variables to the successful delivery of incorporated transgene 
[191]. Although comparing a different synthetic component such as PEG to T904 for in 
vivo transfection would provide motivation for using T904 over PEG, it would be 
extremely difficult to make PEG/fibrin hydrogels with the exact same structural properties 
and cell adhesion/cell migration behaviors as T904/fibrin. While a basic understanding of 
scaffold-mediated transfection using T904/fibrin was established in chapter 5, future 
work should transition from reporter genes to therapeutic genes such as VEGF or FGF 
to analyze functional recovery and/or regeneration of lost tissue in pathology models 
such as diabetic wound healing. The cutaneous wound model was used as the 
preliminary in vivo model in chapter 5 due to the relative ease of surgical access 
afforded by the dermis and applicability of gene delivery in wound healing. However, 
other potential candidates for scaffold-mediated gene delivery such as the peripheral or 
central nerve systems should also be studied. In particular, nerve regeneration 
represents an interesting application due to the high tPa exhibited by certain neuronal 
phenotypes. In particular RNA interference (RNAi) using small interfering RNA (siRNA) 
would be an interesting potential vector for scaffold-mediated transfection in the CNS 
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[293]. As part of preliminary efforts to gauge the potential applications of T904, some 
PEI/pDNA transfection studies were done using primary neurons. However, the 
transfection efficiency of polyplex in neurons that do not rapidly divide was substantially 
reduced compared to cells with high rates of cell proliferation likely due to reduced 
vector uptake and nuclear import in non-dividing cells [103]. However, RNAi acts on the 
cytoplasm and not the nucleus, eliminating the need to penetrate the nuclear membrane 
in neurons. 
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